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THESIS SUMMARY  
Drug resistant epilepsy (DRE) is a neurological complication which 
affects approximately 20 - 40% of epilepsy subjects, causing their overall 
lower quality of life. Thus, it represents a condition which requires further 
understanding of its pathogenesis and optimization of its drug treatment for 
better management of the disease. In this regard, dried blood spot (DBS) 
appears as an attractive matrix for the study of pathogenesis of a disease as it 
can be conveniently collected from patients in a large population scale, and 
DBS can be utilized for selected biomarker profiling or drug quantitation 
assays. Up to date, there are only few but increasing numbers of studies in 
recent years on using DBS for metabolomic profiling and clinical monitoring 
of drug levels. In light of these, I endeavour to explore the application of DBS 
on epilepsy research in 2 main objectives in this thesis: (1) to investigate the 
feasibility of applying DBS in profiling epileptogenesis; and (2) to use DBS as 
matrices for drug monitoring.  
For the first objective, DRE prevalence study to determine the severity 
and relevant risk factors was firstly carried out, followed by investigation of 
the reliability of DBS in metabolomic study. Using finger prick DBS samples, 
it was observed that the metabolomic profiles of drug responsive epilepsy 
subjects were distinguishable from those who were drug resistant (Q
2
 = 0.71). 
From the metabolite profiles obtained through gas chromatography mass 
spectrometry (GC-MS), several metabolites were revealed to have different 
degree of abundance between these 2 groups of subjects. The metabolites were 
putatively identified as glutamine, aspartic acid, pyruvic acid, caprylic acid, 
serine, palmitic acid and oxalic acid. 
For the second objective, clinical validation and population 
pharmacokinetic modeling using DBS derived concentrations (Cdbs) were 
conducted to examine their applicability. After the inclusion of individual 





ratio, AED concentrations derived using the newly developed DBS assay 
could accurately predict its plasma concentrations which were measured from 
plasma immunoassays (within 95% confidence interval of the means of two 
methods). To further enhance the clinical applicability of Cdbs, clearance of 
one of the AEDs was estimated through a population approach.  
Findings from this thesis were to establish the utility of DBS for future 
larger or population-based clinical research, where sample acquisition can be 
done by epilepsy subjects at home. As evidenced by the comparable results 
between DBS and plasma, DBS could be a suitable matrix for both aspects of 
disease and drug monitoring. Once the relevant biomarkers of epilepsy are 
established, simultaneous monitoring along with AED concentrations would 
become feasible. This, in turn, will aid the management of epilepsy subjects 
by rendering monitoring of disease as well drug levels, just from one dried 
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CHAPTER 1. THESIS INTRODUCTION 
In this chapter, epilepsy and dried blood spot (DBS) will be concisely 
reviewed. Firstly, an overview of epilepsy and current knowledge on 
epileptogenesis will be discussed. Secondly, the role of currently available 
antiepileptic drugs (AED) in the treatment and metabolomics in the 
understanding of epilepsy will be evaluated. Thirdly, the significance of drug 
resistant epilepsy (DRE), associated risk factors, current hypothesized 
mechanisms of DRE and some prominent complications will be highlighted. 
This is followed by the utilities of DBS in clinical research and the advantages 
of DBS as sample matrices.  
 
1.1 EPILEPSY 
1.1.1 OVERVIEW OF EPILEPSY 
Epilepsy is one of the most common chronic neurological disorders; 
and the onset of which is independent of age. It is characterized by recurrent 
or spontaneous seizures unprovoked by any immediately identifiable cause (1).  
Seizure arises due to the imbalance in excitatory and inhibitory 
discharges from the neurons in the brain. It is defined as abnormal or 
excessive electrochemical activity in one part (focal) or a more diffuse origin 
(generalized) from the brain, which may manifest as changes in motor activity, 
sensation, behaviour, emotion or consciousness or a combination of these 
symptoms. Seizures that subside after the primary condition, e.g. alcohol 
withdrawal, has resolved are not considered to be epilepsy. In view of the 
complexity of its origin, epilepsy is observed to be a symptom of an 





The incidence of epilepsy in the United Kingdom (UK) is about 50 per 
100,000 per annum, as surveyed in a study published in the year 2000 (3). The 
incidence is 25% in patients less than 15 years old, decreases in adulthood (51% 
for age ranging from 16 to 59 years) and rises again to 24% in patients older 
than 60 years (4). The prevalence for active epilepsy in the UK is 5-10 cases 
per 1,000 while in Singaporean men, the lifetime prevalence rate is about 4.9 
cases per 1,000 (5). The annual incidence rate of childhood-onset epilepsy in 
Singapore is approximately 24 per 100,000 (6).  
The diagnosis of epilepsy is clinically determined and comprised of 
seizure type, epilepsy syndrome and the original cause. Primarily, epilepsy is 
diagnosed based on the detailed description given by the patient and/or 
witness on the events before, during and after a seizure attack. This is then 
supplemented by findings from the electroencephalogram (EEG), magnetic 
resonance imaging (MRI) and computed tomography (CT) of the patient with 
known or suspected epilepsy.  The classification of seizure type, however, is 
more controversial and depends on the (7):  
1. Parts of the brain affected 
2. Pattern of spread of epileptic discharges through the brain 
3. Cause of epilepsy and  
4. Age of the individual 
The decision to treat has to be made after deliberate consideration in 
balancing the likelihood of further seizure attacks with the risk of adverse 
effects from the AEDs. According to established clinical guidelines, treatment 
should not be offered after a single seizure, unless the patient is determined to 









Each type of epilepsy has its own set of cause and mechanism. 
Epileptogenesis is coined with reference to the developmental of changes from 
normal brain activity to repeated spontaneous seizures (10). Experts believe 
that epileptogenesis also constitutes pathway alterations responsible for 
pharmacoresistance (11). Current pharmacotherapy choices are mainly 
preventing symptomatic seizure expressions but do not interfere with 
generation or progression of epilepsy itself. Therefore, a complete 
understanding of epileptogenesis is believed to have significant clinical 
relevance in understanding as well as identifying new targets for intervention. 
The revised terminologies for standardized description of etiology for 
epilepsy are divided into three; genetic, structural-metabolic and unknown 
(12). The etiology provides some insight into the epileptogenesis of the 
particular patient. Epilepsy of genetic etiology is considered for cases where 
seizures arise as a direct consequence of genetic defect such as juvenile 
myoclonic epilepsy (JME), channelopathies and neonatal epileptic 
encephalopathy caused by pyridox(am)ine 5’-phosphate oxidase (PNPO) gene 
mutation (12).  Sometimes, genetic and protein expression abnormalities are 
linked (13). Structural-metabolic etiology encompasses structural or metabolic 
disorder of any parts of the brain (12). Some examples include cortical 
malformation, mesial temporal sclerosis and brain tumour. When the cause is 
unidentified, and could be either genetic or structural-metabolic, it will be 
classified as unknown etiology (12).  
In recent years, several genes have been identified to be responsible in 
epileptogenesis. These genes encode for various receptors located at the 
surface of the neurons, ions channels and metabolism pathway. However, 
locus heterogeneity and variation in expressivity of the mutated genes have 
complicated our understanding on the influence of genetic mutations in 





have been suggested to cause generalized epilepsy with febrile seizure plus 
(GEFS+), illustrating the problem of locus heterogeneity of the genes involved 
in epileptogenesis (14-17). On the other hand, a single gene mutation could 
result in different epilepsy phenotypes, reflecting variation in expressivity. For 
instance, mutations in SCN1A gene is linked to temporal lobe epilepsies, 
typical febrile seizures, febrile seizures plus and severe myoclonic epilepsy in 
infancy (18-22). 
In benign familial neonatal convulsions (BFNC), single gene mutation 
at chromosome 20q13.3 and 8q24 is believed to be the cause. These mutations 
lead to loss of function of KCNQ2- and KCNQ3-voltage–gated potassium 
subunit channels, respectively. These channels are responsible for defying 
sustained depolarization and repetitive firing (23, 24). Loss of these channels, 
or a reduction of 20-25% of their functions, allows continuous depolarization 
that result in seizure (24). The patients could either have generalized tonic-
clonic or focal seizures. Interestingly, BNFC is a syndrome that only appears 
in the first month of life without recurrence. It is speculated to result from a 
change in potassium channels expression genes during the brain development 
(25). To date, there are more than 80 subunit genes that encode for more than 
24 major classes of potassium channels (23). Defects in one or two genes 
seemed to be replaceable by the functionalities of the others. In short, these 
findings suggest that there is no straightforward correlation between genotype-
phenotype in epileptogenesis. It probably takes a certain combination of gene 
defects to contribute to different phenotypic characteristics of epilepsies (26). 
Aside from genetic-related epileptogenesis, there is also 
environmental-acquired epileptogenesis. In structural-metabolic epilepsy such 
as brain trauma, stroke and brain infection, epilepsy occurs in a chronic way. 
In these cases, there is a fixed structural damage but only intermittent 
occurrences of seizures. Researchers hypothesized that the intact synaptic 
inhibition is enough to suppress the effect of persistent excitatory 





proposed that there is transient decrease in inhibitory synaptic transmission by 
γ-aminobutyric acid (GABA) and an increase in excitatory transmission by 2-
amino-3-(5-methyl-3-oxo-1,2- oxazol-4-yl)-propanoic acid (AMPA) and N-
methyl D-aspartate (NMDA) glutamate receptors, leading to sustained 
depolarizing potentials (28). In epilepsy patients, their seizure thresholds tend 
to be lower whereby a small increase in excitatory or decrease in inhibitory 
transmission is adequate to trigger seizure. Acute neuronal loss alone does not 
suffice to cause acute seizure (28), as seizure is likely to arise from a 
collective imbalances in neuronal transmission at the metabolite level. 
Therefore, it seems that epileptogenesis from various origins do converge at 
certain point and a closer look at the neurotransmitter expressions may provide 
a uniform explanation. 
Generally, system biology begins with genes, which are translated into 
proteins whose function leads to the production of various sets of metabolites. 
In line with this, the genomics is the study of total DNA within a cell or 
organism. This could be done using DNA microarray where thousands of 
genes can be analysed simultaneously (29). Moreover, nucleotide 
polymorphism profiling has a role in pharmacogenomic study of individual 
responses to drugs. However, there is a lack of consensus surrounding 
microarray data interpretation . 
Proteomics, on the other hand, is the study of all expressed proteins 
within a cell, tissue and organism with the aim to understand their functional 
relevance. It holds special place in biomarker discovery because proteins are 
most likely to be uniquitously affected in disease and disease response (30). 
Although much  information can be gained from proteomics, it is limited by its 
huge domain size (> 100 000 proteins) and the inability to detect some of the 
low abundance proteins .  
Metabolomics is the study of global metabolite profiles under a given 
set of condition (31). The metabolome is the final downstream product in a 





and proteome (32). It is the closest to the phenotype of the biological system 
studied and can distinguish morphologically indistinguishable but 
phenotypically different condition. Despite being the smallest domain 
(approximately 5000 metabolites), it contains various biological molecules 
whose interactions are physically and chemically more complex (31). These 
complexities allowed metabolomics to reveal more informative observations. 
However, metabolomics can only provide a snapshot of the disease condition, 
it does not provide an answer to the cause of the disease. An overview of 
metabolomics in comparison to genomics and proteomics has been provided 
by Hollywood et al (33). 
Metabolomics is an emerging scientific discipline that look at the 
association between disease and downstream pathophysiology, i.e. the 
metabolic profile in tissues and biofluids. The metabolic profile is a semi-
quantitative measure of all low molecular weight compounds (e.g. nutrients, 
hormones, vitamins, neurotransmittors) in a given biological sample and 
represents fingerprint of the substrates, intermediates and by-products of 
physiological and pathological activities. As metabolite profiles are greatly 
influenced by genetic make-up and associated with enviromental factors such 
as lifestyle and diet, it offers a great opportunity to overcome the shortcomings 
imposed by genetic and proteomic studies.  
The idea of profiling the metabolites in people with epilepsy (PWE) is 
partly coined from the fact that many hereditary epilepsies arise from inborn 
error of metabolism (IEM) (34-37). It is believed that any symptoms of altered 
enzymatic functions remain latent in the child with IEM, until the 
accumulation of the wrong product due to the defective enzymatic process is 
sufficient to trigger a seizure. This implies that variation in metabolite profiles 
have some direct effect in epileptogenesis, making it a possible tool for 
detecting biomarkers of epilepsy. For instance, in pyridoxal 5-phosphate 
(P5P)-sensitive seizures which affect infants of a few weeks-old, serum 





threonine and 3-methoxytyrosine while cerebrospinal fluid (CSF) 
biochemistry showed low concentrations of L-dopa, 5-hydroxy-tryptophan and 
3-O-methyldopa (13). These metabolite fluctuations are now adopted as 
biomarkers for the diagnosis of P5P-sensitive seizures. The seizure ceases in 
neonates after the administration of pyridoxal-5-phosphate, either orally or 
intravenously. In other IEM cases where only transient clinical symptoms 
were observed, the function of the defective gene/s is replaced by others as 
development progresses, highlighting again, the inadequate attribution of 
genetic and proteomic factors to epileptogenesis.The standard treatment 
currently is to administer the defective enzymes or the resulting 
products/metabolites. In some cases, these products will restore their 
endogenous functions or levels and overall balances the activities in the brain 
to halt seizure (37). Therefore, it was hypothesized that the findings from 
metabolomic study would be an important adjunct to contemporary research in 
epilepsy.  
Indeed, as shown by a recent study done in Chinese populations, five 
metabolism pathways were proposed to be involved in epilepsy (38). When 
compared to healthy subjects, serum levels of GABA, creatinine, L-threonine 
and L-tryptophan were lower while the levels of L-glutamate, glycine, glyceric 
acid, lactic acid, inositol and myristic acid were higher in the epilepsy group. 
These metabolites, individually (39-45), has been linked to seizure and their 
work provided the evidence that there is likely a complex network of 
metabolite disturbances in epilepsy which are different from healthy subjects. 
It had been suggested that PWE who died unexpectedly or showed 
signs of hereditary disease should be thoroughly investigated in post-mortem. 
Interestingly, experts recommended that DBS should be acquired to aid 
diagnosis.
 
DBS could be obtained during the first 18 hours after death and 
preserved indefinitely in liquid nitrogen (46). It is therefore more practical 
than the collection and storage of CSF or urine, which are the other common 






1.1.3 ANTI-EPILEPTIC DRUGS  
Unlike other classes of drugs where they can be classified according to 
their pharmacological actions, AEDs are broadly categorized into older and 
newer generation. Specifically, there is 3 generation of AEDs if based on the 
period of their first introduction. Often, each AED has more than one mode of 
action but their detailed mechanisms of actions of AEDs are still largely 
unknown (47). Table 1 summarizes the current knowledge on AEDs actions in 
the treatment of seizure.  
Table 1. Main mechanism of actions of old and new generation of antiepileptic 
drugs (adapted from (47)) 
























Older generation        
Benzodiazepines - - ++ - - - 
Carbamazepine ++ ? - - + + 
Ethosuximide - - - - ++ - 
Phenobarbital - + + ++ ? + 
Phenyotin ++ - - - ? + 
Valproic Acid ? + ? - + ++ 
Newer generation        
Felbamate ++ + + - + + 
Gabapentin ? ? - - ++ ? 
Lamotrigine ++ + - - ++ + 
Levetiracetam - ? + - + ++ 
Oxcarbazepine ++ ? - - + + 
Pregabalin - - - - ++ - 
Tiagabine - ++ - - - - 
Topiramate ++ + + - + + 
Vigabatrin - ++ - - - - 
Zonisamide ++ ? - - ++ + 
++, primary action; +, secondary action; -, no action described; ?, controversial evidence; GABA, γ-aminobutyric 
acid 
 
The first generation of AEDs, such as bromide, phenobarbital, 
phenytoin, primidone and ethosuximide, and second generation of AEDs, such 
as chlordiazepoxide, diazepam, carbamazepine, valproic acid, clonazepam and 
clobazam, are collectively referred to as older generation of AEDs. In this 





The older generation AEDs such as phenytoin, carbamazepine, 
valproic acid and phenobarbitone are well-established as the first choice of 
treatment for a variety of epilepsy syndromes. It is believed that employing 
AEDs with a different mechanism of action than the one ineffective previously 
or as a combination therapy may prove useful (48).  Although a systematic 
review by Costa et al, 2011 suggested that no definitive conclusion can be 
drawn with regards to which new AEDs offer superiority as compared to the 
others in the treatment of refractory partial epilepsy (49), this may not be the 
case when involving both combinations of older and newer generation AEDs. 
A study specifically designed to answer this research question in a general 
PWE population is yet to be conducted. This finding may be useful since 
epilepsy has a long dynamic course of disease; it is likely that physicians will 
reuse a previously unsuccessful AED after due considerations (50). 
The newer generation, specifically, the third generation of AEDs are 
also called ‘targeted’ AED since they were developed based on the rationality 
of mechanism of seizure occurrence. Examples of these drugs are vigabatrin 
(VGB) and tiagabine (TGB) which primarily block the metabolism of 
inhibitory neurotransmitter GABA by irreversibly inhibiting the GABA 
transaminases. The increased presence of GABA at presynaptic neuronal 
junctions may increase seizure threshold or aid in abating sustained epileptic 
firing. The advantage associated with this generation of drugs includes less 
drug-drug interactions. Whether or not they are less toxic than the older 
generation remains debatable as it is often dependent on specific drug-drug 
comparison itself rather than the group per se (51-53). With the more stringent 
requirements in clinical trials since the last two decades, most of them are 
getting approved as second line or adjunct treatment. Only in few cases, they 
could be used as first line for seizure treatment, such as lamotrigine for 
treatment of generalized seizures in women of child bearing potential.  
Attempt to substitute the older generation AED has been so far, 





(VPA) seems unsurpassed and remained the benchmark for newer generation 
AEDs. For example, VPA still outperformed lamotrigine (LTG) as the first 
line treatment for idiopathic generalized epilepsy (IGE), juvenile myoclonic 
epilepsy (JME) and new-onset absence epilepsy (NOAE) of childhood (51, 54, 
55). Topiramate (TPM) and ethosuximide (ESM) was reported to be non 
inferior to VPA in the treatment of IGE and NOAE respectively, although the 
percentage of effective treatment outcome showed a trend favouring VPA (51, 
55). The trial involving ESM, however, was only for 16 weeks and hence the 
result has to be interpreted cautiously. In untreated focal epilepsy, immediate-
release CBZ was undefeated by gabapentin in efficacy but was likely to fail 
due to intolerability when compared to lamotrigine (51). When sustained-
release CBZ was used, tolerability is comparable to LTG group while a trend 
of higher seizure free rates was observed in CBZ group (56). 
There have also been efforts to develop antiepileptogenic drugs. 
Hitherto, the results had been disappointing (57-59). As with all new drugs, 
new antiepileptogenic agent will have to undergo preclinical and clinical 
evaluations. For preclinical studies in epilepsy, it has long been debated 
whether the current kindling and status epilepticus animal models are 
representative causes of human epileptogenesis (60, 61). Besides, evidence of 
antiepileptogenesis is difficult to be captured in human study.  There seems to 
be a critical window between the time of brain insult to the treatment 
commencement and differing mechanisms depending on the type of brain 
insult, gender, age and comorbidities (62, 63). The treatment should begin 
between day 1 to 3 post-insult to halt epileptogenesis while the treatment 
duration should be at least 2 to 5 years to ensure optimum suppression of 
epileptogenesis (64). Thereafter, subjects should be followed up to determine 
sustained epilepsy prevention even after drug withdrawal. Overall, clinical 
trials are difficult and costly to conduct. Each etiology of epilepsy is likely to 
have its own set of epileptogenesis, further complicating both the trial design 
and findings generalization. It will probably take a long time before a new 





clinical trial designs, biomarkers for human antiepileptogenesis are hence, 
favoured since the changes may occur relatively faster and can be objectively 
monitored (64-66). The currently researched independent biomarkers involved 
the microseizures and specific intracranial EEG spike patterns that present 
before seizure attacks (64-66). Further validation work is still required to 
establish them as useful surrogates to antiepileptogenesis. 
On the other hand, some existing AEDs such as ESM and 
levetiracetam (LEV) are also considered as antiepileptogenic due to the 
observed persistent seizure suppression even after drug withdrawal in 
genetically modified spontaneously epileptic rats (SER) (67, 68). This finding 
is in contrast with seizure generation that occurs almost immediately following 
withdrawal of any antiseizure drugs. Nevertheless, the suboptimal efficacy 
observed with these agents suggested that improvement works in both 
preclinical and clinical trials are still required.   
In view of the lengthy process for approval of antiepileptogenic drugs, 
first line treatment drugs such as VPA, CBZ and PHT will likely be the 
mainstay of treatment for years to come. VPA is licensed for use in a complete 
range of seizure types which include primary generalized seizures, absence 
and myoclonic seizures and focal seizures. CBZ is licensed for partial or focal 
seizures while PHT is used in a variety of cases spanning from tonic-clonic or 
partial or a combination of these two seizures, prevention of seizure post-
neurosurgery or severe head injury to the emergency treatment to stop ongoing 
seizures. The use of these conventional AEDs is usually supported with 
plasma drug level monitoring as they have a narrow therapeutic index. Levels 
below the target therapeutic trough may result in inadequate control of the 
seizure attacks while levels above the target therapeutic peak will expose the 
patients to more adverse drug effects. Current plasma monitoring is very well-
established with the therapeutic ranges of 50 – 100 µg/mL for VPA, 4 – 12 





The application of pharmacokinetic principles on antiepilepsy therapy 
is largely inspired by regulatory requirements because the serum 
concentrations of phenytoin and phenobrabital displayed strong correlation 
with their efficacy as well as side effects (69-75), highlighting the importance 
of PK estimations for AEDs. These similar findings had also propelled the 
need for comprehensive PK characterization of AEDs before drug 
registrations. 
It is believed that only the free form of AEDs can penetrate the brain, 
and hence, is able to correlate better with clinical efficacy (76-78). However, 
monitoring of free drug concentrations are too costly to be adopted in routine 
practice and is only applied in cases deemed absolutely necessary by the 
clinicians. This method is also not readily available, further hampering its 
usefulness. The alternative measurements and correlation studies have include 
the use of CSF (79), tears (80), saliva (81) and DBS (82) instead of the 
conventional plasma.  
Many population pharmacokinetic (PPK) studies were then performed 
on these conventional AEDs to better estimate the pharmacokinetic parameters 
(83-91). A precise estimation of the PK parameters will enhance the dosing 
efficiency, where the individualized dose instilled to the patient has a higher 
likelihood of reaching the therapeutic concentrations in a shorter duration 
while avoiding the unnecessary side effects. 
 
1.1.4 DRUG RESISTANT EPILEPSY 
The goal of treatment in PWE is to attain seizure freedom (2, 8, 9) and 
the mainstay of treatment modality is through daily use of AEDs. The most 
commonly prescribed AEDs around the world as well as in Singapore have 
been found to be of the older generation of AEDs, namely valproic acid, 





Approximately 20% to 40% of PWE will have drug resistant epilepsy 
(DRE) in their lifetime (96-101). Conventionally, the PWE are considered to 
have intractable or medically refractory epilepsy when they fail multiple 
antiepileptics drugs (AEDs). Studies conducted in the United States and 
European countries have defined intractability as failure to attain seizure 
freedom after the trials of 2 or 3 AEDs (101-105). In addition, these studies 
varied in their definition of seizure freedom. For example, Kwan and Brodie 
(101) defined seizure freedom as ≥ 1 year without a seizure occurrence from 
the date of last follow up, while Camfield and Camfield (105) utilized a more 
lenient criteria of < 1 seizure every 2 months in the last year of follow up. In 
view of the differing definitions, direct comparison of their findings is 
hindered. Moreover, findings from each study may not be representative of the 
epilepsy population in other settings, such as Singapore.   
 
1.1.5 RISK FACTORS OF DRUG RESISTANT EPILEPSY 
With the high occurrence rate of DRE, research has been attempted to 
identify some common predictors (100, 101, 106-108). It appears that a 
combination of characteristics is more likely to offer a better predictability of 
DRE as compared to any single factor. It has been reported that more than half 
of PWE will respond to their first AED prescribed. For those who did not 
achieve seizure freedom with their first AED trial, less than 20% will respond 
favorably to the following AEDs trial (107).  Hence, poor response towards 
the first AED prescribed seems to be an important factor in predicting DRE 
(100, 107, 108). 
In line with this suggestion, investigators from Scotland conducted a 
study to look for biomarkers that could be indicative of responsiveness among 
epilepsy patients towards their first AED (109). They recruited 125 newly 
diagnosed epilepsy patients who were then randomly assigned to lamotrigine, 





PWE who had no seizure since the start of treatment were classified as 
responders, continuous seizures despite on treatment were classified as non-
responders and failed to reach endpoints were classified as unknown. The 
duration of 12 months seizure freedom was in agreement with the 
International League Against Epilepsy (ILAE) consensus, assuming the 
patients had the longest pre-treatment seizure interval of ≤ 4 months. 
Unfortunately, at the end of their study, no prominent serum biomarker was 
discovered. The authors attributed the lack of discrimination to their relatively 
small and equivocal clinical phenotype cohort (109). Moreover, the duration 
of 12 months may be too short for adjustments in in vivo system biology. It 
will be interesting to investigate the changes after a longer duration of 
treatment.  
Another constantly cited predictor of DRE is the high number of 
seizures prior to treatment initiation (101, 104, 107). It is also generally 
perceived that epilepsy syndromes arising from a lesion in the brain are more 
difficult to be treated and hence, are more likely to render the PWE to be drug 
resistant (106, 107, 110). The age of epilepsy onset is also suggested to be 
another major predictor of DRE, with those presented at the age of ≥ 65 years 
tend to be less likely to develop DRE (111). Insofar, none of the studies 
conducted has considered the effect of Asian ethnicity in predicting DRE. It 
has been proposed that genetic makeup of PWE may influence their responses 
to certain AEDs such as carbamazepine (112, 113). Therefore, there may be a 
need to investigate the role of ethnicity, which indirectly implying geneticity, 
in predicting the treatment response of PWE, especially for multiracial 








1.1.6 MECHANISMS OF DRUG RESISTANT EPILEPSY 
Apart from discovering the risk factors associated with DRE, it is 
actually of more prominence to elucidate the pathogenesis of DRE in order to 
prevent its occurrence. A few hypotheses have been proposed.  
Firstly, it has been shown that enhanced expression of multidrug 
transporters is associated with multidrug resistant epilepsy (114-116). It is 
generally believed that multidrug resistant epilepsy could be related to 
polymorphisms of the gene ABCB1, encoding P-glyprotein (Pgp) in the blood 
brain barrier (114, 117, 118). Pgp is an adenosine triphosphate (ATP)-driven 
efflux pump that is suggested to be over expressed in patients with DRE, and 
reduced the exposure of the brain to AEDs. In one study, ABCB1C3435T 
polymorphism was demonstrated to be significantly correlated with DRE in 
adult Caucasians and PWE with symptomatic etiology (currently termed as 
structural-metabolic), but not in children or PWE with idiopathic and 
cryptogenic etiology (119). The definition of drug resistant used were 
occurrence of at least 4 seizures in the preceding year and failure to more than 
3 appropriate AEDs while drug responsive/seizure free were seizure freedom 
of at least 1 year (119). The result of a meta-analysis done using 19 studies, 
however, concluded otherwise (120). No association between ABCB1C3435T 
polymorphism and DRE was found (120). The difference could be due to the 
different DRE definitions utilized. The latter study’s approach appeared to be 
more clinically relevant as it had adopted the latest ILAE definition of DRE 
(50). The absence of association between ABCB1C3435T polymorphism and 
DRE  could be due to two factors: 1), not all AEDs are substrates for Pgp in 
the human brain; 2) Pgp transporters have yet to be proven to be able remove a 
significant amount of AEDs from the brain (121). Furthermore, there seems to 
be linear relationship between plasma AED levels with the brain AED levels. 
This finding opposed the characteristic of Pgp-mediated efflux because it 





gene involved in DRE. It is becoming increasingly plausible that epilepsies are 
multifactorial diseases involving both genetic and environmental factors.   
Secondly, the altered sites for AEDs’ actions could also be relevant in 
rendering lack of response to the drugs (116, 124). In drug resistant temporal 
lobe epilepsy, altered expression of GABAA receptor subtype had hindered the 
inhibitory actions by AEDs (125). Since most AEDs act by inhibiting the 
voltage-gated sodium channels, drug resistant epilepsy was also thought to be 
related to polymorphisms of SCN2A gene, which modified these channels to 
be non-receptive to AEDs (126). More research is definitely required to 
establish that these mutations occur in all DRE patients and the functions are 
affected significantly without compensation by others.  
Thirdly, in neuroproteomics, the research approach probably arises 
from the development of animal models that best describe epilepsy (127). 
Interestingly, neuroproteins involved seem to be dependent on the origin of the 
epilepsy such as fronto-temporal or temporal lobe. The TARCs/ICAM5 ratio 
in patient plasma had been proposed to be a candidate biomarker for DRE in 
patients with fronto-temporal lobe epilepsy (128). In another study, transient 
inhibition of brain-derived neurotrophic factor (BDNF) receptor TrkB after 
status epilepticus in mice model through chemical-genetic approach had 
prevented epileptogenesis of temporal lobe epilepsy (129). This study 
highlighted the importance of TrkB kinase in promoting epileptogenesis post-
seizure and that there is a critical window time that could prevent generation 
of epilepsy later on in life. Although the generalization of these proteins in a 
heterogeneous general population of PWE remains uncertain, they could 
facilitate development of targeted diagnostic and treatment approach. 
In conclusion, research is still ongoing to determine which of these 
findings is the cause rather than the effect of long-term usage of AEDs and 
recurrent seizures.  This uncertainty could be due to the heterogeneity of the 
DRE population itself. It becomes increasingly complicated when coupled 





before any hypothesis is confirmed to be the trigger of DRE, the current 
ensemble of AEDs, or antiseizure, remains our best weapons against DRE. It 
is henceforth important to design ways to optimize their usages. 
 
1.1.7 COMPLICATIONS FROM DRUG RESISTANT EPILEPSY 
Despite the use of multiple AEDs, it is self-explanatory that DRE 
patients will still suffer multiple recurrent seizures. This high occurrence of 
seizures has been shown to be directly involved in causing deaths of DRE 
patients, at an increased rate of approximately 1.37 per 100 person-years (130-
132). Aside from increased mortality, DRE individuals also have increased 
risk of disability from accidents, poor academic achievement, decreased 
employment and social isolation (133, 134). All these disadvantages have 
contributed towards the lower quality of life of PWE as compared to healthy 
patients (133, 135). 
In contrast, no increased mortality was observed in seizure-free patient 
(136). The quality of life of PWE also improved meaningfully when their 
seizure occurrence is ≤ 1 per year, highlighting the significance of rendering 
seizure freedom in PWE. These substantial observations have led to the 
recommendations of seizure freedom, avoidance of AEDs related side effects 
and improvement in quality of life as the treatment goals in PWE in general.  
To achieve these recommended goals, there is a complex interplay 
between the choices of drugs, access to mental care assistance and social 
encouragement in the form of job training as well as support from family 
members. Therefore, PWE have also to be equipped with self-financial ability 
or at least financial assistance from able bodies for those less fortunate. In the 
United States, the annual cost of epilepsy treatment is estimated to be 
US$5200 per patient (137). Although the estimated cost may not be applicable 





burden borne by PWE. This cost is expected to rise in those with DRE. 
Emphasis is hence required to be placed on appropriate and timely 
identification of DRE to prevent any complications from occurring or 
worsening, and overall, avoiding the rise in financial burden. 
 
1.1.8 RECENT CONSENSUS 
Recently, a joint task force of ILAE has recommended a detailed 
definition of DRE (50). In this definition, the PWE have to fail at least 2 
appropriately chosen AEDs which have been prescribed at adequate dosages 
for a sufficiently long duration for the treatment of their epilepsy syndromes. 
There are no restrictions of the class of AEDs used but they must have been 
approved by the relevant drug control authority for the use in any particular 
syndrome. Seizure freedom is also standardized to at least 3 times the previous 
seizure free interval or 12 months, whichever is longer. With this conformed 
definition, it allows for standardization of DRE categorization across regions.  
By having similar backgrounds of DRE, relevant treatment options that have 
been proven useful in other population could then be adopted in our settings. 
PWE, especially our DRE patients can then be assured that they are being 
evidently treated. Hence, in summary, after considering the debilitating effects 
and complications brought by DRE, it is of utmost importance for us to 
identify our own population’s rate of DRE and seek understanding in the drug 
resistant epileptogenesis in this group of patients, in order to design better 
treatment options in the future. Meanwhile, considering our current ensemble 







1.2 DRIED BLOOD SPOT (DBS) 
1.2.1 OVERVIEW OF DRIED BLOOD SPOT 
Dried blood spot (DBS) is a sampling method popularized since 1960s 
by Dr Robert Guthrie. As implied by its name, drops of whole blood are 
spotted onto a collection paper and allowed to dry in room temperature. 
Generally, the first drop of blood from any needle prick has to be discarded 
due to the presence of interstitial fluid. Subsequent well-formed drops, 
accumulated at consistent and sufficient volume (~ 30 to 50 µL), are to be 
spotted directly onto the pre-printed circle on the collection paper. Only one 
clean attempt per circle is allowed with neither smearing nor direct contact 
between skin and paper. Production and quality of the collection paper, the 
most widely used Whatman 903
®
, is in compliance with the Good 
Manufacturing Practices (GMP) and Food and Drug Authority (FDA) Quality 
System Regulation 21 CFR Part 820. In addition, 903
®
 is controlled for 
homogeneity of its cotton linters content with uniform thickness to ensure 
consistent flow rate, absorbency and purity of every blood spot. Each lot of 
903
®
 is a class II medical device and validated to meet Clinical and 
Laboratory Standards Institute (CLSI) LA4-A5 consensus standards which 
include blood spot diameter and paper weight. To minimize the risk of 
infection and enzymatic degradation of some blood components, a newer type 
of chemically-treated filter papers, FTA
®
DMPK-A and B, are introduced. 
However, clinically applicable methods developed using this filter paper is 
limited as compared to 903
®
 (138, 139). 
DBS was introduced for the screening of an IEM, phenylketonuria, in 
newborns (140).  It has since been extensively researched for its other 
potential applications such as screening for folate deficiency (141), 
hyperthyroidism (142), prostate-specific antigen (PSA) (143), human 
immunodeficiency virus (HIV) (144, 145) and recently, metabolite profiling 





be used to screen for a several IEMs in a single analytical step (147). DBS has 
also been adopted in the studies of drugs pharmacokinetics (148), therapeutic 
drug monitoring (149) and toxicokinetics (150).  
Plasma or serum is the current gold standard for clinical analysis of 
disease and drug monitoring in view that it contains almost all analytes present 
in the blood. Its collection process involves venipuncture for whole blood, 
followed by centrifugation and separation of plasma composition or 
immediate freezing until analysis. Venipuncture itself can be challenging due 
to inaccessible vein and relatively high amount of blood sample required, 
especially in population such as neonates, children and elderly. The amount of 
blood withdrawn will increase with the number of tests and incompatibility 
with relevant vacuum containers for different tests. 
DBS is formed from whole blood and theoretically should contain 
similar amount of analytes as plasma, if not more. The quantities, however, 
may differ, depending on its presence in capillary blood and stability on filter 
paper (146). The sample collection is relatively simple and noninvasive, 
involving a prick needle, similar to the one used by diabetic patients to 
measure their capillary blood glucose levels. This allows patient to collect the 
sample at home, especially in cases where set time point is crucial.  Since DBS 
does not require centrifugation or isolation, once dried at room temperature, it 
can either be mailed to hospital laboratory or kept in fridge/away from direct 
heat source until his next visit (151). Analytes of various physicochemical 
properties has been reported to be stable upon drying for a long duration of 
time, ranging from 30 day to 15 years (152-154). It is also relatively easy to 
store and transport, with minimum hazard to the carrier as compared to plasma. 
Therefore, we decided to explore DBS potentials as sampling matrices for 
epilepsy research studies. 
Nevertheless, many established clinical reference ranges were based on 
plasma levels and DBS levels are not directly comparable to serum or plasma. 





correction factors for the DBS values (155). Alternatively, a new reference 
range for DBS measurements can be proposed (156). In contrast to plasma 
samples where the sample quantity could range from 30 µL to above, one disk 
of punched-out blood spot (≤ 6 mm diameter) contains ≤ 15 µL of blood. The 
amount of information that could be recovered remains uncertain. There is 
also a possibility that the filter paper may adsorb some analytes and cause 
lower extractions. Moreover, the compositions of capillary blood where DBS 
is derived from may be different from the venous blood. The analytes of 
interest are therefore, required to be tested for reproducibility and validated for 
consistency prior to using DBS as sampling matrices. Depending on the nature 
of desired analytes, varying extraction solvent polarities may theoretically 
increase the extraction efficiencies. With the advancement in sensitive and 
robust detection technology such as the mass spectrometry, there is an 
exponential increase in the amount of information that can be recovered from 
a small specimen. The potential of analysing a ≤ 15 µL of blood spot as 
sample matrix is worth exploring.  
Research done using DBS are usually to detect and quantitate known 
analytes. It is rarely used for unknown analyte search such as biomarker 
search. Considering the limited experience most laboratory personnel have 
with DBS handling, it will be desirable for a simple and consistent analysis 
procedure development to facilitate its implementation across various 
laboratories.  
In the subsequent section, we will discuss the utilities of DBS in both 









1.2.2 DRIED BLOOD SPOT IN PHARMACOKINETIC STUDIES 
DBS represents an alternative that overcomes many of current 
plasma/serum sampling problematic issues such as: 
1. Stability of metabolites in plasma or blood samples after 
acquisition  
2. The deeper needle penetration to obtain venous blood which 
could be unbearable for ‘needle phobia’ patients 
3. The requirement of a phlebotomist to withdraw blood 
4. The higher cost and cumbersome logistic considerations 
associated with for plasma and blood samples  
As discussed in the earlier section, the small amount required for one 
DBS makes it attractive to preclinical as well as clinical pharmacokinetic 
studies where multiple time point of sampling and precise timing are required 
to elucidate the drug’s PK characteristics. Similarly, it will facilitate sampling 
from neonates, premature infants and the critically ill patients as well as small 
animals such as mice or rats. In animal study, the lower amount of blood 
required per sampling may also translate into less number of animals required 
per study by reducing the need to sacrifice more animals. These advantages 
had enticed pharmaceutical companies such as Glaxo Smith Kline (GSK) to 
adopt DBS sampling in some of their preclinical pharmacokinetic and 
toxicokinetic studies (148). 
Review paper by Li et al. outlined various drugs that had established 
its DBS monitoring (157). These drugs included antiretrovirals such as 
efavirenz, nevirapine, atazanavir, indinavir and ritonavir, barbiturates such as 
lorazepan, diazepam and nitrazepam, opiods such as morphine and cocaine, 
immunosuppressants such as cyclosporine and tacrolimus, antiepileptics such 
as topiramate and phenobarbital as well as common overdosed drugs such as 
acetaminophen. The type of filter paper use varies, with Whatman 903® being 





mm in diameter. Generally, the research aspect involves either assay 
development (148, 158, 159) or clinical validation with plasma/whole blood 
concentration comparisons (160-162). Clinically validated assays have the 
advantage of immediate applicability. Nevertheless, findings from either type 
of study demonstrated the suitability of DBS for PK study for drugs of varying 
properties. 
Clinical validation involves concurrent quantitation of the analyte of 
interest using capillary DBS assay and the currently accepted standard of 
practise e.g. plasma immunoturbidimetric quantitation of antibiotics and whole 
quantitation of cyclosporine. Due to logistical issue, many studies collected 
whole blood from venipuncture, and prepared DBS using this same pool of 
blood (161-163) before centrifugation to collect its plasma for routine clinical 
measurement. This method facilitates the sample collection procedure (as 
patient will not be pricked twice) while allowing uniform blood spotting with 
pipetting tools. Although theoretically there could be some differences 
between capillary and venous concentrations, the differences for a majority of 
xenobiotics are not obvious, especially after the distribution phase (164-166).  
 
1.2.3 DRIED BLOOD SPOT IN METABOLOMIC PROFILING 
As for detection of disease related information, based on some of the 
research conducted so far, metabolites, proteins and genes seemed to be 
extractable from DBS. Generally the extraction procedures involve the usage 
of specific solvents to selectively recover the desired analyte. This solvent can 
be an additional solvent or a similar solvent used in blood/plasma extractions. 
For example, phosphate buffered saline (PBS), 0.5% Triton X-100 was used as 
washing solution to dissolve relevant genes and proteins at the start of HIV-1 
proviral DNA extraction from DBS (145). After shaking, incubation and 
centrifugation, subsequent amplification steps are similar to the routine whole 





For a profiling study, such as biomarker/s search, a universal solvent is 
proposed to yield as many compounds from the DBS as possible (146). To be 
thorough, subsequent extraction/s using solvent of differing polarity may be 
considered to yield more compounds. A recent approach using dried biofluid 
spots from blood, plasma and urine concluded that biofluid spots can be an 
alternative for metabolite profiling. The number of ions/compounds detected 
could be significantly lower than their conventional plasma counterparts, but 
may be overcome by optimising the extraction procedures (146). The study, 
however, was done in ultra performance liquid chromatography and 
orthogonal acceleration time-of-flight mass spectrometry (UPLC-oaToFMS), 
with electrospray ionization (ESI) without metabolite putative identities. 
Although liquid chromatography (LC) provides better selectivity than 
immunoassays for different analytes, with the unknown metabolites, there is 
limited capability for immediate clinical interpretation and application.  
Gas chromatography with mass spectrometric detection is generally 
more reproducible and robust due to its hard ionization nature as compared to 
LC-MS. This characteristic has allowed the construction of metabolites and 
analytes reference libraries such as the Fiehn, Wiley and National Institute of 
Standards and Technology (NIST) library of mass spectrum fingerprints which 
are unique to each individual compound.  The putatively identified compound 
can then be compared with the pure standards to confirm its identity. For 
biomarker/s search, GC-MS presents an enticing method of analysis. 
Nonetheless, this advantage ought to be balanced with the more complex GC-
MS sample preparation which involves derivatization as well as overall longer 
analytical run time (167, 168). If the identity search is the aim of study, GC-








1.3 CHAPTER SUMMARY 
This chapter has provided background on epilepsy, related treatment 
drugs and the current challenges in epilepsy management, which included 
drug resistant epilepsy as well as unavailability of effective disease modifying 
agents. The reported DBS usages in disease and treatment monitoring had also 
been discussed. In the following chapters, some of these challenges would be 
















CHAPTER 2. OBJECTIVES  
2.1 RATIONALES 
Thus far, some of the challenges observed in the field of epilepsy 
which have been discussed in Chapter 1 included: 
1. Approximately 20% to 40% of PWE will have DRE in their lifetime. 
Risk factors for DRE may differ according to populations and ethnicity. 
DRE in Asians has not been extensively evaluated. In addition, 
differing definitions for DRE used in different studies make direct 
comparison of their findings difficult. As a result, findings from each 
study may not be representative of the epilepsy population in other 
settings, such as in Singapore. 
2. Epilepsy is a multifactorial disease involving both genetic and 
environmental factors. The epileptogenesis of DRE is largely unknown, 
although there are a few hypotheses for DRE. Before any hypothesis is 
confirmed to be the trigger of DRE, and selective treatments for those 
triggers are developed, the current ensemble of AEDs, or antiseizure, 
remains our best armaments against DRE.  
3. The time of sampling for epileptogenesis studies seems crucial in 
understanding of epileptogenesis as well as seizure occurrences. To 
illustrate, sampling should be obtained: 
a. Directly before or after seizure attacks for seizure biomarker 
search 
b. During interictal phase for biomarkers of epilepsy. Comparison 
should be made with healthy subjects 
c. During interictal phase for biomarker of drug resistant epilepsy. 
Comparison should be made with drug responsive subjects 






e. Before and after developing epilepsy or before and after curing 
epilepsy for biomarker of epileptogenesis 
4. Biomarkers for human antiepileptogenesis are favourable as the 
changes can be objectively and timely monitored (64-66). The 
currently researched independent biomarkers involved the 
microseizures and specific intracranial EEG spike patterns that are 
present before seizure attacks (64-66). Both biomarker detections 
required trained epileptogeneticist or EEG technicians and 
sophisticated technology that may not be readily available in many 
healthcare facilities 
5. It remains uncertain whether there is a temporary decrease in plasma 
AEDs levels before or after a seizure attack as it is difficult for plasma 
sampling right after a seizure attack 
6. Overall, clinical trials for antiepileptogenesis are difficult and costly to 
conduct. The currently available first line treatment drugs such as VPA, 
CBZ and PHT will likely be the mainstay of treatment for years to 
come. It is henceforth important to design ways to optimize their 
usages 
7. Serum concentrations of the first line AEDs displayed strong 
correlation with their efficacy as well as side effects. Comprehensive 
PK characterizations of AEDs via relevant biofluids are part of 
regulatory requirements. Population pharmacokinetic (PPK) 
parameters estimation of these AEDs is one possible way to optimise 
their dosing efficiencies 
8. Current plasma or serum sampling for both metabolomic profiling and 
PK study does not ease time point compliance. The lengthy and 
delicate sample acquisition and storage may result in missing the 
critical window period for acquisition. There is a need for alternative 
sampling method, preferably one which patients or carers can obtain 
by themselves, such as dried blood spot, where sampling can be done 







Based on the challenges and rationales observed, it is hypothesized that: 
1. Drug resistant epilepsy (DRE) is a significant ongoing issue in 
Singapore population of people with epilepsy (PWE). It is of utmost 
importance for us to identify our own population’s rate of DRE  
2. Epileptogenesis of various origins, genetic, structural-metabolic and 
unknown, do converge at neurometabolite expressions immediately 
before triggering seizures. Metabolomic profiling during interictal 
phase will provide some useful insights into baseline metabolite 
perturbations involved in drug resistant epileptogenesis and dried 
blood spot (DBS) is a good surrogate to plasma sampling for this 
approach 
3. DSB can also be used for therapeutic drug monitoring of AEDs. An 
accurate conversion factor for each AED could be obtained by 
comparing the DBS to plasma concentrations from clinical samples. 
The plasma and whole blood concentrations are hypothesized to be 
different because of the presence of red blood cells in whole blood and 
partition into erythrocytes or red blood cells. Once the conversion is 
validated, DBS sampling can be obtained by patient/care themselves 
during or post seizure. 
4. Similar to plasma, DBS concentrations can be utilized to derive 
reliable population pharmacokinetic parameters. With this approach, it 
is hypothesized that there is a more direct dose-DBS concentrations 







The overall objective of this thesis is to investigate the utilities of dried 
blood spots in metabolomic and pharmacokinetic studies related to epilepsy. 
This is in hope to facilitate implementation of DBS sampling method for 
population based research in the area of epilepsy, in particularly the 
pharmacotherapy and drug resistant cases. The specific objectives of each 
experiment designed are as follows: 
1. To determine the drug resistant epilepsy prevalence study among 
people with epilepsy in a tertiary referral hospital in Singapore 
 In line with hypothesis 1, the findings will also provide insight 
of possible risk factors involved in developing DRE to gauge if 
metabolomics is a suitable platform. This study is described in 
Chapter 4 
2. To evaluate the use of DBS for metabolites detection in GC-MS 
 This is conducted in part of hypothesis 2. DBS detected 
metabolites have to be firstly proven to be reproducible and 
stable. This work is presented in Chapter 5 
3. To discern the interictal metabolomic profiles between drug resistant 
and drug responsive PWE using the DBS  
 In line with hypothesis 2, the putatively identified 
discriminating metabolites will be highlighted in Chapter 6  
4. To obtain factors to correct DBS measured AED concentrations to its 
predicted plasma concentrations 
 For hypothesis 3, concurrent DBS and plasma quantitation of 
AEDs from PWE will be compared. A previously validated 
assay for simultaneous monitoring of 3 most commonly used 
AEDs in our population of PWE will be used. DBS 
concentrations of AEDs will be measured in GC-MS and 
correlated with its plasma concentrations measured in hospital 





explaining the differences observed will also be investigated. 
Chapter 7 detailed the results obtained. 
5. To characterize PPK parameter using DBS measured antiepileptic 
concentrations  
 This study is designed to test the hypothesis 4. DBS 
concentrations will be subjected to PPK modelling to gauge 
their usefulness in therapy optimization. The comparative 
findings with plasma derived PPK parameter will be discussed 
in Chapter 8 
 
2.4 SCOPE 
To facilitate future applicability, the reliability of DBS and relevant 
assays for both AEDs monitoring and metabolomic profiling of DRE will have 
to be demonstrated. Active PWE who are having venous sampling for 
therapeutic drug monitoring on the visit day will be recruited. As most of these 
patients are at the interictal phase, the metabolite perturbations observed are 
likely to represent the baseline levels of the disease state rather than causal of 
DRE. 
The objective of the animal experiment presented in Chapter 5 was to 
establish that DBS is a suitable matrix for metabolomics study. Rats are 
homogenously bred and were chosen in favor of healthy subjects. This is 
because the definition of healthy subjects could be plagued by a few 
limitations: (1) What is the suitable age range of healthy subjects and where to 
locate as many of them within the study period? (2) For homogeneity, should 
they all be of one race, and which race should be chosen in favor of another, 
and if not, how to ascertain that the heterogeneity observed was not due to 
ethnicity differences? Although rats and humans are different species, their 
metabolite profiles should be comparable in contents as both of them are 





as a platform for metabolomic study rather than establishing the set of 
metabolites that can be detected via DBS. It would be detrimental to the study 
if it was found later that many analytes were not easily extractable from the 
DBS. As outlined in that experiment, it is impractical to assess the recovery of 
every metabolite. In return, three analytes with differing physicochemical 
properties were tested. The results suggested that irrespective of the 
lipophilicity and hydrophilicity of the metabolites, they are extractable from 
DBS in consistent quantities. Extrapolated to metabolites in human blood, they 
also comprise compounds of various physicochemical properties and the 
consistent recoveries could be expected. 
The temporal effects were considered in the animal study (Appendix 
II). As a whole, the related metabolome fluctuations were too subtle to be 
distinguished. Whether or not human samples would yield the same findings 
remains to be investigated and for the purpose of this research work, the 
timing of blood acquisition from subjects was confined to between 9 am and 
12 pm only.  
As for the prandial effects, metabolomics in nutrition is a new and 
unique field by itself and has to involve gut microbiome study in order to 
discuss its effects, which is beyond the scope of this study. Nevertheless, it 
will be good to include this as one of the potential covariate in future studies.  
At the same time, to avoid pricking the same subject twice, the 
concentrations from venous plasma to venous dried blood spot will be 
compared. This method has the advantage of uniform blood spotting via 
pipetting, and hence, ensuring more precise measurements and direct in vivo 
correlations (161-163). Although theoretically there could be some differences 
between capillary and venous concentrations, the differences for a majority of 
xenobiotics are not obvious, especially after the distribution phase (164-166). 
Although the sampling can be done concurrently, two different GC-MS 





metabolomic profiling, the aim is to search for potential biomarkers. Hence, to 
detect as many analytes as possible, exploratory GCMS approach was utilized 
whereby no optimization for any analyte is performed. In the AEDs PK study, 
the aim is for correlation between DBS and plasma concentrations of CBZ, 
VPA and PHT. Accurate quantitation is of more importance and hence, a 
targeted approach is utilized whereby the assay is optimized for quantitation of 
these specific analytes. Nevertheless, after affirmation of the target 
metabolites i.e. biomarkers, a combined GCMS assay for both the metabolites 
of interest as well as AEDs can be developed.  
Then, PPK modelling will be attempted to estimate the 
pharmacokinetic parameters of CBZ using DBS concentrations. Since AEDs 
have narrow therapeutic indexes, the precise dose-whole blood concentration 
relationship elucidation is essential in ensuring maximum efficacy but 
minimum toxicity. PPK for VPA and PHT were not performed due to the 
relatively small number of available observations. Moreover, unfortunately, 
neurologists in Singapore do not routinely monitor the free drug levels of 
AEDs. Therefore, this aspect could not be included into the comparison and 
correlation investigations. 
The findings from this study are hoped to ultimately convince the 
patients, clinicians and authorities that DBS sampling is reliable. Subsequently, 
in the future, researchers can embark on population-based research, where 







2.5 THESIS OUTLINE 
With referral to the experiments outlined in the Objectives section, 
generally, there are two main research questions in this thesis; the utility of 
DBS in metabolomic profiling and the utility of DBS in pharmacokinetic 
study. In congruent with the research questions, the layout for the 
experiments conducted in this thesis write up is vertically-linked initially, 
followed by horizontal linking within each research question arm.  
Since patient data collection and recruitment were done concurrently 
for most of the projects, their simplified descriptions are attempted in the 
Methodology chapter. Some of the technical analysis may have been missed, 
but will be explained in detail in their individual experimental chapters. For 
each study, a chapter introduction will be provided, followed by its methods, 
results, discussion and chapter conclusion. Thereafter, all these findings will 
be summarized and related  to the objectives in the final Conclusion chapter. 






















Figure 1. Simplified workflow of the entire thesis. After the initial assay validation, 
the two research arms converged at the subject recruitment and data collection. 
Two dried blood spots were obtained from each recru ited subject; one for 
metabolomic profiling, one for pharmacokinetic study. The analyses differ and will 
be explained in Chapter 5 and 6 for metabolomic profiling and Chapter 7 for 
pharmacokinetic study. The acquired data will then undergo different proces sing 
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This flow chart outlines the workflow of the entire thesis (Figure 1). 
An assay that can simultaneously quantitate the AEDs of interest from DBS 
was firstly developed and validated. To correlate this method of quantitation 
with the current standard immunoassay quantitation done in hospital 
laboratory, clinical samples were required. If DBS can quantitate the AEDs as 
accurate, the methods should be comparable to each other. Similar approach 
was adopted for metabolomic profiling. Before clinical samples were analyzed, 
3 animal studies were designed to establish that DBS can indeed monitor a 
range of metabolites and detect in vivo metabolomic perturbations. These 3 
models involved healthy rats, valproic acid treated rats as well as mice treated 
with p-glycoprotein inhibitor. The summarized results for the latter two animal 
studies are presented in Appendices I and II. 
The patients’ recruitment process for the two research arms was 
conducted simultaneously in Singapore General Hospital (SGH) from 1 
October 2011 until 31 December 2012. Both studies were approved by 
SingHealth Institutional Review Board (IRB). Figure 2 illustrates the overall 
division of recruited patients according to the different study requirements.  
After the end of recruitment process, DBS collected was analyzed. The 
results were later subjected to statistical compilations. Finally, their clinical 












Figure 2. Schematic representation of the patient recruitment and data collection 
processes. A total of 655 people with epilepsy (PWE) visiting neurology clinic in 
Singapore General Hospital (SGH) was screened, 557 fulfilled the pre -determined 
set of criteria and were included in drug resistant prevalence (DRE) prevalence 
study. Out of this pool of PWE, 244 consented to participate and donate blood 
spots for our research. There were 189 PWE who had TDM on their visit day, and 
were included in both the pharmacokinetic (PK) and metabolomic (Mb) studies, 
while another 55 agreed to donate finger prick blood spots instead of venous 
blood in view that they do not require any monitoring on the visit day. After 
careful stratification, 169 DBS were included in PK study, while 142 DBS were 





DBS analysis criteria 
1. PK study  
 - Plasma concentration must 
    be available from hospital 
    laboratory system 
2. Mb study  
 - Drug responsive or drug 
    resitant categories only  
On visit day  
1. Have TDM for CBZ, PHT and/or VPA  
 - recruited for PK & Mb study 
2. Do not have TDM but agreeable for         
      finger prick  
 - recruited for Mb study only 
DRE Prevalence Study 
All PWE under regular follow up in 
SGH 
 




Eligible for PK 
study 
169 DBS 






Eligible for Mb 
study 
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CHAPTER 4. PREVALENCE OF DRUG RESISTANT 
EPILEPSY IN A TERTIARY REFERRAL HOSPITAL IN 
SINGAPORE  
With reference to the first objective, the prevalence of DRE in local 
population and the associated risk factors are proposed to be determined. 
Findings from this study will aid in gauging whether metabolomic profiling is 
a suitable platform for biomarker search in this target group. 
 
4.1 CHAPTER SUMMARY 
The objective of this study is to determine the proportion of DRE in an 
adult PWE population in Singapore. The objective of this study is to determine 
the proportion of DRE in an adult PWE population in Singapore. All adult 
PWE attending the neurology specialist clinic of a tertiary referral hospital in 
Singapore were profiled for drug responses according to the International 
League against Epilepsy (ILAE) 2010 consensus on the definition for DRE. 
This is a retrospective cohort study. Data collected were demographics, 
characteristics of seizure and epilepsy, blood biochemistry levels, 
electroencephalogram and brain imaging findings, and medication histories. 
The types and dosages of AEDs used were retrieved from case notes. 
Routinely assessed treatment-related adverse effects were categorized in 
congruent to previous publication by Carreno et al, 2008 (169). The dates and 
number of seizures at the start, during and end of each treatment regimen as 
well as at the prevalence date were retrieved. They were later classified as 
daily, weekly, biweekly, in monthly intervals till 6-monthly, followed by 
yearly and rarely. Generally, the most frequent occurrence of seizure is chosen 
to represent the subject’s seizure frequency.  The prevalence rate of DRE in 





free at the point prevalence day (n=557). From multivariate analysis, 
structural-metabolic etiology [odds ratio (OR) 1.78, 95% confidence interval 
(CI) 1.003 – 3.148], mental retardation [OR 2.51, 95% CI 1.073–5.863], 
psychiatric illnesses [OR 3.349, 95% CI 1.181 – 9.501] and pre-treatment 
seizure frequency of more than once monthly [OR 2.775, 95% CI 1.190 – 
6.469] were more likely to have DRE ( p ≤ 0.05). Even though the influence of 
Indian race on the risk of DRE was only found in the univariate analysis, it 
warrants investigation in a larger cohort. The findings may aid policy makers 
in designing treatment guidelines and allocating resources for PWE, in light of 
the situation that at any given time, 1 in 5 PWE had DRE. Based on the 
significant risk factors found in this study, genetic factor may not provide a 
holistic explanation for DRE and metabolomics could complement the 
knowledge in DRE pathogenesis by providing immediate causal or effect of 
frequent seizures in this group of subject. 
 
4.2 CHAPTER INTRODUCTION 
Epilepsy, and to a more severe extent, DRE brings about incapacitation 
to PWE. These unwanted effects include physical and mental disabilities 
which may lead to lower quality of lives (170, 171). It is hence, of prominence 
to identify these PWE to design better management strategy that best suit them. 
Research done so far has identified a few DRE predictors, namely 
symptomatic/cryptogenic syndromes and high number of seizures prior to 
treatment initiation (106, 172, 173). Their populations differ with either 
pharmacotherapy naïve adults or long term follow up children patients. These 
studies were done on Caucasians and Asian ethnicity may have been 
overlooked as a factor. Chinese PWE in Hong Kong were shown to have a 40% 
prevalence of DRE in their population and that poor control was associated 
with mental retardation and mesial temporal sclerosis, a finding that were 





similar risk factors extend to long term follow up Asian PWE, which includes 
Malays and Indians.  
Nevertheless, the definition of ‘refractory’ or ‘resistant’ was somewhat 
different among the studies, hindering direct comparisons. With the formation 
of a consensus for the definition of DRE by ILAE consensus (50), we aim to 
utilize this classification to determine the proportion of DRE patients in our 
PWE population and correlate patient specific characteristics with the seizure 
outcome. This is in hope to unravel pertinent risk factors for developing DRE.  
 
4.3 METHODS 
4.3.1 STUDY PATIENTS 
A study sample of 288 PWE was required to estimate a 25% (relative 
precision of 5%) prevalence rate of DRE with 95% confidence interval (174).  
Therefore, a tertiary referral hospital in Singapore with a PWE population of 
approximately 600 was chosen as the study site. This hospital was chosen as it 
is a public institute with neurological department that caters for suspected and 
confirmed epilepsy cases, regardless of severity, from the whole Singapore 
population, including referrals from inpatient admission, primary care 
providers, other hospitals and overseas.  These subjects were evaluated and 
treated locally by the same team of specialists, ensuring reliable registry and 
routine clinical assessment. Rarely, PWE chose to be seen in other institutions 
instead of this clinic due to proximity and shorter waiting time, with no direct 
connection to seizure control. Hence, despite being relatively accessible from 
the whole country, the study subjects were most likely representing the PWE 
population within the catchment area of Singapore General Hospital. The drug 





Institutional Review Board approval was obtained before study initiation 
(CIRB No: 2011/268/A).  
 
4.3.2 CASE DEFINITION AND ASCERTAINMENT 
Subjects were identified from hospital neurology-specialist-clinic 
appointment system as all neurology cases will be registered under this system. 
A list comprising of 632 epilepsy cases, indexed with identification number 
were retrieved.  This study comprised of subjects above the age of 18 years as 
it was the starting age for follow up cases in this adult population, inclusive 
those discharged from paediatric follow-up elsewhere in Singapore. A final 
total of 557 subjects, being alive and reside within the catchment area were 
included after assessment by the attending neurologist.  
Epilepsy is defined as the occurrence of two unprovoked seizures. It 
was part of the clinic’s routine investigative procedures to incorporate 
biochemical tests, EEG and structural/perfusion/diffusion MRI or CT scan of 
the brain for each subject. The interpretation and revision of EEG was always 
done by the certified EEG technician and attending neurologist for EEG, while 
MRI and CT scan was by the radiologist and neurologist. Etiology of 
epilepsies was reported as genetic, structural-metabolic or unknown, while the 
seizures were focal, generalized or unknown, in accordance to the ILAE 
revised terminology (12). Classification was done retrospectively. Genetic 
epilepsy was revised from idiopathic epilepsy and represents epilepsies with 
presumed genetic origin such as dravet’s syndrome and juvenile myoclonic 
epilepsy based on typical clinical, EEG and MRI findings. Structural-
metabolic epilepsy described the epilepsies resulted from known structural 
lesions in the brain such as atrophy, cortical dysplasia, tumour or stroke, as 
evidenced by radiological imaging and metabolic disorder of the brain such as 





abnormality, it will be categorized as unknown. In subjects with a few seizure 
types, seizure classification was based on the principal seizure type. For 
example, if the subject predominantly had generalized tonic-clonic seizure but 
complained of 2 fainting episodes for the past month, his seizure classification 
will remain as generalized seizure. Other generalized seizures most often seen 
in this study include absence, myoclonic and clonic. Subjects with 
simple/complex partial seizure and auras were redefined as focal seizures. 
Epileptic spasms and unclassified seizure types were referred as unknown.  
In our neurology clinic, PWE were routinely assessed for clinical 
symptoms, seizure occurrences and frequencies, compliance, response and 
adverse drug reactions to antiepileptic drug treatments. Hence, the 
appropriateness of AED for the particular epileptic seizure type was assessed 
based on evidences (175-181) and guidelines (182-184). Data collected were 
inclusive of subjects’ demographics, pretreatment seizures, baseline seizures 
prior to the latest AED intervention and current seizure frequencies. Seizure 
frequencies were recorded and classified into occurrence of at least one 
seizure in daily, weekly, biweekly and in monthly intervals till 6-monthly, 
followed by yearly and rarely. Generally, the most frequent occurrence of 
seizure is chosen to represent the subject’s seizure frequency. For subjects 
with multiple visits over the study period, the clinical assessment from the 
latest visit before the end of study period was used for drug response 
determination.  The following AEDs are available locally:  carbamazepine, 
phenytoin, sodium valproate, phenobarbitone, primidone, clobazem, 
clonazepam, lamotrigine, levetiracetam, topiramate, gabapentin and pregabalin.  
 
4.3.3 DRUG RESPONSE CLASSIFICATIONS 
The recommendations by the ILAE were adopted to define DRE in our 





treatment response (Level 1). Secondly, by summing all the Level 1 responses, 
an overall classification of either drug responsive, drug resistant or undefined 
will be determined (Level 2). Seizure freedom was standardized to at least 3 
times the previous seizure free interval or 12 months, whichever was longer, in 
accordance to the ILAE consensus. Drug resistant was characterized by failure 
of at least two appropriate AEDs, which have been prescribed at adequate 
dosages for a sufficiently long duration for the treatment of their epilepsy 
syndromes. Therefore, a drug resistant PWE will have at least two Category 2 
(treatment failure) outcomes from Level 1 categorization. Any deviation from 
these conditions will render the PWE to have ‘Undefined’ overall response to 
his AED/s therapy.  
It was therefore, recognized that PWE responses to AEDs therapy at 
any particular period of life were not confined to either seizure free or drug 
resistant only. There could be multiple reasons that caused them to be in 
neither category. To further comprehend our PWE’s well-being and better 
design management plans for the future, we attempted to identify some 
possible explanations. These include PWE’s decision in pharmacotherapy 
such as choosing their preferred AED/s and the comfortable dosages.  A pre-
determined checklist with a total of 7 items was formulated, namely failure to 
one AED only, insufficient dose of either 1 or more AEDs, less than 3 times 
the previous seizure free interval, incompliant, new intervention for less than 6 
months, one seizure occurrence after a seizure free period and absence of all 
required information (Table 4). In short, subject’s response to his latest AEDs 
regimen in the ‘Unknown’ group can also be divided into two: (1) with 
ongoing seizure and (2) without seizure (refer Table 3). These items were 
designed to be mutually exclusive.   
Clinically effective dosages are determined with reference to the 
World Health Organization (WHO)’s defined daily dose (DDD) (185). 
However, the individual maximum tolerated dose due to adverse drug 





attainment of therapeutic levels without ADR should not hinder the dosage 
increment in PWE with clinical seizure. In fact, dosage increment was 
observed in our study population despite sufficient TDM levels. Nevertheless, 
as TDM levels were used to approximate individual sufficient AED dosages in 
many clinical settings, we also consider that the dose was the clinically 
effective dose when therapeutic level was reached; and treatment failure if the 
PWE still had seizure (Level 1, Category 2).  
 
4.3.4. STATISTICAL ANALYSIS 
Demographics data collected such as age, gender, race, type of 
epilepsies and seizures, age of seizure onset, baseline seizure frequencies 
before treatment, types of AED used, concurrent illnesses, findings from brain 
imaging and EEG. SPSS version 21 was used for analyses. Chi-square test was 
utilized for categorical variables with counts more than 5 in one category, 
while Fisher’s Exact test was considered when there were less than 5. 
Independent t-test was used for continuous variables. Statistical significance 
was determined when p ≤ 0.05. To examine the risk factors of DRE, all 
covariates from both the seizure free and drug resistant groups of PWE were 
firstly subjected to univariate binomial logistic regression analyses. The 
significant covariates (p < 0.05) were then analyzed using multivariate 
binomial logistic regression analyses to estimate individual odds ratio. Co-












4.4.1 STUDY POPULATION 
As can be seen from Table 2, there were similar number of male and 
female PWE, 274 (49.2%) and 283 (50.8%), respectively. Our patient group 
had an average age of 42.7 years (range 12 – 90 years) and the mean duration 
of follow up was 12 years (range 1 – 28).  Majority of the PWE was Chinese, 
77.2%, while approximately 7.4% each were the Malays, Indians and other 
races. The most common etiology of epilepsy in this group of PWE was 
structural-metabolic, 51.2%, followed by unknown (previously defined as 
cryptogenic), 32.9% and genetic, 16%. Among the structural metabolic, 8.4% 
had a latest MRI finding that was reported to be normal while 34.7% had 
etiology originating from mesial temporal sclerosis, 10.5% from atrophic 
region of the brain and only 2.1% from dysplasia. However, it is noted that 
11.9% of this group of PWE did not have an MRI of the brain. They had 
predominantly manifested focal seizures, 61.4%. The rest were classified as 






Table 2. Characteristics of study subjects 
Demographic Factors  n % 
Ethnic  Chinese 430 77.2 
 
Malay 43 7.7 
 
Indian 40 7.2 
 
Others (Sikhs, Filipinos, Burmese & Caucasians)  41 7.4 
Gender  Male  274 49.2 
 
Female 283 50.8 
Age (years) Median 42 (Range 16 – 90 years old)  Mean 42.7 SD 13.99 
MRI Findings  Normal  149 26.8 
 
MTS  103 18.5 
 
Others  134 24.1 
 
Not Available 171 30.7 
Etiology Genetic 89 16.0 
 
Structural-Metabolic 285 51.2 
 
Unknown 182 32.7 
Seizure  Focal seizure 342 61.4 
Type  Generalized seizure 191 34.3 
 
Unknown 24 4.3 
No of AEDs  Monotherapy  263 47.2 
 
Polytherapy  288 51.7 
 
Not on any AED 6 1.1 
ILAE Level 2  Drug Responsive 228 40.9 
Classification  Drug Resistant  120 21.5 
 
Undefined 209 37.5 
Age is presented as mean ± standard deviation (SD) 
 
The concurrent illnesses were rare and considerably diverged. With 
reference to previous reports on possible risk factors, mental deficiency were 
recorded in 47 PWE (8.4%) and any form of psychiatric illnesses such as 
depression and anxiety were documented in 33 PWE (5.9%). Due to small 







4.4.2 PREVALENCE OF DRUG RESPONSIVE AND DRUG 
RESISTANT EPILEPSY 
A majority of subjects, 228 (40.9%), in this setting was seizure free or 
drug responsive, as defined by ILAE consensus. On the other hand, drug 
resistant epilepsy had a 21.5% prevalent rate in our study population. The age-
specific prevalence, as presented in Figure 3, depicts the prevalence rates for 
both drug responsive and drug resistant. The DRE prevalence rate increased 
from 20% in the 20 – 29 years old group to the highest of 25.8% in the forties 
group and decreased thereafter, to approximately 5% in the elderly (≥ 70 years 
old). Chi-square cross tabulation analysis revealed that only PWE in the age 
group 60 to 69 years was significantly less likely to be drug resistant as 
compared to the other age groups (p ≤ 0.005). The age of seizure onset was in 
fact, significantly younger in drug resistant subjects, median of 12.5 (range 0.3 
– 54) years old, than drug responsive subjects, median of 18.0 (range 0.1 – 86) 
years old (p < 0.001).  
 






4.4.3 RISK FACTORS ANALYSIS FOR DRUG RESISTANT 
EPILEPSY 
From the initial univariate analysis, PWE who were Indians, mentally 
deficient or had concurrent psychiatric illnesses, structural-metabolic epilepsy, 
presence of mesial temporal sclerosis from brain MRI and a baseline seizure 
of at least once a month or a year, but not in between, were at increased risk of 
developing DRE (p < 0.05). Younger age of seizure onset also posed 
additional risk to developing DRE.  After undergoing multivariate analysis, 
Indians, mesial temporal sclerosis and baseline yearly seizure were no longer 
significant risks (p > 0.2). The relevant odds ratio and p values are tabulated 















Table 3. Univariate and multivariate logistic regression analyses of risk factors for 







OR 95% CI p value OR 95% CI p value 
Male 0.76 0.487 - 1.182 0.222 
   
Chinese 0.63 0.364 - 1.081 0.093 
   
Indian 3.73 1.345 - 10.363 0.011 2.083 0.653 - 6.643 0.215 
Family History of Epilepsy 0.89 0.391 - 2.037 0.786 
   
Baseline seizure at diagnosis 
      
     ≥ 1 / month 5.30 3.139 - 8.958 < 0.001 2.775 1.190 - 6.469 0.018 
     ≤ 1 / year 0.78 0.010 - 0.591 0.013 0.267 0.033 - 2.156 0.215 
Brain imaging 
      
     MTS 2.01 1.167 - 3.447 0.012 1.445 0.730 - 2.862 0.291 
     Normal 0.62 0.372 - 1.047 0.074 
   
ILAE Etiology Classification 
    
     Genetic 0.62 0.323 - 1.193 0.153 
   
     Structural-Metabolic 1.73 1.103 - 2.703 0.017 1.777 1.003 - 3.148 0.049 
     Unknown 0.00 NA 0.997 
   
ILAE Seizure Classification 
    
     Focal seizure 0.68 0.434 - 1.063 0.091 
   
     Generalized seizure 1.55 0.986 - 2.44 0.057 
   
Concurrent Illnesses 
      
     Mentally challenged 4.43 2.067 - 9.489 <0.001 2.509 1.073 - 5.863 0.034 
     Psychiatric illnesses 3.34 1.344 - 8.305 0.009 3.349 1.181 - 9.501 0.023 
Age of Seizure Onset 0.96 0.938 - 0.975 <0.001 0.96 0.940 - 0.981 < 0.001 
(OR denotes Odds Ratio; CI denotes confidence interval; NA denotes not available) 
 
4.4.4 PREVALENCE OF UNDEFINED CATEGORY OF PWE 
Approximately 37.6% of PWE were classified as ‘undefined’. After 
careful consideration of the reasons that were best suited to describe individual 
clinical progress, the accepted causes for our PWE to fail attaining seizure 
freedom were identified and presented in Table 4. From our observations, this 
group of PWE had, to the point of this study, been determined to have failed 
only one AED that was prescribed at the adequate dose for a sufficiently long 
period of time (40.2%). This group of subjects could still be on the same drug, 





recently changed to another AED. However, failure was only considered in 
one AED. On another note, inadequate dose/s of current AED/s was observed 
in 65 subjects (31.1%), in which 25 of them were acknowledged by the 
attending neurologist to have declined dosage increments.  
 
Table 4. Reasons for patients with epilepsy (PWE) to be categorized as ‘Undefined’  
Reasons for the 'Undefined' n (%) 
Failed one drug only 84 (40.2%) 
Insufficient dose of either 1 or more AEDs  
     Refusal by patient 
     Titration phase 
25 (12.0%) 
40 (19.1%) 
Less than 3 times previous seizure free interval 18 (8.6%) 
Incompliant 6 (2.9%) 
New intervention (< 6 months) 4 (1.9%) 
Only one seizure occurrence after a seizure free period  25 (12.0%) 
Absence of all required information 1 (0.5%) 
 
4.4.5 ADVERSE DRUG REACTIONS  
In agreement with the ILAE recommendations, there is a clinical 
difference between seizure free patients who suffered considerable extent of 
adverse drug effects (ADRs) and those who did not. Therefore, the frequencies 
of adverse drug reactions were recorded for all patients and summarized in 
Figure 4. Subgroup analysis revealed statistically significant higher incidences 
of ADR in DRE subjects as compared to their seizure free counterparts, 23.3% 






Table 5. Types of adverse reactions reported by people with epilepsy (PWE) and 
the frequencies of occurrences according to the drug response categories  
Adverse Drug Reactions 
 Drug Responsive Drug Resistant Undefined 
n % n % n % 
Sleepiness 1 5.0 5 17.9 2 7.4 
Fatigue 0 0.0 2 7.1 1 3.7 
Headache 0 0.0 1 3.6 0 0.0 
Dizziness 2 10.0 4 14.3 4 14.8 
Tremor 7 35.0 9 32.1 12 44.4 
Weight Gain 1 5.0 3 10.7 2 7.4 
Memory Problems 1 5.0 2 7.1 3 11.1 
Difficulties with Speech 1 5.0 0 0.0 0 0.0 
Double Vision/Blurred View 3 15.0 0 0.0 0 0.0 
Irritability 0 0.0 1 3.6 0 0.0 
Hair Loss 1 5.0 0 0.0 1 3.7 
Gum Problems 1 5.0 1 3.6 0 0.0 
Others 2 10.0 0 0.0 2 7.4 
Total number of PWE 20  28  27  
 
As shown in Table 5, across all three categories of drug responsiveness, 
similar trends of type and frequency of ADRs were observed. For examples, 
tremor was the most commonly reported ADR, contributing 35.0%, 32.1% and 






44.4% in drug responsive, drug resistant and ‘undefined’ groups, 
correspondingly. This was followed by dizziness, memory problems, 
sleepiness, weight gain, difficulty with speech, hair loss and gum problems. 
Their frequencies were reported to be approximately 10% each. Uniquely, 
blurred vision was complained by three subjects (15%) in the drug responsive 
category while irritability was complained by only one subject (3.6%) in the 
drug resistant category. The association of ADRs with the type of AEDs used 
was not examined due to insufficient power for correlation. 
 
4.4.6 CHANGE IN SEIZURE FREQUENCIES 
Despite not attaining seizure freedom, both the drug resistant and 
undefined group of PWE were evaluated for change in their seizure 
frequencies. This is, in part, to gauge the effectiveness of AEDs usage in our 
setting. Inidvidual subject’s pre-treatment and current seizure occurrence 
classes were compared to reflect the change in seizure frequencies. As 
depicted in Figure 5, approximately half of the PWE in ‘undefined’ group and 
drug resistant groups had benefitted from AED/s therapy, reflected by a 
decline in their seizure frequencies. In contrast, 18.2% of the PWE from 
‘undefined’ and 15.0% from drug resistant group suffered increased seizure 
frequencies while the rest was documented to have no changes. Previously, the 
pre-treatment median seizure frequencies were biweekly and monthly, for 
drug resistant and ‘undefined’ group, respectively. Currently, the median 
seizure frequencies were reduced to monthly in the drug resistant group and 









The demographics distribution of PWE was found to be comparable to 
a few studies done locally as well as overseas (5, 6, 96, 98, 99, 172, 173, 186, 
187). The proportion of ethnicity was similar to those reported in an earlier 
Singapore study (5), with the additional of other races in this study. The 
previous study was conducted in Singaporean army men, and hence was 
naturally without ‘other races’. Singapore is a well-known medical hub in the 
Asian region, and thus, not surprising that the current population includes 
some foreigners who seek medical services here. Although Chan et al reported 
a higher proportion of Malays (19.1%), their surveyed population was 
pediatrics, and included first afebrile seizure cases which was contrary to our 
adult population of all PWE.    
Figure 5.Change of seizure frequency from pre-treatment in the (left) Undefined 





The initial finding of significantly more Indians was drug resistant 
suggested that genetic make-up may have a role to play. Among Indians of 
South ancestry, a study conducted on ABCB1 gene which encodes P-
glycoprotein transporter suggested that the association between the genes with 
refractory epilepsy could be random, simply due to the linkage of the gene to 
epilepsy itself, rather than resistant epilepsy specifically (188). Similarly, our 
finding could be random, considering the difference was no longer observed 
after adjustment made to the other parameters listed in Table 3. It will be 
interesting to investigate the true effect of ethnicity on rendering a PWE to be 
drug-responsive or resistant using a larger population. 
Despite differences in definition, prevalence of DRE in this study 
conformed with those found in the French study, where the prevalence ranged 
from 15.6% to 22.5%, depending on the criteria of seizure occurrence; either 
once in 18 months or once in 12 months (96). It was also similar to the rate of 
intractable seizure in a Finnish paediatric population after 30 years of follow 
up (172), and 25% refractory epilepsy in a Glasgow study (97). Refractory 
epilepsy rate in Singaporean men was once reported to be 13% (189). 
However, this study was done in a carefully selected cohort, aged at 18 years 
old that had excluded PWE with incomplete medical records. Hence, it was 
possible that the refractory rate reported at that time was an underestimation. 
In contrast to the Taiwan and western countries findings which had 
documented 25% – 40% of adult PWE being refractory, drug resistant 
prevalence rate in this study was lower (98, 99, 101, 187). It was speculated to 
be a result of the recent conception of ‘undefined’ group, which was not 
available at the time when previous studies were conducted. Moreover, the 
more defined criteria for drug responsive and resistant categorization may 
have caused many PWE to be undefined. For example, there were 
approximately 18 PWE who had no seizure occurrence for at least 12 months 
after their last AED intervention was in the ‘undefined’ group (Table 3). If 
according to previous studies which defined seizure freedom as no seizure 





responsive’ (96, 99). Since the current definition is 3 times the previous 
seizure free interval, which could be a total of more than 12 months, seizure 
free time lapsed over only 12 months was regarded as insufficient. Therefore, 
they were categorized as ‘undefined’.  If these PWE is categorized as drug 
responsive, the percentage of drug responsive PWE will likely attain 51%, 
while there seems to be no changes in the proportion of DRE. Another typical 
example of undefined case was: subjects who had multiple seizures per week 
for years, but were not prescribed the DDD due to unspecified reasons. A 
closer look revealed that most of the current ‘sub-optimal’ dosages in these 
subjects were once effective in controlling individual epilepsy. Based on some 
of the previously discussed studies, these subjects could have been classified 
as drug resistant too. Therefore, in summary, a combination of these scenarios 
may contribute to the lower rates of drug responsive and resistant PWE, 
observed in this study based on the recent ILAE consensus.   
As expected, polytherapy prevails in the drug resistant group. Studies 
had shown that for PWE who did not achieve seizure freedom with their first 
AED trial, less than 20% will respond favourably to the following AEDs trial 
(107). This group of subjects was believed to be inherently more difficult to 
treat (190). Additionally, long term follow up cases were included in this study, 
implying that substitutions and additions of AEDs, if deemed required, would 
have already been tried. Since the use of AED combination was superior to 
monotherapy for PWE with inadequate response to their first or second AED 
(191), more than 1 AED could have been given in attempts to abate seizure 
recurrences. This phenomenon was especially important when the PWE 
suffered multiple seizures despite being on a few ineffective therapies.  
Relapse, as manifested by one seizure occurrences after a seizure free 
period could be attributed to incompliance upon realizing the possibility of 
AED withdrawal (172). Among the patients with relapses in our study, after 
examining the previous actions taken before the relapse occurred, nineteen 





(more than 3 times their previous seizure free intervals), received no changes 
in their therapy on their last visit to the clinic, while only 12% (n=3) had their 
AED dosages reduced. Although frequencies of these actions slightly differed 
from those reported by Callaghan et al., it suggested that reduction in AED 
dosages might not trigger seizure (192). However, this finding should be 
interpreted cautiously as it was only a point prevalence rate that was reported 
to aid in defining our ‘undefined’ category subjects and not to determine the 
probability of relapse in our PWE population. 
Prospective studies done in the Japan, UK, US and Europe in the last 
few decades, mostly utilizing treatment naïve PWE, had managed to unravel a 
few potential predictors for developing DRE. These factors were namely the 
presence of mesial temporal sclerosis or lesional region in the brain, high 
number of pre-treatment seizures, poor response towards the first AED 
prescribed, earlier age of seizure onset, presence of mental retardation and 
psychiatric illnesses (101, 106, 107, 110, 193). Our findings of risk factors 
were comparable to these previous works. PWE with structural-metabolic 
etiology, formerly termed as symptomatic, had been reported to negatively 
affect the likelihood for remission, a finding that echoed the other studies (96, 
101, 106, 172). It was speculated to be harder to treat because the influential 
factor does not seem to originate from the focal epileptogenic  zone (194). 
Seizures probably arise from a more complex network, which could be from 
any triggers or any parts of the brain.   
Contrasting to a few earlier studies (98, 186), mesial temporal sclerosis 
(MTS) was not a risk factor in our population. It was noteworthy that most of 
the PWE in our center with operable lesion, inclusive of MTS had already 
undergone surgery. Many of these operated PWE had attained seizure freedom 
for more than 5 to 10 years and were already discharged from further follow 
up visits prior to this study initiation. There was a small number of PWE who 
chose not to have surgery (data not shown), even though they are good 





populations where MTS was still intact at the point of their investigation. In a 
randomized trial done in the US, resective surgery combined with AEDs 
demonstrated a reduction in seizure occurrences when compared to using 
AEDs alone (odds ratio=∞; 95%CI 11.8 to ∞; p < 0.001) (195). This projected 
improvement in seizure control by a subgroup of operated subjects, coupled 
with a small fraction of subjects with more benign form of MTS, may account 
for the lack of contribution by MTS to DRE in this study, as demonstrated in 
multivariate regression.   
Aside from MTS, younger age of seizure onset and higher frequencies 
of pre-treatment seizures were also associated with a higher risk of developing 
drug resistant (12, 99, 101, 172, 173, 187). These characteristics could be 
signs of a more resistant type of epilepsy (101, 196). Although the influence of 
age appears to be only marginally negative, odds ratio of 0.96, it is still a 
powerful predictor considering that with every one year of increase in seizure 
onset age, there is a 4% decrease in risk of becoming drug resistant. 
In the chi square analysis, however, PWE who were in the sixty years 
of age (60 - 69 years old) demonstrated superior seizure freedom prevalence 
than the other age groups. Age of epilepsy onset had been suggested to be a 
major predictor of DRE, with those presented at the age of ≥ 65 years are less 
likely to develop DRE (111, 197). It could be inferred that the underlying 
pathogenesis of epilepsy varies by age group. Additionally, recognition of 
seizures in the elderly itself is challenging, especially by the non-medically 
trained family members. This could result in under-recognition and under-
reporting of seizures recurrence in this age group. It is tempting to attribute the 
high frequency of remission to the dynamic nature of the disease itself (198-
200), although evidence to support the optimal age at sixties, is lacking. An 
alternative explanation would be the changes in lifestyle. Experts suggested 
that as one matures, it is likely that one will become more conscious of well-
being. Therefore, one become more compliant, emphasizes on sufficient rest 





serenity) as well as avoids known triggers, most commonly documented in our 
setting; alcohol and long duration of computer use (201). Interestingly, sixty to 
sixty-five years old are the general retirement age range in Singapore. We 
speculate that lifestyle changes in this group of PWE could have improved 
their seizure control. In addition, the low prevalence rate of DRE did continue 
to subjects >70 years old, although the difference was not statistically 
significant, likely confounded by the small number of PWE in that age group 
(Figure 3).  
Presence of psychiatric illnesses or mental retardation was known to 
increase the risk of unprovoked seizure (98, 172, 202-205). Our PWE with 
either one of these conditions were at 2 to 3 fold higher risk of persistent 
seizures. It is generally perceived that psychiatric disorders could further 
perturb the already imbalanced neuronal transmissions in the brains of PWE. 
This in turn may worsen the epileptogenicity and render it more difficult to be 
treated (99, 206). Likewise, this complexity of neuronal network interactions 
might occur in mental deficiency cases. Moreover, mentally deficient PWE 
could have difficulty in adhering to their prescribed regimen, unless they were 
accompanied by dedicated caretakers. It is noteworthy that there were 
approximately 5% of mentally deficient PWE in the drug responsive group. 
This outlined that although they are likely to have DRE, it is still possible for 
them to attain remission, as shown by Sillanpaa and Schmidt, 2006, where 35% 
of patients with mental retardation and symptomatic etiology may possibly 
achieve terminal remission (200). 
 
4.6 CHAPTER CONCLUSION 
Based on our findings, the recommendations from the ILAE global 
consensus for the definition of DRE are realistic and practical. Although the 





prevalence and risk factors determination still conforms to each other. The 
recent consensus provides a detailed description of our PWE group, without 
overrepresentation of either drug responsive or drug resistant. In view of the 
long and dynamic course of epilepsy, our clinicians adopted ‘prescribe, wait 
and assess’ strategy. This is clearly depicted from the ‘undefined’ PWE, where 
sufficient time is allowed to elapse before adjustment is made to their 
pharmacotherapy.  By identifying the ‘undefined’, it allows our clinicians to 
include other aspects in their routine management of insufficient control PWE. 
To illustrate, in PWE who are satisfied with their current therapy but have not 
achieved seizure freedom, prompt counselling and referral to social support 
group may change their perception about receiving alternative therapies.  
We acknowledged that this study is limited by several factors. Firstly, 
it was conducted only in one hospital – based referral center. It is generally 
perceived to have a higher proportion of drug resistant patients and the current 
prevalence may be an over estimation. Secondly, the retrospective natures of 
the study design, which is well-known to be restricted by the availability of 
data. Genetic testing results were not available for most of the PWE, as it is 
not routinely performed. However, due to the site being a neurology specialist 
clinic, most of the essential information required for accurate diagnosis and 
drug response categorization were readily available. Hence, it cannot be 
guaranteed that the documentation is as complete if studies were to be 
conducted in primary care settings. Nevertheless, our observations should be 
reflective of the usual clinical practices around the globe. 
In conclusion, this study has managed to determine the prevalence rate 
of DRE in our population of PWE. At any one time, 1 in 5 PWE could have 
DRE. PWE with structural-metabolic etiology, concurrent psychiatric illnesses 
or mental deficiency and pretreatment seizure frequencies of more than once a 
month are at increased risk of developing DRE. Gender, ethnicity, focal 
seizures and presence of MTS do not seem to hinder seizure remission. 





chance to be seizure free. This study could alert clinicians of the informative 
parameters that should be assessed and recorded during clinical consultations 
in order to determine PWE’s treatment responses and offer timely alternatives. 
The findings may also aid policy makers in designing treatment guidelines and 
allocating resources around PWE. 
 
With these findings, the first objective was achieved whereby DRE is 
still a significant on-going issue in PWE that deserves more attention. 
Moreover, genetic etiology and ethnicity did not emerge as prominent risk 
factors associated with DRE. Structural-metabolic etiology and psychiatric 
disorder/mental insufficiency which are known to have imbalances in 
neurometabolite transmitters were strongly linked to DRE occurrences. 
Metabolomics is hence, deemed as a rational approach. In the next chapter, the 
applicability of dried blood spot as sampling matrix for metabolomic study 
will be presented before the profiles between drug responsive and drug 
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CHAPTER 5. EVALUATION OF DRIED BLOOD SPOTS AS 
SAMPLE MATRIX FOR GAS CHROMATOGRAPHY –  MASS 
SPECTROMETRY (GC-MS) BASED METABOLOMIC 
PROFILING 
This work had been published in Analytical Chemistry 2011;83:4314-8. 
 
5.1 CHAPTER ABSTRACT  
We propose using DBS as sample matrix for GC-MS based 
metabolomic profiling for the benefits of higher sample stability, more 
convenient sample acquisition with DBS; higher analyte separation power, and 
readily analyte identification with GC-MS analyte libraries. To establish this 
proposition, the metabolomic profiles generated from DBS were compared 
with that obtained from the conventional whole blood and plasma matrices; 
and also with dried plasma spots (DPS) as another covariate control.  Our 
findings indicated that whole blood produced the most number of detectable 
markers (866), whereas DPS yielded the least number (614). DBS and plasma 
matrix, on the other hand, produced the most similar numbers of detectable 
(695 vs 749) and identifiable markers (137 vs 147, matching with Fiehn 
library). From the analysis of the DBS and plasma metabolomic profiles, it 
was concluded that when L-lysine 2, iminodiacetic acid 2, DL-threo-beta-
hydroxyaspartic acid, citric acid or adenosine-5-monophosphate 2 are not 
involved as markers, DBS could be a suitable substitute for plasma for 







5.2 CHAPTER INTRODUCTION 
Metabolomics is a rapidly developing field and has brought about 
many contemporary discoveries, among which are metabolite-biomarkers for 
diseases. Some of these findings include biomarkers for Crohn’s disease (207) 
and Onchocerciasis (208). The analytical tools commonly used in metabolites 
detection include nuclear magnetic resonance (NMR) spectroscopy, gas 
chromatography (GC), high performance liquid chromatography (HPLC) and 
ultra-performance liquid chromatography (UPLC) coupled with mass 
spectrometry (MS), and the more specialized Fourier transform infra-red 
(FTIR) spectroscopy. The analysis of the data obtained from the untargeted 
screening of metabolites has been eased with the advances in chemometric and 
bioinformatic methods. The clinical interpretation of the plethora data 
obtained from metabolic profiles of biological samples has also been enhanced.  
The usual biological samples used are plasma, urine, amniotic fluids, 
cerebrospinal fluid and tissue extracts, and more recently, dried blood spot. 
DBS is a sampling method popularized since the 1960s, when it was 
introduced for the screening of a metabolic disease, phenylketonuria, in 
newborns.  DBS has recently been extensively researched for its other 
potential such as screening for folate deficiency (141), hyperthyroidism (142) 
and metabolite profiling (146). DBS represents an alternative that overcomes 
many of current plasma metabolome problematic issues such as stability of 
metabolites in plasma or blood samples after acquisition and the invasive 
sampling technique involved. 
Very recently, biofluid spotting has been shown to be a potential 
alternative to conventional plasma in metabolite profiling using UPLC oa-
TOF-MS (146). In this regard, GC-MS has several advantages over UPLC-MS 
in offering high separating power and sensitivity, and generally better 
reproducibility of concentration and retention times (209). An introduction of 
chiral derivatization as part of sample preparation for GC-MS can help 





of the specific enantiomers from the endogenous metabolites (210, 211). There 
is also a readily available library created especially for the analysis of human 
metabolome e.g. the Fiehn library and Human Metabolome Database (HMDB). 
As GC-MS is one of the most widely used analytical tool in profiling of 
primary metabolites (212), it will be interesting to investigate the range of its 
detectable metabolites in different matrices for metabolomic profiling. 
This has led us to our proposition of using GC-MS to explore the type 
of metabolites that might be identifiable when using DBS as sample matrix, 
and comparing with that generated from the conventional whole blood and 
plasma samples. To serve as a covariate for comparison, metabolomic profile 
in dried plasma spots was also investigated. We hypothesized that these 
findings might aid in refining the selection of sampling matrix that best fits the 
type of metabolomic studies.  
 
5.3 MATERIALS &  METHODS 
5.3.1 CHEMICALS 
Methanol of analytical grade was purchased from Prime Products Pte 
Ltd. (Singapore); and caffeine, palmitic acid 99% and cholesterol 99% were 
purchased from Sigma-Aldrich (St. Louis, MO). D,L α alanine was purchased 
from Merck & Co. (Whitehouse Station, NJ). N-methyl-N-
trimethylsilyltrifluoroacetamide (MSTFA) with 1% trimethylchlorosilane 
(TMCS) was obtained from Thermo Scientific Pte. Ltd.  (Waltham, MA). 
Deionized water was obtained from a Milli-Q system (Millipore, Boston, MA) 







5.3.2 ANIMAL STUDY 
The in vivo metabolic study was carried out according to the 
“Guidelines on the Care and Use of Animals for Scientific Purposes” 
(National Advisory Committee for Laboratory Animal Research, Singapore, 
2004). The animal handling procedures of this study were reviewed and 
approved by the Institutional Animal Care and Use Committee of the National 
University of Singapore (NUS).  
Sprague-Dawley rats (7-8 weeks old) were purchased from 
Comparative Medicine Center (CMC) of NUS. The rats were kept at a specific 
pathogen free animal facility (24°C, 60% relative humidity) at CMC and 
maintained on a 12-h light/dark cycle with free access to food and water. 
Twenty four hours before the metabolic study, a polyethylene tube (I.D. 0.58 
mm, O.D. 0.965 mm, Becton Dickinson, Sparks, MD 21152, USA) was 
inserted into the right jugular vein under isoflurane anesthesia.  This catheter 
was used for blood sampling at 9am on the study day. Blood samples 
(approximately 1 mL) from each of the 3 male rats were collected and kept in 
ice box until they were transferred back to laboratory for processing. Within 
30 min of collection, each collected blood sample was aliquoted in triplicates 





 Neonate Blood Collection Cards, Whatman GmbH, 
Dassel, Germany) respectively. The remaining blood sample was then 
centrifuged at 3,000 g (4 °C) for 10 min, the plasma collected was treated 
similarly as the blood sample (i.e., 25 µL of plasma aliquoted into 3 x 1.5 mL 
of Ependorff tube; and spotted in triplicates onto 903
®
 cards). The spotted 
blood and plasma were first left dried in the fume hood for at least 3 hours, 
which was the observed minimum time required for complete dryness. During 
this drying period, the blood and plasma samples were stored at -80 °C. Then, 






5.3.3 SAMPLE PROCESSING 
The processing of the dried blood spot (DBS), dried plasma spot (DPS), 
the blood and plasma samples were carried out as similarly as possible, to 
minimize bias. The DBS and DPS were punched and the cores (6 mm) 
obtained were placed inside the respective Ependorff tubes. Extraction of DBS 
and DPS was done using 160 µL of methanol (Prime Products Pte. Ltd.) with 
caffeine (Sigma-Aldrich Pte. Ltd.) as the internal standard at a concentration 
of 6.25 ng/mL and vortexed for 20 min. The blood and plasma samples were 
thawed once at 22°C and mixed well before extraction. 160 µL of cold 
methanol (-20°C) with caffeine (6.25 ng/mL) was used to precipitate protein 
and to extract both blood and plasma, which were then vortexed for 1 minute. 
The extracts were centrifuged at 20 800 g, 22°C for 10 min and 120 µL of the 
resulting supernatant would be transferred to 15 mL Kimble centrifuge glass 
tubes (Gerresheimer Co. Glass, Germany) for evaporation. First drying was 
done at 40°C under a stream of nitrogen.  Thereafter, 100 µL of toluene was 
added, vortexed for 15 seconds and subjected to the similar condition for 
drying again. Toluene was used to ensure removal of water. Next, 
derivatization of the dried sample was accomplished using 100 µL of N-
methyl-N-trimethylsilyltrifluoroacetamide (MSTFA) with 1% 
trimethylchlorosilane (TMCS) (Thermo Scientific Pte. Ltd.). The derivatized 
samples were vortexed for 1 minute and incubated at 60°C for 1 hour. After 
being cooled to room temperature, the products of derivatization were 
centrifuged at 3500 g, 22°C for 20 min. Finally, 90 µL of this final supernatant 
was transferred into 200 µL conical base inert glass insert placed inside a 2 








5.3.4 STABILITY OF METABOLITES IN DBS 
In metabolomic studies, there seems to be no generally accepted 
criteria for assessing the stability. Here, we adopted the approach by Zelena et 
al (213), that accepted a tolerance of 20% in variation in the analyte levels as 
stable for metabolomic analysis. Since we were interested in the detection of a 
wide range of metabolites rather than any specific metabolite, the detected 
responses of ten metabolites across the analytical time were randomly chosen 
to be compared.  These metabolites could represent compounds of different 
physicochemical properties as reflected by their differences in retention times 
in the chromatographic separation. The stability of these ten metabolites in 
triplicates of DBSs stored at either 25°C or - 20°C at intervals of 0, 6, 24 and 
48 hrs after complete drying were then evaluated.  
 
5.3.5 RECOVERIES OF METABOLITES FROM DBS 
It is impossible to evaluate recoveries of all metabolites detected. 
Therefore, the recoveries of three analytes which eluted at three distinct 
retention times; alanine (~7.00 min), palmitic acid (~18.45 min) and 
cholesterol (~27.00 min) were selected and investigated. Blood samples from 
the three rats were pooled and triplicates of quality control (QC) blood spots 
were spotted onto the 903
®
 cards. Then, triplicates of DBS prepared with 
blood samples spiked with the three analytes at various concentrations were 
processed similarly as above. Since these analytes are naturally present in 
blood, the concentrations spiked were at least 50% higher than the normal 
blood concentrations i.e. 1 µg/mL and 100 µg/mL for alanine; 1 mg/mL and 5 
mg/mL for palmitic acid; 1 mg/mL and 2 mg/mL for cholesterol. The standard 
solutions for the respective analytes were prepared in distilled water for 
alanine and in methanol for palmitic acid and cholesterol. Absolute recovery 





Absolute recovery = 
                                                                    
                                                          
 
 
5.3.6 GC-MS SETTINGS 
Analyses were done using GC-MS that comprised of 7890A GC 
System coupled to 5975 inert MSD with Triple-Axis Detector (Agilent 
Technologies) and in-built Fiehn method of analysis for metabolomic 
screening (214). The in-built settings included injector temperature at 250°C, 
split ratio of 10:1 at the starting temperature of 60°C held for 1 min, increased 
at 10°C per min to 325°C followed by a final hold for 10 min (total run time of 
37.5 min). Ion source temperature was set to 250°C, while the scanning mass 
range was set as 50 to 600 m/z.  
 
5.3.7 STATISTICAL SOFTWARE 
Automated Mass Spectral Deconvolution and Identification System 
(AMDIS) 32 Version 2.66, 2008 was used to deconvolute the data. The 
minimum match factor of 40% was utilized while other deconvolution settings 
included adjacent peak subtraction of one, medium resolution of the peaks 
with high sensitivity and medium shape requirements. They were then 
matched against their putative identities with Fiehn library (with the addition 
of caffeine). The peak list data acquired were subjected to multivariate 
analyses by Mass Profiler Professional (MPP) Version B.02.00 (Agilent 
Technologies, Inc.). In the analysis of the MPP parameters, a retention time 
tolerance of 0.1 minute, with matching factor of at least 0.6 was adopted. 







5.4.1 METABOLITES DETECTED FROM THE FOUR SAMPLE 
MATRICES 
A typical total ion chromatogram (TIC) for each of the samples (DBS / 
Blood / DPS / Plasma) showed similarities in the initial detected peaks (Figure 
6). After deconvolution, the total number of detected metabolites were 866 for 
blood with 268 (30.9%) of reproducible compounds, 749 for plasma with 237 
(31.6%) of reproducible compounds, 695 for DBS with 196 (28.2%) of 
reproducible compounds and 614 for DPS with 178 (29%) of reproducible 
compounds. The reproducibility is defined as the presence of a compound in at 
least 2 out of 3 technical replicates in at least 2 of the 3 rats. Among the 
reproducible TICs, the numbers of identified compounds were 171, 147, 137 










Figure 6. Typical total ion chromatogram (TIC) for the respective blood, plasma, 
dried blood spot (DBS) and dried plasma spot (DPS) matrices. The chromato grams 









The deconvoluted data with their putative identity lists, normalized 
against the internal standard (caffeine) and adjusted to median across samples, 
were then subjected to principal component analysis (PCA). The data 
clustered differently according to the type of sample (Figure 7, left). Similar 
clustering was also seen with partial least square discrimination analysis 


















Figure 7. (left) Principal component analysis (PCA) and (right) partial least square (PLS) score 


















Figure 8. Hierachical clusters of the 4 sample matrices: blood, plasma, dried 






Table 6. MPP derived discriminating compounds for the four sample 
matrices: DBS, blood, DPS, and plasma in number of fold change in relative 
to the internal standard  
(L – 5 to 10 fold change; M – 10 to 15 fold change; H - more than 15 fold change; X- 
absent) 
Compound DBS Blood DPS Plasma 
urea L H L H 
stearic acid H L L L 
phosphoric acid M H L M 
palmitic acid H L L L 
oleic acid H H X H 
methyl-beta-D-galactopyranoside L H L H 
methyl linolenate L H X L 
L-threonine 2 M H X L 
L-lysine 2 X H X L 
linoleic acid H H L H 
L-glutamine 3 L H X L 
L-glutamic acid 3 (dehydrated) L H L L 
L-alanine 1 L H X L 
L-(+) lactic acid L H L H 
iminodiacetic acid 2 X L L H 
glycine L H X L 
DL-threo-beta-hydroxyaspartic acid X L X H 
citric acid X H X H 
cholesterol M H X L 
allo-inositol L H X H 
adipamide 3 X L X H 
adenosine-5-monophosphate 2 X H X X 
79.0@21.1883  L H X M 
2-amino-2-methyl-1,3-propanediol 2 H H L M 
204.0@17.228256  L H X M 
204.0@16.245567  L M L H 
 
Generally, metabolites in the blood and plasma samples gave higher 
peak areas for similar compounds found in DBS and DPS. It is expected as the 
whole 25 µl was subjected to sample processing for the blood and plasma 
samples. However, for the DBS and DPS, 25 µl was spotted onto the 903
®
 
cards, and from which a disc of 6 mm in diameter that would contain less than 
25 µl of sample was punched out from the middle of the spot for further 





metabolites among the 4 sample matrices are listed in Table 6, with most of 
them present abundantly in blood, but lesser or absent in DBS, DPS or plasma. 
  
5.4.2 STABILITY OF METABOLITES IN DBS 
Table 7. Average responses and standard deviation s of 10 metabolites detected in 
DBS stored in freezer at (-20
 o
C) for 0, 6, 24 and 48 hr. The last column showed the 
relative standard deviation (RSD) of the average responses in the detection of the 
respective metabolites over the 48 hour period  
Peak Time 
(min) 
0 hr 6 hr 24 hr 48 hr RSD 
(%) Average±SD Average±SD Average±SD Average±SD 
1 6.37 29.20±1.63 27.24±3.72 24.22±0.86 25.53±2.28 5.90 
2 6.46 25.12±1.62 25.46±1.75 24.09±1.16 24.54±0.87 2.84 
3 7.08 20.18±1.57 21.93±3.47 20.03±0.78 20.66±0.83 4.62 
4 7.11 20.29±1.53 20.94±2.36 18.03±0.43 18.65±1.63 8.00 
5 7.80 6.22±1.35 6.09±0.92 6.04±0.03 6.11±0.48 0.62 
6 8.89  19.78±1.29 21.47±0.90 22.06±0.22 21.31±2.21 1.83 
7 9.45  9.02±0.58 8.37±2.20 9.61±0.77 9.63±0.69 7.84 
8 16.86 47.26±4.83 40.28±5.74 43.49±3.44 52.79±4.60 14.27 
9 18.46 3.62±0.28 4.33±0.52 4.42±0.21 4.27±0.52 1.70 
10 27.00 30.83±0.80 41.29±2.12 32.72±7.29 44.70±9.70 15.58 
 
Table 8.  Average responses and standard deviations of 10 metabolites detected in 
DBS stored at room temperature (25
o
C) for 0, 6, 24 and 48 hr. The last column 
showed the relative standard deviation (RSD) of the average response in the 
detection of the respective metabolites over the 48 hour period  
Peak Time 
(min) 
0 hr 6 hr 24 hr 48 hr RSD 
(%) Average±SD Average±SD Average±SD Average±SD 
1 6.37 29.20±1.63 24.96±1.46 25.31±1.05 26.42±2.21 5.86 
2 6.46 25.12±1.62 22.80±0.95 25.36±0.41 25.77±2.08 4.16 
3 7.08 20.18±1.57 19.08±1.06 20.71±0.34 21.65±1.62 5.55 
4 7.11 20.29±1.53 17.37±0.80 19.32±0.60 20.34±1.44 4.62 
5 7.80 6.22±1.35 5.66±0.54 5.98±0.09 5.87±0.39 9.45 
6 8.89 19.78±1.29 22.16±1.32 21.62±0.83 22.45±2.52 5.98 
7 9.45 9.02±0.58 9.74±0.23 9.83±0.90 9.82±1.25 2.38 
8 16.86 47.26±4.83 53.53±5.26 40.19±5.03 49.16±5.34 9.83 
9 18.46 3.62±0.28 3.75±0.31 4.27±0.22 5.08±0.30 3.32 





Tables 7 and 8 showed the detected responses of 10 selected 




C respectively. The results 
indicated that the relative standard deviations of responses of each of these 
metabolites over the time period from 0 to 48 hrs were all less than 20% at 
both storage temperatures. These were within our tolerance acceptance range, 
suggesting stability of the metabolites in the matrix.  
 
5.4.3 RECOVERIES OF METABOLITES FROM DBS 
Table 9. The percentage recoveries from DBS of alanine, palmitic acid and 
cholesterol spiked at two different concentrations  
Analyte Concentration Mean absolute recoveries ± SD (%) 
Alanine 1 µg/mL 125.32 ± 0.37 
 100 µg/mL 88.94 ±1.26 
Palmitic acid 1 mg/mL 99.45 ± 1.92 
 5 mg/mL 98.81 ± 6.15 
Cholesterol 1 mg/mL 69.77 ±1.84 
 2mg/mL 55.58 ±1.96 
The differences in the mean absolute recovery between the 2 
concentrations were less than 1% and 15% for palmitic acid and cholesterol 
respectively; but for alanine, the difference was more than 30% , probably due 
to the vast difference in the 2 concentration for this analyte (1 vs 100 µg/ml) 
(Table 9). Nevertheless, the recoveries of these metabolites at any one 
concentration remained consistent across the triplicates, as reflected by the 
small standard deviations (less than 2% for most cases). 
 
5.5 DISCUSSION 
Although direct comparison cannot be made in the detection ability 
among different metabolomic studies, especially when they use different 
instrument platforms, the number of identified peaks from plasma, DBS and 





in the study by Begley et al. (Table 10) (215). The smaller number of detected 
peaks in our study as compared to those from UPLC-oa-TOF-MS could be due 
to multiple factors. Firstly, the metabolites detected through GC-MS include 
only low-polarity volatile metabolites such as fats and esters, and high-polarity 
metabolites of amino acids and organic acids converted into volatile 
derivatives (216). Hence, there is a chance that non-volatile compounds are 
not detected. Secondly, the derivatization itself may affect certain classes of 
metabolites and hamper the detection of compounds (217). The putative 
identities of compounds, however, could not be made in the study using UPLC 
coupled to oa-TOF-MS (146). This hindered our ability to discern the type of 
metabolites identified through different analytical tools. Nevertheless, within 
our own settings, blood, as expected, provided the most number of identified 
compounds while DPS yielded the least number.   
 
Table 10. Comparison of the numbers of the detectable and identifiable markers 
using different sample matrices and analysis platforms among different studies  
Study Michopolous et al, 
2010 (146) 
Begley et al, 2009 
(215) 
This study 
Analytical tool UPLC – ao-TOF-MS GC-TOF GC-MS 
Type of sample Rat Human Rat 












DBS 1239   
   **
DBS 695 
*
DPS 1039   
   **
DPS 614 
    
**
Blood 866 












DBS 768   
   **
DBS 196 
*
DPS 208   
   **
DPS 178 
    
**
Blood 268 
Number of identified targets 
Plasma N/A   Serum 130 Plasma 147 
DBS N/A      DBS 137 
DPS N/A      DPS 121 
       Blood 171 
 
The metabolites (as putatively identified by Fiehn Library in GCMS) 
lost after processing by blotting blood or plasma onto 903
®





to binding to the paper or lost on drying, which had been reported before (158). 
A better approach could be to dry the spotted biological fluids in an enclosed 
chamber with flowing inert gas to minimize degradation or loss due to 
oxidation. Nevertheless, in our experiment, upon drying, the 10 metabolites 
randomly selected across the analysis time appeared to be stable in DBS for up 
to 48 hours in our study. However, we cannot eliminate the possibility that 
some other metabolites may be degraded under the sample storage and process 
conditions. This scenario could also be applied to any sample matrix. 
Therefore, it is paramount to have all samples stored and processed under 
similar conditions, so that any difference in the metabolic profiles could be 
due to the experimental covariates rather than to the experimental artifacts.  
The recoveries of metabolites from DBS were found to be consistent 
for the particular analyte at the specific concentration. However, for some 
metabolites as demonstrated by the example of alanine, the absolute recoveries 
could be different at different concentration levels. Since it is impossible to 
predict the concentration level of an individual analyte in the respective 
sample, we may have to accept this as a limitation in metabolomic study, and 
be aware that the difference in some of the metabolite levels could be due to 
difference in recoveries of analytes during sample extraction.  
We have attained our aims whereby, in delineating the differentiating 
types of detectable metabolites (as matched against Fiehn Library) from the 
blood, plasma, DBS and DPS sample matrices. There are overlapping 
compounds between DBS, DPS and blood with plasma, suggesting that either 
one of these may be able to substitute the conventional plasma as the tool for 
metabolomic studies. Of note, DBS offers great advantages as it can be 
obtained easily as compared to the plasma; only one needle prick and an 
approximately 25 µL of blood volume is required as compared to the more 
invasive technique involved in acquiring the plasma sample. In comparison to 
blood, the dried blood spots are easier to be stored and transported. Moreover, 





as they will not be subjected to hydrolysis degradation. Generally, most 
chemicals are more stable in the dried form than in the aqueous form. In our 
study, there seemed to be more metabolites detected from the whole blood. 
This can be explained by the situation that both the whole blood and plasma 
samples were frozen shortly after collection; whereas the DBS and DPS were 
allowed to dry in air at room temperature for approximately 3 hrs. During this 
period, some naturally occurring enzymes in whole blood or plasma may 
hasten the degradation of certain metabolites. Alternatively, the lower 
numbers of metabolites recovered from DBS and DPS could be due to binding 
of some metabolites to the 903
®
 cards and they were not readily extracted 
from the paper during sample processing.  
 
5.6 CHAPTER CONCLUSION 
This experiment is meant to be explore the use of DBS as sample 
matrix for GC-MS based metabolomic profiling. In our study, it was found 
that the number of detected metabolites in DBS was not much less than that 
from the plasma sample, which is a gold standard matrix in metabolomic 
studies. In our study, most of the discriminating compounds have a putative 
identity in the Fiehn library. Nevertheless, if there are any compounds 
identified to be promising biomarkers or new metabolites detected but without 
identity, the chromatogram could be matched against other libraries, such as 
HMDB or NIST for a wider search for identification.  
Since most of the compounds detected in plasma, are also presenting in 
DBS extracts, DBS could be a substitute to plasma in metabolite profiling. 
However, caution has to be taken in studies where L-lysine 2, iminodiacetic 
acid 2, DL-threo-beta-hydroxyaspartic acid, citric acid or adenosine-5-
monophosphate 2 is potential biomarker. As these metabolites are absent in 





studies. It warrants investigating the cause for the loss of these metabolites 
from DBS and endeavoring to overcome these shortcomings with the objective 
to further increase the number of detectable compounds in DBS. That will 
make DBS an even more formidable tool for metabolomic studies.  
 
Two animal studies were later developed with the aim to ascertain 
DBS capability to capture metabolite fluctuations in vivo. Modified approach 
using double solvent extraction for compounds in DBS was conducted to 
improve the extraction process. Simultaneously, individual detected 
compounds were examined for the presence of any of the L-lysine 2, 
iminodiacetic acid 2, DL-threo-beta-hydroxyaspartic acid, citric acid or 
adenosine-5-monophosphate 2 to establish DBS comparability to plasma. The 
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CHAPTER 6. USE OF DRIED BLOOD SPOT FOR 
METABOLOMIC PROFILING OF RESPONSE USING GAS 
CHROMATOGRAPHY MASS SPECTROMETRY IN THE 
LONG-TERM DRUG TREATMENT OF EPILEPTIC 
PATIENTS  
Considering the comparability of the of the number of compounds 
detectable between plasma and DBS as well as the ability of DBS in 
discerning metabolite profiles from the previous animal models, use in our 
setting, we embarked on recruiting subjects for this study. 
 
6.1 CHAPTER SUMMARY 
Epilepsy from various origins, e.g. genetic or proteomic abnormality, 
seem to converge at the neurometabolite levels. In an attempt to understand 
the epileptogenesis of drug resistant subjects, we aim to investigate their 
metabolite profiles; how they may differ from drug responsive subjects. Local 
ethics committee approval was obtained. DBS was contributed via 
venipuncture or finger prick. GC-MS analysis, multivariate data processing 
and biological pathway visualization were applied for metabolomic profiling 
of drug responsive and drug resistant subjects. The profiles of 125 DBS 
samples, which were obtained from venipucture, the modelling failed to 
converge to privde a conclusive outcome using multivariate analyses. Only 17 
DBS contributed via finger prick revealed clear distinction between these 2 
groups of subjects. Seven discriminating metabolites and their related 
metabolism were highlighted in this study. These metabolites and pathways 
perturbations were comparable to those identified from earlier studies in 
epilepsy. Metabolomic profiles yielded from DBS of finger prick origin, 
appeared to be more informative attributable to its different concentration of 
some endogenous metabolites from the venous DBS. It may also be a good 





significant metabolites in the profiles of drug resistant PWE, it could still be 
useful for targeted metabolite measurements. This work demonstrated the 
usefulness of DBS in understanding the altered pathology of a disease. A 
targeted assay has to be developed to quantitate the change in levels of the 
relevant metabolites to gauge the threshold above/below which, seizure 
occurrences become favourable. 
 
6.2 CHAPTER INTRODUCTION 
Gas chromatography with mass spectrometric detection is an effective 
analytical platform for metabolite profiling, as it is reproducible and robust 
due to the resultant consistent molecular ion fragmentation pattern from its 
electron impact (EI) ionization (218-220). This characteristic allows the 
construction of metabolites and analytes reference libraries such as the Fiehn, 
Wiley and National Institute of Standards and Technology (NIST) library of 
mass spectrum fingerprints for each individual compound.  
Epilepsy has long been thought to be a disease which is closely related 
to genetics, probably related to the booming era of genomics in the 1960s. 
Research done had also showed that epilepsy could arise from various origins, 
e.g. genetic or proteomic abnormality. Despite the obvious differences, they 
seem to share similar physiological changes at the metabolite levels (221). The 
manifestation in acute epileptogenesis with increase in excitatory 
neurotransmitter, glutamate and decrease in inhibitory neurotransmitter, 
GABA, further rationalize the research in metabolomics (28). Although 
researchers did not unravel any biomarker for drug response towards newer 
antiepileptic drugs (AED) using metabonomic approach in one study (109), 
PWE were shown to have lower serum levels of GABA, creatinine, L-
threonine and L-tryptophan and higher levels of L-glutamate, glycine, glyceric 
acid, lactic acid, inositol and myristic acid when compared to healthy subjects 





of findings to the mixed clinical phenotypes in their sample population. 
Additionally, 12-months follow up may be a relatively short duration to 
capture significant metabolite changes. Biomarkers of specific drug response 
may be too subtle for detection. 
As shown in the Chapter 4, approximately 1 in 5 PWE will have DRE. 
In an attempt to understand the epileptogenesis of this group of subjects, we 
aim to investigate their metabolite profiles; how they may differ from drug 
responsive subjects. In contrast to Al Zweiri et al study, PWE who are on 
chronic AEDs treatment will be recruited in our study (109). We hypothesized 
that irregardless of their etiologies, seizure types and AEDs, there should be 
similar metabolite perturbations in all DRE subjects.  
 
6.3 METHODS 
6.3.1 PATIENT RECRUITMENT  
The target sample size was estimated to be 50 subjects per group after 
consultation with the biostatistician and with reference to the previous 
metabolomics studies (38, 109). Local ethics committee approval was 
obtained. Study period was from October 2011 to August 2012. PWE who had 
venous blood sampling between 9 am to 12 pm on their visit to the neurology 
specialist clinic of a tertiary referral hospital were approached for informed 
consent. Two drops of blood, ~30 µL each, from their withdrawn blood in 




 Neonate Blood Collection 
Cards, Whatman GmbH, Dassel, Germany) and dried at room temperature, 
25ºC for at least 3 hours. PWE who did not have any blood test but were 
agreeable for donation of two drops of blood via finger prick, were also 
included. The first drop from finger prick was discarded per protocol (222). 
After drying, DBS samples were kept at -80ºC until analysis. Clinical records 





clinical history and biochemistry results. Drug response categorization was 
done in accordance to the recent International League Against Epilepsy (ILAE) 
recommendations (50). Only PWE who were categorized to be drug 
responsive (Category 1) and drug resistant (Category 2) were included in the 
final analyses. 
 
6.3.2 DRIED BLOOD SPOT SAMPLES PROCESSING 
A 6-mm diameter DBS from each PWE was punched and extracted 
with double solvents. First solvent used was 160 µL of HPLC grade methanol 
(Prime Products Pte Ltd, Singapore) premixed with internal standards (IS). 
Three IS were used for retention time comparison; D3-L-glutamic acid, D27–
myristic acid and D5-L-tryptophan at 6.25 ng/mL each. Vigorous vortexing 
was done for 20 min on a large capacity mixer (Glas-Col, USA) before 
centrifugating at 6000 g. One hundred twenty microliter of the clear 
supernatant was transferred into 15 mL silanized glass tube (Gerresheimer Co. 
Glass, Germany). Similar process was repeated for the second solvent, 
chloroform (Fisher Scientific International Inc., Hampton, New Hampshire) 
before transferring 120 µL of the resulting supernatant into the same glass 
tube. After gentle mixing, the combined supernatant was dried under nitrogen 
at 10 psi, 30ºC for 15 min.  For complete removal of water, 100 µL of toluene 
was added and then evaporated under similar condition. Thereafter, 
derivatization with 100 µL of N-methyl-N-trimethylsilyltrifluoroacetamide 
with 1% trimethylchlorosilane (Thermo Scientific Pte. Ltd., Waltham, 
Massachusetts, USA) and incubation at an optimum 70ºC for 1 hr were carried 
out. Subsequently, the clear mixture was cooled to room temperature and 80 
µL was transferred into 200 µL conical base inert glass insert inside a 2 mL 
amber glass vial (Agilent Technologies, Santa Clara, California, USA). 
Quality control (QC) samples were derived from pooled DBS extracts within 





during and ending of its batch of samples. Their replicates were averaged 
before pattern recognition analysis.  
 
6.3.3 GC-MS SETTINGS 
GC-MS that comprised of 7890A GC system coupled to 5975 inert 
MSD with triple-axis detector (Agilent Technologies Inc., USA) and its in-
built Fiehn method for metabolomic analysis, retention time locked to D27-
myristic acid, was used in this study (214). MSD ChemStation E.02.01.1177 
was utilized for data acquisition and peak area computation. DB5ms (30 m × 
0.25 mm × 0.25 µm) capillary column was purchased from Agilent 
Technologies J&W, Inc.  
 
6.3.4 STATISTICAL ANALYSIS 
Chromatogram deconvolution was achieved using Agilent MassHunter 
Workstation Software Qualitative Analysis version B.03.01. Compound 
identification was matched against Fiehn library of metabolites; with at least 
40% mass spectra match. Individual AEDs and relevant peaks were added to 
the compound library for identity matching & eliminated from compound lists 
before analysis. Metabolites that were present in less than 60% of the samples 
were also removed. Missing values were replaced with half of the minimum 
value detected within its category and finally, peak areas were normalized to 
internal standards. Pattern recognition software used was SIMCA P+ 12.0.1. 
T-test and other statistical analyses were done in Microsoft Excel 2007®. 
Biological pathway analyses for significant metabolites were conducted using 
Metabolomics Pathway Analysis (MetPA) (223, 224). MetPA is a freely 
available web-based metabolomics tool for biologic pathway analysis 







6.4.1 CLINICAL OUTCOME 
At the end of study period, a total of 244 PWE were recruited. 189 
DBS were obtained via venous samples while 55 were via finger prick. Only 
142 DBS were included in the final analysis. The other 102 DBS were 
excluded as their clinical drug responses were categorized as Undetermined, 
Category 3. Out of 142 DBS, 58 belonged to drug resistant PWE (Category 2) 






6.4.2 METABOLITE PROFILES 
 
 
Typical total ion chromatograms (TIC) are illustrated in Figure 9. The 
compound lists, which contained the putatively identified metabolites, 
retention time and peak area, were generated from the deconvoluted 
chromatogram. After normalization to IS, the peak table lists were subjected to 
Figure 9. Typical total ion chromatogram (TIC) for the drug responsive epilepsy subjects, 






principal component analysis (PCA) in SIMCA P+. As QC samples were 
derived from pooled patient samples which should be distinctive from the rest 
but similar among each other, they clustered together in the middle of the PCA 
scores plot (Figure 10). Manual observations and PLS-DA plots with 
additional classification information did not unravel distinctive clustering as a 
result of drug response category, gender, age, epilepsy type, AEDs used, 
number of AEDs used, duration of sample storage and day of analyses. 
Generally, for these cases, ‘autofit’ option for PLS-DA yielded at least 6 
components to characterize the specified classes. Addition or deletion of any 
component/s resulted in worsened goodness-of-fit (R2Y) and goodness-of-
prediction (Q2), and in some cases, reversal of Q2, which was indicative of 
failure to fit as well as data vulnerability to random variation. 
 
 
Figure 10. Principal component analysis (PCA) score plots for all subjects in this 
study (n = 142). Although quality control (QC) samples clustered toge ther, there 
were no obvious clustering of the recruited subjects based on drug response 
categories, gender, type of antiepileptic drug used, age, time of sample storage 






Subgroup analysis was later conducted to further attest the 
indiscrimination. Contrasting to the previous findings, PCA score plots for 
subgroup of finger prick PWE only, demonstrated clear clustering between 
drug responsive and drug resistant PWE (Figure 11). Principal component (PC) 
1 accounted for 14.5% of the variance in the data while the successive PC2 
accounted for 13.5%. Clear discrimination was achieved with 2 PC, loadings 
with higher principal components may cause over-fitting and were deemed 
unnecessary. Following data scaling to unit variance and inclusion of drug 
response category for discriminant analysis using Orthogonal PLS method, 
optimized separation was attained for metabolome from drug responsive and 
drug resistant subjects. The R2Y calculated was 0.989 while the Q2 was 0.742, 
indicating good fit and prediction. As can be seen from Figure 12, drug 
responsive subjects tend to cluster on the right while the drug resistant subjects 







Figure 12. Principal component analysis (PCA) sc ore plots for dried blood spot 
samples obtained through finger prick in this study (n = 17). Clustering was 
demonstrated for drug responsive and drug resistant subjects  
Figure 12. Orthogonal partial least square-discriminant analysis (OPLS-DA) score plots 
for dried blood spot samples obtained through finger prick in this study (n = 17). 
Clear discrimination was observed for drug responsive and drug resistant 






Based on their demographics which are presented in Table 11, no trend 
or bias is observed neither in the etiologies, seizure types, time from last 
seizures nor the AEDs used. Of note, only 4 out of 11 seizure free subjects 
were on polytherapy while all 6 of the DRE subjects were on polytherapy. 
Although not statistically significant, the potential clinical significance of this 
characteristic requires further investigation. A following response permutation 
test confirmed the reliability of this model predictive ability, with R2Y 
intercept at 0.769 and Q2 intercept at -0.169 (Figure 13). This suggested that 
the metabolome of DRE subjects was significantly different from their drug 
responsive counterparts. 
 
Table 11. Demographics of subjects who had contributed finger prick samples in 
this study 
Characteristics  Drug Responsive (n=11)  Drug Resistant (n=6) 
Male, n (%)  5 (45%) 2 (33%) 
Chinese, n (%)  10 (91%) 5 (83%) 
Weight, Mean±SD (kg)  64.4 ± 9.0 74.7 ± 18.3 
Age, Mean±SD (years)  46.0 ± 12.6 35.3 ± 18.5 
Etiology, n (%)    
Structural-metabolic 7 (64%) 5 (83%) 
Genetic Nil 1 (17%) 
Unknown 4 (36%) Nil 
Seizure Type, n (%)    
Focal 7 (64%) 4 (67%) 
Generalized 4 (36%) 2 (33%) 
Monotherapy, n (%)  7 (64%) Nil 
Polytherapy, n (%)  4 (36%) 6 (100%) 
*Antiepileptic Drug/s, n    
Carbamazepine 7 4 
Lamotrigine 4 3 
Phenobarbitone Nil 1 
Valproate 1 2 
Levetiracetam 1 1 
Clobazam 1 3 
Topiramate Nil 2 
Days from last seizure,  
Mean±SD (Range)  
1978 ± 1247 (442 – 4350) 43 ± 49 (2 – 118) 
*Total number of drugs does not coincide with number of subjects as some subjects were on more than 1 








Table 12. Discriminating metabolites from cross-validated PLS-DA list. Their 
levels were significantly different between the drug responsive and drug 
resistant subjects (p < 0.05) 
Putatively Identified Metabolites Difference in levels 
L-glutamine Higher in Drug Resistant 
Pyruvic acid Higher in Drug Resistant 
Caprylic acid Higher in Drug Resistant 
L-serine Higher in Drug Resistant 
Palmitic acid Lower in Drug Resistant 
Oxalic acid Higher in Drug Resistant 
Aspartic acid Higher in Drug Resistant 
 
 
Figure 13. Response permutation test with 2 components revealed R2Y intercept 





The variable importance plot (VIP) list of metabolites generated from 
the cross-validated PLS-DA was further examined using t-test for level 
differences between drug responsive and resistant subjects. A few significant 
putatively identified metabolites were highlighted here (Table 12). L-
glutamine, pyruvic acid, caprylic acid, L-serine, oxalic acid and aspartic acid 
were revealed to be higher while palmitic acid was significantly lower in the 
drug resistant subjects.  
 
6.4.3 BIOLOGICAL EXPLANATION 
As can be seen from Figure 14, MetPA biological pathway 
visualization revealed that the discriminating endogenous metabolites are 
involved in a few metabolism pathways, namely, (A) alanine, aspartate and 
glutamate metabolism; (B) glycine, serine and threonine metabolism; (C) 
glyoxylate & dicarboxylate metabolism; (D) fatty acid biosynthesis; (E) 
cysteine & methionine metabolism; (F) aminoacyl-tRNA biosynthesis; (G) 
purine metabolism; (H) citrate cycle and (I) pyruvate metabolism. The x-axis 
is the p values compiled by MetPA using enrichment analysis, based on 
location of the metabolite in the biological pathway. The more upstream the 
metabolite is in the pathway, the higher impact value it will derive. The y-axis 
is plotted based on the degree of betweenness centrality. The more number of 
‘hits’ i.e. metabolites affected in that biological pathway, the more important 
the pathway seems to be. Hence, generally, the nodes highlighted in this study 



























Figure 14. Visualization of pathway analysis result using MetPA. Only the most 





Figure 15 depicts a simplified connectivity illustration between some 
of these pathways alongside the discriminating metabolites, which are shaded 
in grey boxes. Coefficients column plot of the respective metabolites is shown 
in Figure 16.  
 
Figure 15. Simplified connectivity illustration between some of the biological 
pathways involved in discerning drug resistant epilepsy from drug responsive 
epilepsy. The grey shaded boxes represent the putatively identified metabolites 









Methanol is used for extraction as it is deemed to be a universal 
solvent. It has a polarity index of 5.1, indicative of its inclination towards 
hydrophilicity. Water is avoided as it tends to rupture erythrocytes and 
dissolve the filter paper components, releasing pigments and paper debris into 
supernatant that interfere with metabolites analyses and detections in GC-MS. 
Furthermore, the filtering process usually involves laborious extractions that 
will reduce throughputs. To maximize the number of metabolites extracted, a 
second more lipophilic solvent, chloroform, which has a polarity index of 4.1 
was used. Chloroform tends to favorably dissolve compounds which are 
slightly more hydrophobic. Indeed, combination of methanol and chloroform 
outperformed other combinations which included ethanol, propanol, 
Figure 16. The coefficient plots from OPLS-DA generated using 17 finger prick 
DBS samples for drug resistant subjects. Only 7 most significant metabolites 
(total of 129 metabolites) are presented here. Var1, L -glutamine; Var 2, oxalic 
acid; Var 3, pyruvic acid; Var 4, caprylic acid; Var 5, L -serine; Var 6, aspartic acid 





dichloromethane, hexane and acetonitrile and was ultimately chosen as the 
solvents of choice. 
In terms of metabolite profiling, similar to the study utilizing venous 
plasma and newer generation of AEDs, venous blood did not detect 
discrimination between the metabolome of DRE and drug responsive PWE 
(109). PWE in this study were on the older generation of AED and their drug 
responses were synchronized to the latest recommendation from ILAE, which 
differed from the previous study. Yet, no biomarkers were identified, which 
could be due to the similar shortcoming of heterogeneity of the sample 
populations (109). In the subgroup analysis using only finger prick DBS, clear 
discrimination was observed despite the small number of subjects. This 
suggests that the endogenous metabolites and their levels in the capillary 
blood could be different from venous sources, which has been previously 
demonstrated (225, 226). Additionally, venous blood composition of 
endogenous metabolites varies depending on the origin e.g. femoral vein on 
the leg and basilic or median cubital vein on the hand. Generally, the 
concentrations of some metabolites especially amino acids are much lower in 
CSF as compared to venous plasma (227-229). Therefore, in comparison, 
capillary blood may be more useful for metabolomic profiling of DRE in PWE 
as it has been reported to resemble the arterial blood composition more than 
venous blood (230).  
From the biological pathway analysis, alanine, aspartate and glutamate 
metabolism was found to be the most significant pathway identified. There 
were 3 distinguishing metabolites involved in this pathway which were 
detected in this study, namely glutamine, aspartic acid and pyruvic acid. All 3 
metabolites were upregulated in the drug resistant subjects, presumably in the 
brain. Glutamine (Gln) is a precursor of the excitatory amino acids, glutamic 
acid (Glu) and aspartic acid (Asp), and the inhibitory amino acid, GABA in 
astrocytes. High Gln in astrocytes has been shown to trigger release of Glu to 





levels or the resulting transmembrane electrochemical gradient can also 
activate an outward redistribution of Gln from astrocytes (232, 233). Accrual 
of Gln in EC causes depolarization and resulted in seizure. In addition, Gln 
also appears to directly affect neurotransmission by interacting with the 
NMDA class of Glu receptors, causing the ion channels to remain open for 
persistent transmission. This excess of Gln in extracellular could ‘spillover’ to 
the periphery arterial blood (227). Interestingly, the concentration of Gln in 
arterial blood is very close to extracellular fluid (ECF) and CSF (227, 233). 
This similarity was not observed between venous blood and CSF. Therefore, 
the concentrations of Gln in CSF and ECF are better represented by arterial 
blood than venous, and this finding may be true for some other metabolites as 
well (156). Since Asp is a product of Gln that exists in equilibrium with Glu, 
similar shift of its excess into periphery blood might have occurred. 
Alternatively, high intake of Gln from diet could also cause an increase in 
brain levels of Gln, and the subsequent consequences. Gln is known to be 
unstable and readily converts to 2-pyrrolidone-5-carboxylate, glutamic acid 
and carboxylic acid. The immediate drying on filter paper may have halted 
this conversion as opposed to venous collection, where the whole blood is left 
in the EDTA tube for a short duration before spotting. The fact that the DBS 
samples were acquired at inter-ictal phase could reflect a persistently high 
steady-state concentration of Gln in the brain of DRE subjects. Overall, these 
disturbances supported that glutaminergic and GABAergic transmissions are 
strongly associated not just with epilepsy, but also with drug resistant epilepsy. 
Glu did show an increase trend in DRE subjects although the 
difference was not significant (p = 0.12). Despite being the discriminating 
metabolite when compared with healthy subjects (38), the insignificance 
elevation in DRE subjects could be attributable to the subtlety amongst PWE 
themselves. It is also interesting to note that at high concentrations, Glu will 
form glycine, which will be oxidized to ammonia, carbon dioxide and serine 
(234). In this study, instead of Glu, L-serine was found to be significantly 





link to the direct result of high Glu oxidation. In contrast to the previous report 
where glycine and threonine were upregulated more than healthy subjects (38), 
L-serine seems to be more prominent in discriminating drug resistant from 
drug responsive subjects. However, all three metabolites are part of the 
glycine, serine and threonine metabolism pathway, another well-known 
perturbed pathway in epilepsy (38, 235, 236). Glycine is a preferred amino 
acid for storage in the epileptic site of the brain to shield against seizure (237). 
It acts as an inhibitory neurotransmitter. The inhibition of glycine action at the 
central nervous system was thought to be the main reason for strychnine-
induced-convulsions (238). Serine has also been reported to have different 
concentrations between capillary and venous blood (156), highlighting again, 
the possible benefit of capillary samples in detecting metabolite disturbances, 
especially when the differences are subtle, such as amongst PWE.  
In a related context, L-serine is an interchangeable product with 
pyruvic acid, which in this study, was also elevated in the drug resistant 
subjects. However, increased pyruvic acid concentrations could also result 
from perturbation of many other biological pathways such as alanie, aspartate 
and glutamine metabolism which was discussed earlier, glyoxylate and 
dicarboxylate metabolism, citrate cycle and pyruvate metabolism. It is an 
intermediate compound from the metabolisms of carbohydrates, proteins as 
well as fats. Its accumulation in tissues, especially the nervous structures is 
usually caused by impaired oxidation (239). PWE on AEDs has been reported 
to have folate and thiamine deficiencies (240). In the latter scenario, pyruvic 
acid oxidation is hindered and its accumulation has been reported (241, 242). 
On the other hand, pyruvic acid elevation could also indicate compensatory 
mechanism as it is known to exert cytoprotection against hydrogen peroxide 
(H2O2) toxicity in the central nervous system (243). In rats, pyruvic acid 
supplementation had prevented epilepsy-induced neuronal damage (244-246). 
This animal study was designed in conformance with natural neuroprotective 
mechanism where pyruvic acid is upregulated to quench the extra Glu in 





increase efflux of Glu from brain, thus preventing excitotoxic neuronal cell 
damage caused by prolonged epileptic seizures (244, 246). 
Caprylic acid is a medium chain triglyceride (MCT) which has 
biochemical advantage of fast oxidation. It forms the main component, 55%, 
of Huttenlocher’s ketogenic diet (248, 249). There is evidence of carrier 
mediated transport of caprylic acid through the blood brain barrier that 
facilitates its permeation through the cerebral capillary bed (250). This feature 
is important for caprylic acid to directly exert anticonvulsant effect upon brain 
exposure (249). It has also been demonstrated to potentiate VPA antiseizure 
actions in pentylenetetrazole-induced seizure using Albino Swiss male mice 
(249). Perhaps, in PWE with frequent seizures, there is a tendency to store 
MCT as an attempt in defence against seizures. In turn, long chain fatty acids 
such as palmitic acid, may be produced less, indicating perturbation in fatty 
acids biosynthesis. Palmitic was shown to be lowered in the presence of higher 
dose Pgp inhibitor, LY335979, as a result of either less absorption, production 
or removal from intracellular. There seems to be no direct correlation between 
palmitic acid and seizure (251), although it has been reported to displace VPA 
from plasma protein rendering higher concentrations of free VPA (252). Since 
we did not measure free levels of VPA in drug responsive subjects, it remains 
unknown if this effect has indeed occurred. If it had occurred, the higher free 
fraction of VPA may be the contributory factor for better response observed in 
the seizure free subjects. Besides, chronic treatment VPA and CBZ are known 
to affect lipid profiles (253, 254). Nevertheless, the preference for the stronger 
lipid profile perturbation observed in DRE subject as compared to their drug 
responsive counterparts has yet to be determined. 
Oxalic acid overproduction is linked with impaired metabolism of 
glycoxylic acid or ascorbic acid. Systemic oxalosis and primary hyperoxaluria 
in human is a rare, autosomal recessive disorder which is usually hereditary 
(255-257). It is also found in vegetables such as spinach and rhubard and fruits 





induced neurotoxicity with symptoms including tetany, seizures and 
paraesthesia (258). Although it is unlikely that all drug resistant subjects have 
undiagnosed hyperoxaluria, it does seem that over-ingestion or over-
production due to impaired metabolism have occurred in this group of subjects. 
Oxalic acid was found to be significantly elevated at 2.5 hr after 
administration of high dose VPA (refer Appendix II), suggesting that this 
could be an effect of long term treatment with antiepileptic drugs. Therefore, 
Oxalic acid elevation could be a potential biomarker for AEDs compliance 
assessment, where its low or non-elevated level can be associated with 
incompliance. Alternatively, the high levels of pyruvic acid, may have 
encouraged its transformation into 4-hydroxy-2-oxoglutaric acid and thereby, 
increasing oxalic acid production (Figure 15). 
 
6.6 CHAPTER CONCLUSION 
 Although DBS and plasma concentrations may differ from 
brain extracellular and cerebrospinal fluid, the bi-directional transport of 
metabolites through blood brain barrier allows for estimation of abnormalities. 
Coupled with advances in biological pathways visualization, these platforms 
could aid in revealing collective changes in metabolite expressions.  
To the best of our knowledge, this is the first study that demonstrated 
metabolite profile differences between drug responsive and drug resistant 
PWE using DBS obtained from finger prick. Hence, in this instance, DBS 
collected from finger prick may be suitable for metabolomic study of epilepsy. 
The metabolite pathway perturbations observed in this study were 
comparable with those of other studies on epilepsy. What we have observed so 
far, the increase in glutamine, aspartic acid and serine indicated that alanine-
aspartate-glutamate and glycine-serine-threonine metabolisms perturbations 





with the imbalanced excitatory and inhibitory neurotransmissions that forms 
the foundation of seizure occurrences. Being a dynamic biological system, 
some auxiliary metabolites such as oxalic acid from glyoxylate-dicarboxylate 
metabolism pathway was also affected. It is difficult to attribute these 
perturbations to the effect of either long term seizure recurrences or 
antiepileptic drugs use. However, based on previous animal studies that our 
group has conducted, which are outlined in Appendix, there is a high 
possibility that alanine-aspartate-glutamate perturbations are both disease- and 
treatment-related. This was evidenced by the alteration observed in glutamic 
acid levels by Pgp inhibition (disease-modification) and VPA-treatment 
(treatment-modification) models. With reference to the Pgp-inhibition mice 
study (refers Appendix I), glycine-serine-threonine metabolism is suggested to 
be altered either as part of epileptogenesis or as consequences of frequent 
seizure occurrences rather than drug-induced. 
It is also noted that among these complex interactions, in vivo 
compensatory mechanisms could have been in place, such as the pyruvic acid 
quenching and storage of more MCTs instead of long chain fatty acids. In 
view that seizure frequencies are still high among the drug resistant subjects, it 
is clear that these protective effects are neither sufficient nor timely. In fact, 
these presumed defence mechanisms could bring about detrimental effects if 
they are responsible to trigger even more production of excitatory 
metabolites/amino acids. Targeted treatment strategies which could help 
restore the balance; particularly aiming at these few biological pathways are 
deemed preferable in rendering a subject seizure free from drug resistant.  
In reference to our study objectives, DBS from venous blood did not 
unravel significant metabolites in the profiles of drug resistant PWE. However, 
it could still be useful for targeted metabolite measurements. Metabolomic 
profiles yielded from DBS of finger prick origin, appeared to be more 
informative, attributable to some endogenous metabolite concentration 





surrogate for CSF. A targeted assay has to be developed to quantitate the 
change in levels of these relevant metabolites to gauge the threshold 
above/below which, seizure occurrences become favorable. 
Moving forward, there is a need to coincide the time of blood sampling 
with seizure occurrence to investigate if any of these biomarkers is the causal 
or at least indicative of an imminent seizure attack. If this pathophysiology 
could be delineated, it will aid delivery of timely antiseizure drug and in near 
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CHAPTER 7. CLINICAL VALIDATION OF DRIED BLOOD 
SPOT SAMPLING FOR QUANTITATION OF 
CARBAMAZEPINE, VALPROIC ACID AND PHENYTOIN 
USING GAS CHROMATOGRAPHY-MASS SPECTROMETRY 
Using a previously validated assay for simultaneous monitoringof CBZ, 
PHT and VPA, we embarked on recruiting clinical samples for validation of 
DBS quantitation with the plasma turbidimetric immunoassay in hospital. This 
work was in line with Objective 4 where both methods can be compared for 
agreement. Appropriate conversion factors for each AED could then be tested 
and proposed.  
 
7.1 CHAPTER SUMMARY 
To facilitate faster therapeutic AEDs monitoring process by healthcare 
professionals for PWE, we (1) developed a GC-MS assay to concurrently 
measure three AEDs i.e. carbamazepine (CBZ), phenytoin (PHT) and valproic 
acid (VPA) concentrations using one dried blood spot (DBS), and (2) 
correlated DBS measured concentrations with their plasma levels. A hundred 
and sixty nine PWE on either mono- or polytherapy of CBZ, PHT or/and VPA 
were included. One DBS, containing ~15 µL of blood, was acquired for the 
simultaneous measurement of the drug levels using GC-MS. Simple Deming 
regressions were performed to correlate DBS levels obtained from GC-MS 
with plasma levels measured at the hospital laboratory. Statistical analyses 
were done using MedCalc
®
 Version 12.6.1.0 and SPSS 21. DBS 
concentrations (Cdbs) were well-correlated to plasma concentrations (Cplasma): 
r=0.8381, 0.9305 and 0.8531 for CBZ, PHT and VPA, conversion formulas 
obtained were [0.89×CdbsCBZ+1.00]µg/mL, [1.11×CdbsPHT-1.00]µg/mL and 
[0.92×CdbsVPA+12.48]µg/mL, respectively. After including RBC/plasma 
partition ratio and individual hematocrit levels in the estimation of Cplasma from 





and VPA were demonstrated. Bland-Altman plots revealed good agreements 
between observed Cdbs and Cplasma of CBZ and between theoretical and 
observed Cplasma, of PHT and VPA where >93.0% of concentrations was 
within 95%CI (±2SD). The conversion factors for Cdbs were accurate in 
estimating the Cplasma of CBZ, PHT and VPA. Hence, DBS could be an 
alternative tool for drug monitoring in PWE who are on any of these drug/s. 
Future studies to establish the pharmacokinetic parameters such as clearance 
and apparent volume of distribution using Cdbs could be considered to improve 
the usefulness of measuring whole blood concentrations. 
 
7.2 CHAPTER INTRODUCTION 
It is well-known AEDs have narrow therapeutic indexes for maximum 
efficacy and minimum toxicity. Hence, routine plasma concentrations 
monitoring has been practised, especially during dose adjustments, compliance 
check and to rule out adverse drug reactions (259). Approximately 40% to 50% 
of PWE will require two or more AEDs at any one point of their therapy (94, 
260, 261). Therefore, simultaneous monitoring of AEDs has always been an 
attractive alternative to the immunoturbimetric assay of each drug individually 
(262-264). The simultaneous assay of relevant AEDs is deemed to reduce 
workload and cost incurred by both patients and laboratories.  
Among all the investigated sampling techniques which involve 
cerebrospinal fluid, tear and saliva (79-81, 265), DBS is convenient to collect 
and has better storage stability. These advantages have enabled patients to 
acquire their own sample at home and mail it to designated laboratory (149, 
157). Moreover, acquisition of blood spot does not require professional 
phlebotomist and sample volume of DBS is small (<100 µL). The only caveat 
is patients’ agreeability to be needle-pricked. Comparable phenytoin and 





previously demonstrated, indicating equivalence in accuracy between venous 
and capillary concentration (165). It seems likely that venous blood 
concentration of drug is comparable to capillary blood concentration after its 
distribution phase (266). Nevertheless, it remains debatable if DBS can be 
used to determine free drug concentrations.  
Previous studies on concurrent monitoring of multiple AEDs from one 
DBS were mostly done in high performance liquid chromatography (HPLC) 
and included whole blood concentrations of AEDs such as carbamazepine, 
phenytoin, lamotrigine and barbiturates with limited clinical validation (262-
264). Recently, a group in N. Ireland published a detailed HPLC ultraviolet 
method for concurrent determination of carbamazepine (CBZ) and its active 
metabolite carbamazepine-10,11 epoxide (CBZE), levetiracetam (LEV), 
lamotrigine (LTG) and phenobarbital (PHB) in paediatrics (267). However, 
there were no correlations made with plasma concentrations. 
In our population of PWE, CBZ, sodium valproate (VPA) and 
phenytoin (PHT) are the most popular antiepileptic drugs (AEDs) used,  either 
as mono or polytherapy (261). This has prompted us to investigate the 
applicability of monitoring all three AEDs using only one DBS.  Considering 
the volatile nature of VPA, and previous successful quantitation of CBZ and 
PHT using gas GCMS (268), GCMS was ultimately chosen as the analytical 
tool for simultaneous determination these AEDs. Subsequently, to enhance the 
clinical applicability of this quantitation method, the DBS-measured 
concentrations will be validated against their corresponding plasma 
concentrations determined by the conventional immunoturbimetric assays in 
hospital laboratories. Most often, drug concentrations in whole blood will be 







7.3 MATERIALS & METHODS 
7.3.1 PATIENT RECRUITMENT 
Assuming constant analytical standard deviations, the sample size 
recommended for method validation is at least 41 per AED (range ratio = 2, α 
= 5%, power = 90%, standardized slope deviation of 4) (269, 270). PWE who 
were on either CBZ, VPA or/and PHT were recruited from October 2011 to 
August 2012 at neurology specialist clinic of a tertiary referral hospital. This 
study had obtained the local ethics committee approval. Only PWE who had 
routine plasma CBZ, VPA and/or PHT, blood and liver biochemistry 
monitoring on the day of visit were approached for informed consent prior to 
blood sampling. PWE characteristics and biochemistry results were retrieved 
from clinical records and hospital information system while the timings of last 
AED dose taken were obtained from PWE. Drug response categorization was 




Venous whole blood samples were collected in EDTA tubes. Two 





 Neonate Blood Collection Cards, Whatman GmbH, Dassel, 
Germany) and dried at room temperature, 25ºC for at least 3 hours. The rest of 
the whole blood was sent to hospital laboratory for plasma quantitations as per 
routine protocols. To maintain its direct comparability to the plasma 
quantitation, which is usually completed within 6-8 hours after collection, 






7.3.3 PLASMA AEDS QUANTIFICATION  
Hospital laboratory-based, particle enhanced turbidimetric inhibition 
immunoassays (Beckman Coulter Inc. Unicel DxC800, USA) with inter- and 
intra-assay coefficient of variation < 8%. 
 
7.3.4 DBS SAMPLES PROCESSING 
One 6-mm diameter DBS, containing approximately 15 µL of blood 
from each patient was extracted for simultaneous AEDs quantification using a 
previously validated GCMS assay.  AEDs extraction was optimized using 500 
µL of analytical grade (99%) acetonitrile (Prime Products Pte Ltd, 
Singapore):1 molar sodium hydroxide (JT Baker, Phillipsburg, NJ, USA)  at a 
ratio of 24:1, v/v with 1 µg/mL 5-(p-methylphenyl)-5-phenylhydantoin (5MP) 
(Sigma Aldrich, St Louis, MO) as internal standard. The extraction procedure 
involved 1 min of vortexing and 5 min of sonication. Then, the mixture was 
centrifuged for 15 min at 6000 g. Four hundred microliters of supernatant was 
transferred into 15 mL Kimble glass tube (Gerresheimer Co. Glass, Germany) 
for evaporation under nitrogen gas for 15 min at 40ºC. After addition of 100 
µL of toluene to the dried sample, second drying phase under similar condition 
was carried out. Subsequently, derivatization was attained using 50 µL of N-
methyl-N-trimethylsilyltrifluoroacetamide with 1% trimethylchlorosilane 
(Thermo Scientific Pte. Ltd., Waltham, Massachusetts, USA) incubated at an 
optimum 70ºC for 50 min. Derivatised samples were cooled to room 
temperature and diluted with 50 µL of heptane before vortexing for 1 min. 
Finally, 80 µL of mixture was transferred into a 200 µL conical base inert 
glass insert placed in a 2 mL amber glass vial (Agilent Technologies, Santa 






7.3.5 GC-MS SETTINGS 
The analytical assay was developed using GC-MS that comprised of 
GC 2010 Shimadzu GC coupled to a GCMS-QP2010 Plus quadrupole MS 
(Shimadzu Corporation, Nishinokyo-Kuwabara-cho, Nakagyo-ku, Kyoto, 
Japan). GCMSsolution (version 2.0), was utilized for data acquisition and 
peak area computation. DB5ms (30 m × 0.25 mm × 0.25 µm) supplied by 
Agilent Technologies J&W, Inc. was used as the capillary column Injector 
temperature was set at 250ºC while ion source at 220 ºC. Split ratio of 1:5 was 
applied and column flow was set at 1.9 mL/min. Column temperature began at 
90 ºC with a 0.2 min hold time. Temperature was then ramped at 4 different 
rates: (1) 10 ºC /min to 120 ºC, held for 0.5 min (2) 65 ºC /min to 285 ºC, held 
for 0.5 min (3) 10 ºC/min to 291 ºC, held for 0.2 min and (4) 60 ºC/min to 300 
ºC for a final hold time of 5 min. Selective ion monitoring (SIM) mode was 
used for detection of target analytes at their respective retention times and are 
tabulated in Table 13.  
 
Table 13. Tabulation of selective ion monitoring (SIM) attributes and the ions 
monitored for the respective analytes  
Analytes  Retention Time Quantifying Ion Qualifying Ions 
Valproic Acid 3.453 min 201 129, 145 
Phenytoin 7.068 min 281 165, 176, 253 
Carbamazepine 7.166 min 193 194, 293 
5-methylphenylhydantoin 7.245 min 267 290, 395 
 
7.3.6 BIOANALYSIS 
Calibration and quality control standards were prepared in blood and 
spotted onto the 903
®
 cards at 30 µL each. One 6-mm diameter disc was 
punched out from each DBS and used for analysis. The assay was validated 





100 – 110% and imprecision was < 10%. The recoveries of analytes were 
relatively high (75% – 97%) and consistent (SD ≤ 5.7%). Although the 
inconsistency increased to 11% at the lower limit of quantitation for CBZ, it 
was still within the acceptable limit. 
 
7.3.7 STATISTICAL ANALYSIS 
DBS concentrations (Cdbs) and plasma concentrations (Cplasma) 
determined by respective methods were directly compared. Theoretical Cplasma 
was calculated using a formula which incorporates individual hematocrit 
values and red blood cell-to-plasma partition (RBC/plasma) ratio (271-274). 
                     
    
           
 
where Hct is the individual hematocrit value and R/P is the 
RBC/plasma ratio of the AEDs. Since the RBC concentration is not routinely 
measured, individual specific R/P cannot be derived. To ease the clinical 
applicability, the R/P was fixed at literature values of 0.29 (275) and 0.43 for 
PHT (271) and 0.04 (276) and 0.20 (277) for VPA . The theoretical plasma 
concentration for CBZ was not calculated since its R/P was reported to be 
approximately 1, diminishing the effect of Hct (278).  
Simple Deming regression was utilized to compare the methods and 
estimate the conversion factors. Paired sample t-test was used to assess the 
differences between methods. As the objective of this study is to correlate Cdbs 
to Cplasma, Bland-Altman plots were compiled using Cplasma and Cplasma 





 Version 12.6.1.0. Outliers were confirmed using standardized score 







7.4.1 PATIENTS  
A total of 181 PWE were recruited but only 167 PWE, providing DBS 
were included in the final analyses. Fourteen PWE were excluded due to 
undetectable Cplasma (< 2 µg/mL), while 2 PWE were excluded due to 
standardized score more than 2.5 during outlier check. Characteristics of PWE 
within each AED group were tabulated in Table 14. There were equal 
proportions of male and female PWE who were on each AED. Some PWE 
contributed 2 AED concentrations, resulting in total DBSs of more than 167. 
No significant elevation in biochemistry results was noted. Median hematocrit 
of the venous samples was 41.3 (range 29.8 – 51.0). The average doses of 
CBZ, PHT and VPA used in this population were 870.5 ± 413.2 mg, 284.1 ± 















Table 14. Characteristics of the people with epilepsy (PWE) grouped according to 
the type of antiepileptic drug. Total recruited PWE were 183. Only 169 were 
included in the analysis. The remaining 14 subjects were excluded due to missing 
plasma levels from hospital laboratory system.  (Note: Some recruited PWE 
contributed to the levels of two AEDs)  
Characteristics Valproic Acid  
(n = 90) 
Phenytoin 
(n = 49) 
Carbamazepine  
(n = 108) 
Number of Eligible DBS 81 42 101 
Number of Excluded DBS  











Number of Subjects 80 41 100 
Male 46 (57.1%) 21 (51.2%) 48 (48%) 
Age, Median (Range) 44.3 (19 - 78) 50.6 (18 - 72) 42.9 (20 - 78) 
Ethnic, No. Subjects (%)   
Chinese 71 (87.7) 37 (90.2%) 89 (89%) 
Malay 5 (6.2%) 3 (7.3%) 5 (5%) 
Indian 3 (3.7%) Nil 6 (6%) 
Others 2 (2.5%) 1 (2.4%) nil 
Concurrent medications, No. Subjects (%)  
None 7 (8.3%) 22 (53.7%) 22 (22%) 
Valproic Acid  10 (24.4%) 46 (46%) 
Phenytoin 10 (11.9%)  nil 
Carbamazapine 46 (54.8%) Nil  
Other AEDs 21 (25.0%) 9 (21.9%) 32 (32%) 
Blood Chemistry, Median (range)   
Hematocrit (%) 41.6 (30.7 - 51) 42.7 (33.3 - 49.2) 41.3 (29.8 - 49.7) 
Hemoglobin (g/dL) 13.9 (9.8 - 16.8) 14.0 (10.5 - 16.4) 13.6 (9.2 - 16.8) 
Liver Function Test Median (range)   
Albumin (g/L) 40 (31 - 46) 41 (31 - 47) 41 (31 - 46) 
ALT (U/L) 20 (8 - 109) 24 (12 - 79) 19 (9 - 43) 
AST (U/L) 22 (12 - 59) 22 (16 - 78) 21 (12 - 59) 
GGT (U/L) 53 (9 - 333) 84 (27 - 417) 50 (21 - 213) 
Drug Monitoring (µg/mL), Mean (standard deviation)   
Mean plasma levels  57.2 (22.35)* 9.1 (4.67)* 8.4 (2.32) 
Mean DBS levels 28.9 (14.67)* 6.3 (3.92)* 8.3 (2.56) 
Mean predicted plasma levels  57.1 (22.34) 8.9 (5.06) 8.3 (2.56) 
Average dose (mg), Mean (standard deviation)  
 870.5 (413.22) 934.0 (317.89) 284.1 (71.33) 
ILAE Classification of Drug Response   
Drug Responsive 28 (34.6%) 21 (51.2%) 31 (31%) 
Drug Resistant 30 (37.5%) 9 (22.0%) 38 (38%) 
Undefined 23 (28.4%) 11 (26.8%) 31 (31%) 
*Denotes significant difference 
 
7.4.2 DBS AND PLASMA CONCENTRATIONS 
Figure 17 illustrated the relationships between the Cdbs and Cplasma for 
the three AEDs, namely CBZ (Figure 17, top left), PHT (Figure 17, top right) 





three AEDs, correlation coefficient, r = 0.8381, 0.9305 and 0.8531 for CBZ, 
PHT and VPA, respectively. Cdbs and Cplasma of CBZ were almost identical. In 
contrast, Cdbs of PHT and VPA were consistently lower than their 
corresponding Cplasma, averaging at 2.8 ± 1.9 µg/mL (29.7 ± 13.6%) and 28.3 ± 
12.7 µg/mL (49.5 ± 22.3%), respectively (p < 0.005). Moreover, 95% CI for 
the slope of PHT and VPA did not cross the value 1, indicating there was at 
least a proportional increase between Cplasma and Cdbs of the two AEDs.  
 
 
Figure 17. Plasma concentrations of (top left) carbamazepine (top right) 
phenytoin and (bottom) valproic acid regressed against their dried blood spot 
concentrations using Deming regression. The broken line is the line of unity 
while the continuous line is the line of regression. The (top left) slope is 0.84 
(95% CI, 0.76 to 1.00) and the intercept is 1.00 (95% CI,  0.04 to 1.97) for 
carbamazepine, (top right) slope is 1.61 (95% CI, 1.39 to 1.84) and the intercept 
is -1.14 (95% CI, -2.40 to 0.12) for phenytoin and (bottom) slope is 1.57 (95% CI, 





When regressed against theoretical Cplasma, definite improvements in 
line of regression and distribution of points with marginal decrease in 
correlation coefficients for PHT and VPA were observed (Figure 18). The 
theoretical Cplasma of PHT was found to be comparable to its observed Cplasma 
(Figure 18, top). However, regression line drawn using theoretical Cplasma of 
PHT obtained from R/P of 0.29 showed a better fit with 95% CI of slope 
included 1 (Figure 18, top left) than the one obtained from R/P of 0.43 (Figure 
18, top right). As for VPA, the observed Cplasma was still higher than both 
theoretical Cplasma calculated using R/P of 0.20 (Figure 18, bottom left) and 







Figure 19 shows the Bland-Altman plots of all three AEDs using the 
respective predicted Cplasma. The concentration used for CBZ was Cdbs while 
for PHT and VPA, theoretical Cplasma was used in comparison with their 
observed Cplasma. Mean difference between the concentrations from proposed 
new method and conventional plasma immunoassay was -0.1 µg/mL for CBZ. 
For theoretical PHT Cplasma calculated using R/P = 0.43, the mean difference 
Figure 18. Plasma concentrations of (top) phenytoin and (bottom) valproic acid 
regressed against their theoretical plasma concentrations estimated from dried 
blood spot concentrations using Deming regression. [Theoretical plasma 
concentrations = Dried blood spot concentrations/1 - Hct × (1 – R/P)], where Hct 
is hematocrit and R/P is the RBC/plasma partition ratio. The broken line is the 
line of unity while the continuous line is the line of regression. The (top left) 
slope is 1.21 (95% CI, 1.04 to 1.38) and the intercept is -1.04 (95% CI,  -2.32 to 
0.24) for phenytoin with R/P=0.43, (top right) slope is 1.11 (95% CI, 0.95 to 1.27) 
and the intercept is -1.00 (95% CI,  -2.28 to 0.29) for  phenytoin with R/P=0.29, 
(bottom left) slope is 1.03 (95% CI, 0.87 to 1.20) and the intercept is 12.16 ( 95% 
CI, 5.95 to 18.37) for valproic acid with R/P=0.2 and (bottom right) slope is 0.92 
(95% CI, 0.77 to 1.07) and the intercept is 12.48 (95% CI, 6.15 to 18.81) for 





was -0.7 µg/mL while with R/P = 0.29, the mean difference was zero. The 
difference was -13.7 and -8.1 µg/mL for VPA with R/P of 0.20 and 0.042, 
respectively. Most of the differences fell within the acceptable limit of ±1.96 
SD for all three AEDs. The converted Cdbs reflected observed Cplasma well and 
these methods of approximating Cplasma for CBZ, PHT and VPA could be used 
interchangeably. The theoretical Cplasma of VPA estimated from R/P = 0.04 and 
PHT estimated from R/P = 0.29 yielded findings which were closer to the line 
of unity and were therefore, recommended for clinical use. 
 
Figure 19. Bland Altman plots for plasma concentrations of (top) 
carbamazepine, (middle left) phenytoin, R/P=0.43, (middle right) phenytoin, 
R/P=0.29, (bottom left) valproic acid, R/P=0.20 and (bottom right) valproic acid, 
R/P=0.042. The broken lines represent the 95% CI (±1.96 SD)  and the 








7.4.3 PLASMA CONCENTRATIONS FOR SEIZURE AND DRUG 
RESISTANT SUBJECTS 
There were no significant differences between Cdbs in seizure free and 
drug resistant PWE for all three AEDs studied (p > 0.05). Similarly, Cplasma did 
not differ significantly between the two groups. Furthermore, the distributions 
and trends of Cplasma appeared diverse and alike between these two groups 
across all three AEDs studied (Figure 20). As illustrated, most of the 
concentrations measured for CBZ and VPA fell within the therapeutic ranges. 
In contrast, the measured concentrations of PHT mainly clustered at levels 











Figure 20. Observed plasma concentrations in seizure free (left panels) and drug 
resistant (right panels) people with epilepsy (PWE). Therapeutic ranges for 
individual AED is outlined by the broken lines in each figure. The average 
concentrations for seizure free versus drug resistant PWE were  8.21±2.47µg/mL 
versus 8.29±1.82µg/mL for carbamazepine, 8.13±4.18µg/mL versus 
11.11±6.16µg/mL for phenytoin and 59.79 ±21.09µg/mL versus 






This group of PWE represents the typical population of PWE who 
would undergo routine plasma monitoring. In CBZ with presumed K of 1.06, 
the dilutional effect by RBC is minimal, if not none (272, 278). As CBZ 
partitioned significantly into the RBC compartment, the concentrations 
measured in whole blood were approximately the same as those that measured 
in plasma. This allowed a direct comparability between Cdbs and Cplasma of 
CBZ giving a conversion factor of about 0.9.   
Contrasting to CBZ, Cdbs of VPA were constantly lower than its 
Cplasma,. Lower Cdbs of VPA had previously been observed by Vermejiv and 
Edelbroek in their study, using HPLC for AED detection. They had found a 
conversion factor of 1.46 from Cdbs to Cplasma, which implied that Cplasma was 
46% higher than Cdbs (279). The lower concentrations measured from DBS 
could be attributed to a combination of factors. Firstly, the dilutional effect by 
red blood cells (RBC). RBC accounted for 99% of cellular space of blood and 
its presence may serve to dilute the VPA concentrations compared to those 
measured in plasma alone (280). Secondly, for drugs with whole blood-to-
plasma concentration ratio of less than (1 – Hct), such as VPA, they should not 
partition into RBC significantly (272). VPA whole blood-to-plasma 
concentration ratio in our study averaged at 0.51 while the (1 – Hct) averaged 
at 0.58. Furthermore, VPA had been shown to partition into RBC from plasma 
at ratios ranging from 0.04 to 0.20 (276, 277, 281). It is projected that only the 
unbound drugs can partition into RBCs (282, 283) and that this partition is 
consistent at varying concentrations (281, 284). Since most of our patients had 
plasma VPA concentrations within the therapeutic ranges, and normal albumin 
levels,, the K was presumably consistent (281). Hence, the relatively small 
amount in RBC compartment was likely unable to contribute any substantial 
value towards overall Cdbs.  Thirdly, VPA, being lipophilic, could dissolve and 
detach from RBC during centrifugation of whole blood to obtain the plasma 





(285, 286). Alternatively, despite extraction yield of > 80% (RSD < 6.0%) 
between 1 to 250 mg/L, (Table 15) the binding of VPA to 903
®
 cards may 
have some effect in the lower Cdbs.  
 
Table 15. Percentage of mean extraction recovery of analytes along with their 
respective residual standard deviation (RSD) at different concentrations in 
spiked blood. The consistent and high recovery (>70%) of the analytes allowed 
for reliable quantitative studies  
Concentration 
(µg/mL) 
Mean Recovery (RSD) in percentage (%) 
Carbamazepine Phenytoin Valproic Acid 
1 70.28 (11.10) 84.22 (8.21) 94.67 (4.64) 
10 89.98 (1.73) 96.88 (4.76) 92.90 (1.13) 
50 74.62 (3.67) 93.60 (3.00) 90.34 (5.69) 
250 89.01 (1.57) 80.21 (1.02) 80.43 (4.10) 
 
Although metabolism of VPA by enzymes present in RBC could have 
occured while the blood spot was being left to dry on the cards, enzymatic 
activity is thought to decrease at temperature lower than 37ºC, and this effect 
should be minimal (287).  
There was definitive improvement found for theoretical Cplasma after 
incorporation of hematocrit and RBC/plasma partition ratio. Yet, a constant 
lesser theoretical Cdbs was calculated. The most probable explanations include 
the domination from RBC dilutional effect and VPA binding to 903
®
 cards. In 
clinical practice, however, the potential effect of the difference in calculated 
Cplasma from Cdbs may not be obvious. An example of a worst case prediction 
would be for an actual Cplasma of 60 µg/mL, the predicted Cplasma could either 
be 48 or 72 µg/mL. At either concentration, physicians are likely to increase 
the dose if the PWE has uncontrolled seizure, which is a similar clinical 
decision to the result of 60 µg/mL. Therefore, it is unlikely that Cdbs would 





On the other hand, PHT readily partitions into and dissociates from the 
red blood cells, with a R/P reported to be approximately 0.29 (275) and 0.43 in 
healthy patients (271). Its whole blood-to-plasma concentration was 
approximately 1.33 in both studies, which was comparable to 1.14 and 1.23, 
before and after corrected for Hct and R/P, found in this study. PHT binds to 
hemoglobin in RBCs (288). At higher Cplasma of PHT, plasma protein binding 
sites start to be saturated and increases in R/P ratios were observed. This could 
be result from increase in unbound fraction of PHT that will readily partition 
into RBC (289). RBC had been shown to release PHT disproportionally in in 
vivo (275). At higher Cplasma where a presumably higher amount of PHT is 
transported by RBC, its unequal release may have been more prominent, 
especially during centrifugation and resulted in the higher concentrations 
measured from plasma. Therefore, an overall concentration from whole blood 
might provide an alternative explanation for scenarios such as uncontrolled 
seizure despite having therapeutic plasma PHT concentrations. Indeed, for 
drugs with high partition ratio into RBC such as neuroleptic drugs haloperidol, 
butaperazine and thioridazine, the RBC concentrations tend to have better 
association with treatment outcomes as compared to their plasma 
concentrations (290-292).  
It is noteworthy that most of the PWE classified as drug-responsive by 
ILAE exhibited steady state Cplasma of below 10 µg/mL. One possible 
explanation could be these PWE were on decreasing doses of PHT due to long 
term seizure free. Hence, their levels were no longer maintained within 
therapeutic ranges. Incompliance to PHT regimen might be another 
contributing factor as incompliance upon realizing the possibility of AED 
withdrawal is not uncommon among the seizure free PWE (172). However, it 






7.5.1 EFFECT OF HEMATOCRIT AND COMPOUND SPECIFIC 
RED BLOOD CELL-TO-PLASMA RATIOS  
In this study, we had demonstrated that compound specific red blood 
cell-to-plasma binding and individual hematocrit level explained the 
difference in concentrations detected from DBS and plasma. It seems that the 
higher the drug partition into RBC, e.g. 1.06 for CBZ, the closer the Cdbs is to 
its Cplasma. Conversely, higher hematocrit levels will cause a lower Cdbs. DBS 
does seem to equate whole blood characteristics which were outlined in 
previous studies (272, 284). For lipophilic drugs such as AEDs, RBC is an 
important and very useful transporter with high capacity but low affinity to the 
drugs. RBC readily releases the drug it carries and equilibrates with 
surrounding tissues in capillary system. Although Cplasma is an optimum 
representation of tissue concentration, RBC concentration of drug may be able 
to function similarly. The constant ratios of RBC/plasma water over a wide 
range of AEDs concentrations proved that RBC is not a saturable system (275, 
281). Therefore, RBC concentration of drug may be negligible at low 
concentration, but will gain importance as the concentration increases.  
 
7.6 CHAPTER CONCLUSION 
DBS concentration of AEDs was generally lower than the plasma 
concentrations, predominantly driven by the dilutional effect of RBC presence. 
The differences lessen with increasing RBC/plasma partition ratio of the drugs 
and decreasing hematocrit values. At clinically relevant blood and liver 
biochemistry variations, correcting the Cdbs to hematocrit and RBC/plasma 
partition improved the theoretical prediction of Cplasma for PHT and VPA. 
Nevertheless, this study did not cater for investigation of patient specific 





was fixed at 2 diverse values for PHT and VPA to approximate the suitability 
as evidenced by improved graphical fit. Aside from recommended to be 
consistent among varying concentrations (275, 281), a constant value was used 
to ease clinical applicability.  Since PWE recruited had levels that were within 
normal ranges, it may be assumed that at these ranges, the effects of AEDs 
binding to blood cells and albumin should not fluctuate significantly.  In this 
study, DBS was obtained from venous source. Theoretically, there could be 
some differences between capillary and venous concentrations but the 
differences for a majority of xenobiotics are not obvious, especially after the 
distribution phase (164-166). At steady state drug concentrations, difference 
between capillary and venous should be insignificant and could be used 
interchangeably (166). In conclusion, the theoretical Cplasma can be estimated 
through the equations below for the respective AEDs: 
                                          
                   
       
            
             
                   
       
            
              
where Hct represent individual hematocrit value, Cplasma CBZ, Cplasma 
PHT and Cplasma VPA represent the plasma concentrations of CBZ, PHT and 
VPA, respectively while Cdbs CBZ, Cdbs PHT and Cdbs VPA represent the dried 
blood spot concentrations of CBZ, PHT and VPA, respectively For theoretical 
Cplasma of PHT and VPA, the conversion equation using R/P = 0.29 and R/P = 
0.04, respectively were recommended due to its proximity to the line of unity.  
In view of the good agreement between the theoretical Cplasma using 
DBS levels and observed Cplasma for all three AEDs, DBS is deemed suitable 
as an alternative to conventional plasma quantitations. Future studies that 





volume of distribution using Cdbs and then correlate these concentrations to the 
treatment outcomes could be considered.  
 
In the following chapter, the use of Cdbs in estimating the clearance of 
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CHAPTER 8. ESTIMATION AND COMPARISON OF 
CARBAMAZEPINE POPULATION PHARMACOKINETICS 
USING DRIED BLOOD SPOT AND PLASMA 
CONCENTRATIONS FROM PEOPLE WITH EPILEPSY: 
THE CLINICAL IMPLICATION 
This work is published in The Journal of Clinical Pharmacology 
2014;54(2):225-233. 
 
8.1 CHAPTER SUMMARY 
 To clarify the potential of using DBS as a surrogate to plasma for 
TDM of CBZ, we compared the population pharmacokinetic (PPK) estimates 
from concurrent DBS and plasma levels. The dose-concentration relationship, 
estimated parameter and variability were determined. A total of 98 
observations from 97 PWE were included in this study. Data was split into 3:1 
ratio, with the larger dataset forming index group and the smaller set for 
evaluation. Non-linear mixed effects regression with one compartment, first 
order absorption and elimination model was utilized. Covariates were screened 
for inclusion into final model via forward stepwise addition and backward 
elimination method. Predictive performances of the final models were 
assessed for bias and precision. The typical clearance for CBZ was estimated 
to be 5.85 and 5.68 L/h from plasma and DBS concentrations, respectively. 
The final models for clearance estimates obtained from plasma concentrations 
(Cplasma) included total daily CBZ dose per unit weight (DD) and gender while 
from DBS concentrations (Cdbs) included only DD. The final models were 
both precise and non-bias.  The developed PPK models had comparable 





and Cdbs could be used interchangeably in the future for pharmacokinetic 
studies of CBZ. 
 
8.2 CHAPTER INTRODUCTION 
Carbamazepine (CBZ) is an established first line antiepileptic drug 
(AED) for the treatment of focal seizures by rendering neuronal cells more 
resistant towards excitation. It acts by stabilizing the inactive state of sodium 
channels and enhancing the inhibitory actions of gamma amino butyric acid 
receptors. CBZ is primarily metabolized by the CYP3A4 enzyme in the liver 
and less than 3% excreted unchanged in the urine. Doses are usually started at 
200 – 400 mg/day and eventually increased to 800 – 1600 mg / day or 15 – 20 
mg/kg/day. Higher doses may be required during maintenance phases due to 
either its inherent autoinduction or concurrent heteroinduction by other drugs 
(293-297). The period of induction varies between individuals, although 
complete induction has been proposed to occur between 3 – 5 weeks after the 
start of the interaction. Therapeutic plasma CBZ concentrations of 4 – 12 
mg/L have been used as a gauge for rational dosing throughout its therapy.  
Recently, DBS was proposed to be an alternative sampling matrix to 
conventional plasma CBZ monitoring (Chapter 7). The conversion factor from 
DBS concentrations to plasma concentrations was found to be approximately 
0.9, indicating that CBZ partitions considerably into red blood cells (RBCs). 
Of note, there are studies that demonstrated superior relationships between 
whole blood concentrations and clinical outcomes as compared to their plasma 
concentrations for drugs that partition into RBCs at a significant amount (290-
292). Considering that CBZ is the most used AED in our adult population of 
PWE, it has prompted further investigation to estimate the PK parameters 
using DBS concentrations of CBZ (261). Population pharmacokinetic 
modeling of DBS concentrations is hypothesized to provide a better 





concentrations. This finding may facilitate future work in delineating RBCs 
concentration of CBZ and seizure treatment outcome relationship. 
Thus far, compilations of pharmacokinetic properties of CBZ using 
plasma concentrations had shown somewhat differing covariates and estimates 
amongst various populations e.g.  pediatrics (298), adults (90), elderly (299), 
Caucasian (300) and Chinese race (301). An estimation of CBZ 
pharmacokinetics (PK) in our own population of PWE is postulated to 
improve the understanding between dose and therapeutic outcomes during 
epilepsy treatment. In Singapore, study by Chan et al, showed that plasma 
CBZ CL is ~ 3.12 L/h for a 12-year-old child weighing at 35 kg and is 
concurrently taking phenobarbitone (85). In view that they had included 
mostly children and adolescent, with differing set of concurrent AEDs, its 
usefulness in a general adult population may be limited. Therefore, in this 
study, the population pharmacokinetic parameters in adult PWE were 
estimated. Simultaneously, the PPK estimates obtained from both plasma and 
DBS were assessed. Thereafter, the potential of DBS as a surrogate to plasma 
for TDM could be established. 
 
8.3 METHODS 
8.3.1 STUDY DESIGN 
This is a cross sectional, retrospective cohort study approved by the 
local ethics committee and conducted in a Neurology Specialist Clinic of a 
tertiary referral hospital. The study was conducted in accordance to 
Declaration of Helsinki and the protocol was approved by the local ethics 
committee (CIRB2011/269/A). Prior to blood sampling, informed consent was 
obtained from PWE who had routine plasma CBZ monitoring on the day of 
visit. PWE characteristics such as demographics and concurrent medications, 





activities of liver enzymes were retrieved from clinical records and hospital 
information system. To ensure that the plasma levels were representative of 
the steady-state concentrations, only PWE who had constant therapeutic 
regimen for at least 3 months were included in the analysis. PWE who were 
suspected to be incompliant for the past 1 week before sampling were 
excluded. Hence, in conjunction with the constant therapeutic regimen, 
laboratory results were accepted if they were taken within 3 or more months 
(whichever in congruent with previous regimen change) before the samples 
were drawn. Blood panels were obtained on the same day of CBZ sampling. 
Missing values were later replaced with the median of all existing 
observations. PWE were interviewed for their usual time of dosing intake and 
last dose of CBZ administered. ILAE recommendations were utilized to 
categorize drug responsiveness of the PWE (50). Category 1, 2 and 3 
represents PWE with drug responsive, drug resistant epilepsy and undefined 
treatment outcome, correspondingly. 
 
8.3.2 SAMPLING AND ASSAY 
Venous whole blood samples were collected in EDTA tubes for routine 
complete blood counts. Approximately two 30 µL drops from the withdrawn 




 Neonate Blood Collection Cards, 
Whatman GmbH, Dassel, Germany) and dried at room temperature, 25ºC for a 
minimum of 3 hr. Hence, technically the dried blood spot used in this study is 
dried EDTA blood spot. The rest of the blood was sent for laboratory 
measurement. Plasma quantitations were done in hospital laboratory, using 
particle enhanced turbidimetric inhibition immunoassays (Beckman Coulter 
Inc. Unicel DxC800, USA) with inter- and intra-assay coefficient of variation 
< 8%. The dried blood spots were punched at 6-mm diameter, extracted with 
alkalinized organic solvent The dried blood spots were punched at 6-mm 





Sodium Hydroxide 1M (JT Baker, Phillipsburg, NJ, USA) in 480 µL of 
analytical grade acetonitrile (Prime Products Pte Ltd, Singapore). After 
vortexing for 1 min, sonicating for 5 min and centrifugating for 15 min at 
6000 g, 400 µL of supernatant was transferred into silanized glass tube for 
drying under nitrogen at 40ºC. This is followed by addition of 100 µL of 
toluene for further drying with similar condition. Fifty microliters of N-
methyl-N-trimethylsilyltrifluoroacetamide with 1% trimethylchlorosilane 
(Thermo Scientific Pte. Ltd., Waltham, Massachusetts, USA) was added to the 
dried sample for derivatization under optimum temperature of 70ºC and 
duration of 50 mins. Finally, dilution was achieved using 50 µL of heptane 
before injected into gas chromatography mass spectrometry (Shimadzu 
Corporation, Nishinokyo-Kuwabara-cho, Nakagyo-ku, Kyoto, Japan) for CBZ 
quantitations in accordance to a validated assay. GC-MS settings included 
injector temperature of 250ºC, ion source at 220ºC, split ratio of 1:5 and 
column flow at 1.9 mL/min. The quantifying ion for CBZ was 193, while 194 
and 293 were used as qualifying ion at 7.166 min. Capillary column was 
DB5ms (30 m × 0.25 mm × 0.25 µm) (Agilent Technologies J&W, Inc.) and 
starting temperature was 90ºC. Temperature was ramped at 10ºC/min to 120 
ºC, held for 0.5 min, followed by 65 ºC/min to 285 ºC, held for 0.5 min, 10 
ºC/min to 291 ºC, held for 0.2 min and finally 60 ºC/min to 300 ºC, held for 5 
min.  The accuracy (within 15% of the actual value) and precision (%CV < 
15%) of the assay for all measurements were in accordance to FDA guidance 
for industry on bioanalytical method validation (please also refer to Chapter 7, 
Materials and Methods; DBS samples processing and GC-MS settings for 
more details). T-test was utilized for comparison of continuous variables while 
chi-square was used for categorical variables. Statistical compilation and 
testing were done in Microsoft Excel 2007
®
 and significance values were set 








8.3.3 POPULATION PHARMACOKINETIC ANALYSES 
Structural Basic Model  
The non-linear mixed effects regression modelling software 
(WinNonMix Version 2.0; Pharsight, Corp, Mountain View, CA) was utilized 
to model the data. One compartment, first order absorption and elimination 
model was chosen to describe the concentration-time profiles of CBZ.(85, 90, 
301, 302) First order estimation was employed. The data was randomly split 
into 3:1 ratio, with the larger data set as the index group for modelling and the 
smaller set as evaluation group. The bioavailabilty, F was not assumed nor 
estimated since majority of the observations were obtained at trough levels. 
Hence, clearance is denoted as CL/F while apparent volume of distribution is 
denoted as Vd/F throughout the study. At an average of one observation per 
patient, this data set does not allow for estimation of more than one parameter 
and hence only the CL/F was estimated. The Vd/F and absorption constant, ka 
were fixed at literature values (90, 299, 301, 303). ka was fixed based on 
controlled-release formulation because all subjects were taking this form of 
CBZ. The fixed values were varied systematically to at least 3 times lower and 
higher than the literature values to obtain a model with the lowest model 
objective function value (OBJ) as well as estimate errors with a plausible CL/F. 
Inter-individual and residual variabilities were modelled with either 
exponential, proportional or additive errors. 
 
Covariate Model 
Covariates were screened for influence on the individual estimated 
clearance using analysis of variance (ANOVA). The covariates tested included 
gender, age, age ≥ 60 years old, age of seizure onset, weight, ethnicity, current 
drug response class, total daily CBZ dose per kilogram of weight, concurrent 





aspartate aminotransferase (AST), alkaline phosphatase (ALP), and gamma-
glutamyltransferase (GGT); and the concentrations of albumin, total bilirubin, 
haemoglobin and hematocrit. Significant covariates (p ≤ 0.05) were added 
either linearly or nonlinearly into the model via forward stepwise addition and 
backward elimination method. A covariate is considered significant if its 
inclusion into the basic model or deletion from the full regression model 
altered the OBJ ≥ 3.841 (χ2, p=0.05, df=1). In addition, assessment of 
goodness-of-fit plots, reduction in the inter-individual variability, residual 
variability and plausible model parameter estimation were also considered. 
Confirmation of the final model parameters was assessed using first order 
conditional estimation (FOCE) method (304). 
 
Evaluation 
Predictive performance was assessed on the evaluation group The 
predicted and observed CBZ concentrations of the evaluation group were then 
compared. The mean prediction error (ME) was compiled to assess model 
biasnes while mean absolute prediction error (MAE) and root mean square 
error (RMSE) to assess model precision. A model is considered to be non bias 
when 95% confidence interval (CI) of ME included zero, and precise when 
MAE and RMSE have values close to zero. 
 
8.4 RESULTS 
8.4.1 SUBJECT SAMPLES 
A total of 97 PWE who contributed 98 observations were included. The 
index group comprised of 72 observations from 71 PWE while the validation 
group consisted 26 observations from 26 PWE. There were 15 PWE (15.3%) 





unavailable in more than 80% of the PWE and therefore, was excluded as 
covariate for PPK modelling. As can be seen from Table 16, the characteristics 
of the PWE in both the index and evaluation groups were comparable (p > 
0.05). There were equivalent proportions of sex in both groups with a 
seemingly higher representation of drug responsive subjects in the index as 
compared to the evaluation group. This difference, however, was not 
significant. The average age of the subjects was 42.7 ± 10.9 years old while 
the weight was 65.8 ± 15.1 kg. Valproic acid (VPA), clobazam (CLB) and 
levetiracetam (LEV) were most commonly used as adjunctive therapy in this 
population. 
 
Table 16. Demographics  of study population according to index and validation 
group 
Characteristic Index Group Evaluation Group 
No. of observations 72 26 
Sex, n (%)   
Male 33 (46.5%) 12 (46.1%) 
Female 38 (53.5%) 14 (53.9%) 
Ethnic, n (%)   
Chinese 60 (84.5%) 27 (92.3%) 
Malay 7 (9.9%) 0 (0%) 
Indian 4 (5.6%) 2 (7.7%) 
£
Age (years) 42.7 ± 11.23 (22.3 - 77.8) 42.6 ± 10.60 (19.7 - 64.6) 
£
Weight (kg) 65.7 ± 19.01 (39.5 - 107.4) 66.2 ± 13.46 (40 - 96.1) 
£
CBZ dosages (mg/day) 936.1 ± 322.26 (200 - 1600) 924.1 ± 269.46 (400 - 1600) 
£
CBZe plasma concentrations (mg/L) 8.1 ± 2.23 (2.5 - 13.8) 8.4 ±  (3.5 - 13.2) 
£
CBZ DBS concentrations (mg/L) 8.2 ±  2.40 (3.3 - 14.4) 8.3 ±  (4.2 - 14.1) 
Monotherapy with CBZ, n (%) 17 (23.9%) 4 ±  (15.4%) 
*Polytherapy, n (%) 54 (76.1%) 22 ±  (84.6%) 
Valproic Acid, n 31 13 
Clobazam, n 17 6 
Levetiracetam, n 13 5 
Phenobarnitone, n 3 3 
£
Hematocrit, % 41.2 ± 4.48 (32.4 - 49.4) 41.1 ± 4.01 (29.8 - 47.4) 
£
Hemoglobin, U/L 13.6 ± 1.64 (9.5 - 16.8) 13.7 ± 1.52 (9.2 - 15.8) 
£
Albumin (g/L) 39.9 ± 3.17 (31 - 45) 40.5 ± 2.98 (33 - 46) 
£
Alkaline phosphatase (U/L) 72.8 ± 19.73 (36 - 137) 72.9 ± 17.35 (40 - 112) 
£
Alanine aminotransferase (U/L) 20.4 ± 6.60 (9 - 42) 21.7 ± 7.09 (13 - 43) 
£
Aspartate aminotransferase (U/L) 22.7 ± 6.78 (12 - 59) 21.3 ± 4.56 (14 - 34) 
£
Gamma-glutamyltransferase (U/L) 61.2 ± 33.66 (21 - 168) 68.0 ± 45.41 (21 - 213) 
ILAE Classification of Drug Response(50) 
Drug Responsive, n (%) 25 (35.2%) 6 (23.1%) 
Drug Resistant, n (%) 25 (35.2%) 11 (42.3%) 
Undefined, n (%) 21 (29.6%) 9 (34.6%) 
£ Mean (range); *Subjects may be on more than 1 concomitant antiepileptic drugs; ILAE, International League 






Generally, PWE who were in the DRE group documented higher 
frequency of side effects. There were a total of 15 PWE who complained of 
side effects from the AEDs they were on, with no specific attribution to CBZ 
use. Their Cplasma ranged from 6 – 12 mg/L and was within the therapeutic 
range. Among these cases, 6 (40%) had persistent tremor, 3 (20%) had 
occasional dizziness during the day, 3 (20%) had weight gain, 2 (13%) felt 
sleepy during the day and 1 (7%) complained of memory problems.  
On the other hand, the observed Cplasma and Cdbs were plotted according 
to their corresponding drug response categories. As shown in Figure 21, PWE 
who were categorized as having DRE (Category 2), were observed to have 
Cplasma clustering around 7-9 mg/L. In comparison, those who were seizure 
free (Category 1) had a wider range of Cplasma (2.5 -13.8 mg/L). Despite on 
lower doses of CBZ (11.90 ± 4.82 mg/kg) than DRE subjects, (17.70 ± 6.21 
mg/kg) (p <0.001), a few seizure free PWE had Cplasma which exceeded the 
therapeutic range. Interestingly, this scenario was not observed in Cdbs, where 
seizure free PWE had similar concentration distribution with their DRE 







8.4.2 STRUCTURAL BASIC MODELS 
 
Inter-individual variability was best described with exponential error 
while residual variability with additive error estimates. The typical CL/F 
values obtained from the population modelling were 5.88 L/hr (CV 5.16%, 95% 
CI 5.81 – 5.95) for Cplasma and 5.68 L/hr (CV 5.63%, 95% CI 5.53 – 5.77) for 
Cdbs. The fixed Vd/F was 50 L for plasma and 66 L for DBS structural PPK 
model. Interestingly, both models shared similar ka values, 0.47 h
-1
 as well as 
the inter-individual and residual variability, 0.1% and 0.22 mg/L, respectively. 
The scatter plots of the weighted residual versus the individual and population 
predicted Cplasma did not show any bias issue with the structural models built 
(Figure 22). 
Figure 21. Observed carbamazepine concentration of (left) plasma and (right) 
dried blood spot in people with epileps y grouped according to the drug response 
categories. Category 1, 2 and 3 represents drug responsive, drug resistant 
epilepsy and undefined category, respectively. The broken line s outline the 







8.4.3 COVARIATE MODELS 
Plasma concentrations 
Of all the potential covariates added to the model, only daily dose per 
body weight, male gender and concurrent therapy with VPA influenced the 
model significantly. The changes induced were tabulated in Table 17. A 
preliminary full model was generated with the covariates outlined in Equation 
1. 
 
Figure 22. Weighted residual plots for predicted concentrations using indi vidual 
and population estimates for the structural models of (top left & right) plasma 





Table 17. Summary of forward stepwise addition and backward elimination of 
covariates during final model building  
Effect OBJ ΔOBJ 
P value / 
Comment 
Plasma clearance (CL)    
Base model 191.68   
Forward inclusion     
Weight (kg) 191.01 -0.67 NS 
Age (years) * 210.74 19.06 Worsened  
Age> 60 190.05 -1.63 NS 
Total daily dose per unit weight (mg/kg) 170.18 -21.49 <0.001 
Albumin (g/L) 191.39 -0.29 NS 
Gender 185.47 -6.21 <0.05 
Chinese 188.62 -3.06 NS 
Valproic Acid 179.39 -12.28 <0.001 
Seizure Free 190.45 -1.23 NS 
Drug Resistant Epilepsy 189.85 -1.82 NS 
Alkaline phosphatase (U/L) 190.43 -1.25 NS 
Alanine aminotransferase (U/L) 190.45 -1.23 NS 
Aspartate aminotransferase (U/L) 190.46 -1.22 NS 
Full Model (preliminary) 150.25   
Backward Elimination    
Sex 164.03 13.78 <0.001 
Total daily dose per unit weight (mg/kg) 173.94 23.69 <0.001 
Valproic Acid 153.99 3.74 NS 
    
Final Model   153.99   
Final Model FOCE 149.70   
    
Dried blood spot clearance    
Base model 219.60   
Forward inclusion     
Albumin (g/L)* 230.01 10.41 Worsened 
Weight (kg) 219.58 -0.02 NS 
Age (years) 218.23 -1.37 NS 
Total daily dose per unit weight (mg/kg) 195.82 -23.78 <0.001 
Sex 
 219.02 -0.57 NS 
Final Model   195.82   
Final Model FOCE 193.72   
    
FOCE = first order conditional estimation; OBJ = objective function value; ΔOBJ = change in objective function 
value; NS = not significant 










                
              
         
         
       
   
 
 
where CL/Fplasma is the clearance (L/hr) estimated using Cplasma of CBZ, 
 ,   1 ,  2 and   3 are the fixed effect parameters for the clearance intercept,  
total daily dose per weight (mg/kg), sex (female is denoted as 1 and male is 
denoted as 0) and concurrent therapy with VPA (presence of VPA is denoted 
as 1 and absence of VPA is denoted as 0). Backward elimination established 
the importance of total daily dose per weight and female gender in CBZ 
clearance. The inter-individual variability rose slightly to 0.20% while the 
residual variability was 0.86 mg/L. Therefore, the final model obtained is as 
represented by Equation 2. 
 
        Equation 2 
                    
              
         
                    
where CL/Fplasma is the clearance (L/hr) estimated using Cplasma of CBZ, 
total daily dose per weight (mg/kg) and sex (female is denoted as 1 and male 
is denoted as 0). 
The parameters estimated from the final model conformed to those from 
FOCE algorithm. The differences of estimated were marginally higher in 
FOCE, but less than 1.7%. After systematic variation of estimates, the final 








Dried blood spot concentrations 
Similar approach of forward stepwise inclusion revealed total daily dose 
per body weight to be the only covariate that improved clearance estimates in 
the final model generated by Cdbs (Equation 3). Backward elimination was not 
performed since there was only 1 significant covariate. 
        Equation 3 
                 
              
      
        
 
where CL/Fdbs is the clearance (L/hr) estimated using Cdbs of CBZ and 
the total daily dose per weight is in mg/kg. Inter-individual variability rose to 
1.45% while residual variability was consistent at around 0.26 mg/L. Similar 
to the population estimates calculated using Cplasma of CBZ, estimates from the 
final model also conformed to that calculated from FOCE (< 2%). The 
objective function values, however, were higher in all the models generated 
using Cdbs. The optimized fixed effect of ka was 0.47/hr and Vd/F was 88 L for 
the final model. 
 
8.4.4 EVALUATION 
The prediction errors determined from basic and final models of 
CL/Fplasma (Equation 2) and CL/Fdbs (Equation 3) were similar. As can be seen 
from Table 18, the final models generated from Cplasma and Cdbs are unbiased 
(95% CI of ME included zero) and precise (MAE and RMSE are close to zero). 
These final models gave a 10% and 40% improvement in the predictions of 
Cplasma and Cdbs, respectively. The scatter plots of the predicted concentrations 





Table 18. Comparison of prediction errors of estimation between basic and final 




Plasma Concentrations Dried blood spot concentrations 
Basic Model Final Model Basic Model Final Model 
ME 
-1.31 
(-2.06 to -0.55) 
-0.72 
(-1.49 to 0.05) 
0.20 
(-1.38 to 1.78) 
-0.64 
(-1.59 to 0.30) 
MAE 
2.00 
(1.55 to 2.46) 
1.73 
(1.27 to 2.18) 
2.72 
(1.55 to 3.88) 
1.91 
(1.28 to 2.54) 
RMSE  
2.32 
(1.42 – 3.22) 
2.09 
(1.17 to 3.01) 
4.03 
(1.86 to 6.20) 
2.50 
(1.36 to 3.64) 





In the present study, total daily dose per unit weight (DD) and gender 
influenced the CBZ CL/Fplasma. As the DD increases, there is a non-linear 
increase in CL/Fplasma and CL/Fdbs, a finding that echoed many others (Table 
19) (301, 305, 306). The higher CL/F observed with higher CBZ doses could 
be a result of either lower bioavailability (F) or induction of hepatic 
metabolism (301, 305-308). In practice, doses are adjusted based on both 
clinical response as well as Cplasma. Therefore, it is likely that PWE receive 
Figure 23. Observed concentration plotted against its predicted concentration  by 
the final models of (left) plasma and (right) dried blood spot carbamazepine 





higher doses because their clearances of CBZ are higher. Indeed, this is 
supported by the observations of similar concentrations distribution among all 
the PWE although PWE in DRE category were receiving significantly higher 
doses of CBZ as compared to the rest. The inclusion of DD into our PPK 
models resulted in an improved overall fit, amidst the suggestion that this 
covariate could be bias since the model development itself was based on the 
dose input (298). Moreover, the observed correlation between DD and 
CL/Fplasma could have been induced by the process of TDM itself. Nevertheless, 
the improved fit with DD could reflect that in our setting, slower dissolution, 
incomplete absorption and the induction of hepatic metabolism with 
increasing doses of CBZ may better justify CL/F estimates than bias effect by 
the dose input (306, 307). 
Table 19. A summary of characteristics and clearance estimates from different populations  




















USA (300) 113 (833) NA 80.6±19.4 46.1±14.9 11.7 (CLun) Caucasian 
Serbia (305) 256 (423) 11.9±0.6 71.0±16.0 37.0±16.0 5.35 DD, TBW , 
PHB, VPA 




















193 (302) 16.7±8.4 34.9±20.5 12.5±10.1 2.92* TBW, Age, 
PHB 
China (301) 585 (687) 9.9 (1.2-
16.0) 
53 (5-115) 23.3 (1.2-
85.1) 
5.71* DD, TBW, 
PHT 
China (309) 408 (459) 9.7±5.7 52.4±18.1 22.6±14.9 5.23* TDD, TBW, 
VPA, PHT 
USA (90) 829 (1834) 12.9 (1.3-
42.7) 




France (310) 23 (~138) 19.8±5.7 53.4±11.9 21.0±5.4 5.60 NA 
USA (311) 52 (57) 14.7±4.7 40.2±21.6 9.1±4.4 3.58 NA 
UK (312) 48 (149) 9.7±4.4 60.8±14.4 27.8±13.0 8.41 (CLun) NA 
Egypt (313) 302 (302) 15.0±7.84 55.3±19.7 22.1±12.4 3.51 NA 
Singapore 
(This study) 









NA = not readily available from publication; SD = standard deviation; CLun = clearance of unbound carbamazepine; DD 
= total daily dose per weight; TDD = total daily dose (mg); TBW = total body weight (kg); PHB = phenobarbitone; VPA 
= valproic acid; PHT = phenytoin; FBM = felbamate; DBS = dried blood spot 
*clearance is an approximate as It is estimated based on a 65kg male, with CBZ dose of 15mg/kg, taking concurrent 






On the other hand, male PWE had approximately 22.7% higher 
CL/Fplasma than their female counterparts, an observation that had been 
previously demonstrated (298, 314). It is suggested that estrogen in female 
could have inhibited the microsomal enzymes responsible in metabolizing 
CBZ and resulted in lower CL/Fplasma.(315) In addition, female PWE had a 
significantly higher total body weight than the male PWE (71.53 ± 14.64 kg 
versus 60.42 ± 15.0 kg). This had given rise to a greater DD in the male PWE. 
As both body weight and total daily dose per unit weight were generally 
associated with increased clearance (301, 305), a complex interplay between 
these few factors could have contributed to the increased CL/Fplasma in male 
PWE. Nevertheless, it is important to note that in the final PPK model built, 
the fixed effects of DD and SEX were not correlated, r < -0.131, indicating 
that they are independent of each other in this study.  
In contrast, SEX was an insignificant covariate when estimating 
CL/Fdbs. In an earlier plasma and whole blood drug concentrations correlation 
study (Chapter 7), it was suggested that CBZ do reside in RBCs, although the 
magnitude and binding site/s are yet to be determined. In that study, despite 
being diluted by the presence of RBC in whole blood, Cdbs and Cplasma were 
comparable with an almost 1:1 conversion. As male PWE has higher RBC and 
hematocrit values, the additional amount of CBZ concentrated in RBC could 
have annulled any potential increment in CL/Fdbs. However, in view that the 
CL/Fdbs was estimated based on Cdbs, the subtle effect by RBC and its 
component was already incorporated, in part, during the model building. 
Therefore, independently, SEX does not seem to improve PPK of Cdbs model 
fitting. However, there is another school of thought whereby the observed 
significance of SEX as a covariate in CL/Fplasma estimation could be just an 
incidental finding. It was demonstrated that SEX do not withstand allometric 
scaling to size, which decoupled the effect of size and diminished the 





a definitive increase in CBZ CL/Fplasma of 7% to 23% as compared to those 
who were not taking VPA (306, 309). Here, CL/Fplasma seems to increase by 13% 
with the presence of VPA, but this increment failed to attain clinical 
significance after non-linear adjustment made to the model for DD and SEX. 
Aside from inhibition of microsomal enzymatic metabolism of CBZ, which 
leads to reduction in CL/Fplasma, VPA could also displace CBZ from its 
binding site of proteins, which if not metabolized, would lead to increment in 
CL/Fplasma. Depending on which effect is more prominent, CL/Fplasma of CBZ 
could either be higher, lower or unchanged.(317, 318) In this study, the effect 
could be unchanged. Researchers from a Chinese population had utilized a 
dichotomous approach for total daily VPA dose per unit weight as a covariate 
and concluded that significant change in CBZ CL/Fplasma was only 
demonstrated when the VPA dose exceeds 18mg/kg/d (309). The average total 
daily VPA dose per unit weight in this population was found to be 14.71 ± 
7.12 mg/kg/d, which might be too low to impact CBZ pharmacokinetics. 
However, considering the complexity and projected magnitude of interactions 
between VPA and CBZ, it is still advisable to continue therapeutic monitoring 
when these two drugs are used concurrently, especially during dosing 
adjustments of either drug.  
For CBZ elimination, it is primarily metabolized via epoxide hydrolase, 
forming an active metabolite CBZ-epoxide (CBZ-E). There are various reports 
on the effect of concurrent AEDs in altering CBZ CL/Fplasma, particularly the 
older generation drugs, which are well-documented to be either enzyme 
inducers or inhibitor (85, 90, 301, 305, 309). For example, PHT and PHB can 
induce CBZ biotransformation, resulting in a higher CBZ CL/Fplasma. The 
magnitude of biotransformation differs, with approximately 40 to 45% and 17 
to 40% increase in CL/Fplasma when subject is on concurrent therapy with  PHT 
(90, 301, 308) and PHB (85, 90), respectively. However, this study did not 
include any subject on PHT and only 6% were on PHB. It is likely a result of 
change in clinical practice where VPA, LEV and CLB are favoured over PHT 





PHB influence on CBZ CL/Fplasma, probably due to the small number of 
related subjects. 
Generally, DRE subjects received higher doses of CBZ than seizure 
free subjects and demonstrated an approximately 4% higher CL/Fplasma as 
compared to their counterparts. Nevertheless, this difference was not 
significant, a result comparable to an Egyptian study (313). These 
observations support the fact that PWE with harder to control seizure does 
require significantly higher amount of CBZ in order to attain therapeutic 
concentrations, and it may be related to the lower free fraction of CBZ. In 
contrast, similar trend of increment was not observed in whole blood clearance 
as calculated from Cdbs. It is hence speculated that in DRE subjects, there may 
be preference for CBZ to reside in RBC compartments, rendering them 
‘inactive’ for elimination. This additional compartment may also explain the 
increased Vd/F required for Cdbs PPK model convergence. As only unbound 
CBZ will penetrate brain, distribution into RBCs may pose as hindrance for its 
action. This suggests that there may be a need for higher therapeutic range for 
PWE with harder to control seizures. However, caution is required against 
appearances of adverse drug reaction with higher CBZ concentrations. 
Meanwhile, side effects occurrence within therapeutic ranges is not 
uncommon. Good correlations between plasma total and free CBZ 
concentrations and dose-related side effects, predominantly diplopia and 
nystagmus were previously demonstrated (319-321). In addition, intermittent 
occurrences of side effects are postulated to be related to diurnal fluctuations 
of CBZ Cplasma in between doses (320, 322). It is also noteworthy that unbound 
CBZ decreases with higher total CBZ concentrations (323) and hence, 
measurement of either one of the total or free CBZ might not suffice to explain 
the occurrences of side effects. On the other hand, previous works did not 
support correlation between the concentrations of CBZ active metabolite, 
CBZ-E (total and unbound) and side effects (319, 321). Theoretically, 





resulting in overestimation of Cplasma of CBZ. A quick look at the CBZ 
concentrations of this group of PWE who complained of side effects revealed 
that their range was between 6 – 12 mg/L for Cplasma and 4.3 – 11 mg/L for 
Cdbs. In view that Cdbs measures only CBZ and not CBZ-E, the lower range of 
concentrations seems justifiable. Considering that at trough concentrations of 
CBZ, CBZ-E exists between 15% to 20% of the parent drug concentrations 
and cross-reaction was reported to be approximately 8% in Beckman system, 
it was likely that cross reaction in immunoassay observed here was minimum 
(324). Although tempted to correlate the Cdbs concentrations with side effects, 
it is uncertain at this point if Cdbs could provide a better correlation with the 
occurrences of these events as the sample size is too small. Generally, for 
PWE who are on normal release formulation of CBZ, lowering the dose but 
increasing frequencies of CBZ administration (to retain total effective daily 
doses of CBZ), may aid in reducing the degree of fluctuations in both Cplasma 
and Cdbs, and overall, minimise extend of side effects. Alternatively, they 
could be put on a trial of controlled release (CR) formulation. Thereafter, 
direct attribution of side effects to CBZ use must be affirmed before further 
changes in therapy can be proposed. Future PPK studies incorporating a larger 
population and concurrent measurement of plasma and DBS concentrations of 
CBZ, CBZ-E, unbound CBZ and CBZ-E should be more informative in 
delineating this relationship.  
The population estimate of CL/Fplasma of approximately 5.89 L/h 
concurred with those found in previous studies, as summarized in Table 19. As 
majority (72%) of this population was on polytherapy, CL/Fplasma estimated are 
similar to the other polytherapy populations (90, 310, 313, 325). Interestingly, 
CL/Fdbs derived using similar PPK approach resulted in similar model 
specifications and identical parameter estimate with CL/Fplasma.  A typical 
CL/Fdbs in this population is 5.68 L/h. Cdbs of CBZ could be an alternative to 
Cplasma for PPK parameters estimation due to a few positive observations. 
Firstly, both the DBS and plasma models yielded similar inter-individual and 





error encompasses intra-individual, model misspecification as well as 
sampling and/or assay errors of pharmacokinetic parameters. This may imply 
that these variations, as a whole, are adequately and comparably addressed in 
both models, and that CL/Fdbs derived from Cdbs are as representative of the 
population as CL/Fplasma derived from Cplasma. Secondly, their final prediction 
models gave an almost identical precision estimates which further suggests 
that Cdbs and Cplasma could be used interchangeably for PPK studies. As such, 
the target therapeutic ranges for Cdbs are assumed to be similar to those of 
Cplasma, which is within 4 – 12 mg/L. However, for DRE subjects, there may be 
a need to establish a different effective range since the current range does not 
seem practical in controlling their seizures. Finally, there appears to be a more 
direct relationship between the dose and Cdbs since no other tested covariates 
showed significant influence. This may ease dosing adjustments in clinical 
practice if Cdbs is to be monitored routinely. To illustrate, for every1 mg/kg/d 
of increment in CBZ dose in a 65 kg individual, there will be a 0.44 L/h 
increase in clearance, assuming F is constant and there is no change in 
formulation. In a PWE with twice a day dosing, this increment, will result in a 
post 3-hr, post 8-hr and post 11.5-hr Cdbs increment of 1.77 mg/L, 1.51 mg/L 
and 1.24 mg/L, correspondingly. For Cplasma adjustment, however, the dose 
increase would be different for male and female PWE. 
 
8.6 CHAPTER CONCLUSION 
In summary, in this adult population of PWE, ethinicity, age and 
concurrent AEDs do not significantly alter their CBZ PK. For Cdbs, only the 
total daily dose per unit weight is the significant determinant of CBZ 
concentration. Similar to many PPK studies, the retrospective design of the 
study was the main limitation.  The non-availability of data, especially the 
renal profiles prevented a more thorough investigation. Also, to ease sample 
collection and for direct comparison with venous plasma, DBS in this study 





prick DBS, this whole blood DBS is dried but not coagulated. Caution may be 
required for its similarity to finger prick DBS. Provided that the technique is 
correct, direct drop of blood onto filter paper would distribute uniformly 
through the filter paper, (326) minimizing coagulation effect. Usually the 
extraction of xenobiotic from blood dried on filter paper is related to 
hematocrit and blood spot volume (149, 327). In addition, researchers 
suggested that blotting onto filter paper rather than presence of EDTA is more 
likely the reason for different analyte yield (328). Of note, EDTA did not exert 
any stabilizing effect on ciclosporin extracted from DBS, although its 
influence on CBZ (329). In another study which also involved whole blood 
concentration of ciclosporin, the concentration from finger prick blood spot 
was similar to those from EDTA-anticoagulated venous blood, (160) outlining 
the comparability in recovery. 
Nevertheless, it is demonstrated here, that for CBZ PPK studies, the 
use of DBS could be comparable to the use of plasma. Further studies 
involving more observations per individual and utilization of Bayesian 




















CHAPTER 9. THESIS CONCLUSION & FUTURE 
DIRECTION 
In Chapter 1, an overview of DRE, TDM of AEDs and DBS are 
presented. Some of the gaps and limitations of current knowledge on these 
three topics which are directly related to the study objectives are then 
discussed in Chapter 2. 
In short, epilepsy is a dynamic disease where sampling time is crucial. 
As outlined in Chapter 2, Objectives, depending on the type of information 
required, sampling had to be timed appropriately to capture the most 
representative change in metabolite profiles of these patients. Same theory 
applies to TDM of some of the most effective and most commonly used AEDs 
such as CBZ, VPA and PHT where the drug concentration in the body at 
specific designated time could yield specific information. To illustrate, the 
concentration of AEDs directly after a seizure attack would be indicative of 
their relationship to disease control. 
Dried blood spot usage has been expanding in recent years for various 
type of research. It is an attractive matrix as it can be collected by PWE 
themselves. With DBS, the accurate timing for sampling can be assured. The 
findings from this thesis can serve as a stepping stone for larger or population-
based clinical research where patient does not need to travel to hospital for 
sample acquisition. The caveat is of course, proper training on eligible DBS is 
instilled on the potential sample collector. 
To facilitate the implementation of DBS use in clinical practice and 
research, this thesis set out with 2 main objectives; (1) to investigate DBS 
feasibility in epilepsy and (2) its drug treatments monitoring.  
For the first objective, a DRE prevalence study to determine the 





Chapter 4. Then, the reliability and utility of DBS in metabolomic study by 
comparing its findings with those from plasma (Chapter 5) and in treatment 
modified animal models (Appendices 1 and 2) were examined. Finally, in 
Chapter 6, the results obtained from 142 DBS samples belonged to subject 
who was either drug responsive or drug resistant at the point of recruitment 
were presented.  
Drug resistant epilepsy has been a longstanding complication among 
epilepsy patients. DRE prevalence and risk factors have always been topics of 
investigations. The last survey done in Singapore was on 1997, among the 
army cohort. With the development of a new consensus for definition of DRE, 
we embarked in characterizing the drug response of clinic population of PWE. 
As illustrated in Chapter 4, 1 in 5 PWE of the studied population had drug 
resistant, and this finding is comparable to the others. Genetic factors, as 
assessed by genetic aetiology and ethnicity, did not seem to directly contribute 
to a subject’s drug resistant condition. However, as genetic testing was not 
routinely tested, specific genetic abnormalities was not correlated with the 
likelihood of having DRE. Based on the metabolite pathways that were 
affected from metabolomic profiling study discussed in Chapter 6, future work 
could incorporate genetic testing for diseases which were related to these 
pathways. For example, SNAT transporters mutation which could affect 
glutamine transport can be included for concurrent investigation with DRE 
metabolomic study. This can ascertain whether glutamine metabolism was 
affected during the drug resistant epileptogenesis or because of inherent 
genetic defects.  
Neurological disease is best studied using CSF. In chapter 6, there is an 
incidental finding that capillary blood is more informative than venous blood 
in discerning drug resistant from drug responsive metabolomic profiles. It is 
probably attributable to capillary blood’s resemblance to CSF in certain aspect. 
Verification, however, is best done with concurrent analysis of CSF samples. 





advantage of DBS and capillary blood in study of epilepsy patients. As 
discussed in Chapter 6, direct spotting of blood drop onto 903
®
 cards could 
have halted some possible enzymatic degradation of endogenous metabolites 
and improved the information retrieval from whole blood. Nevertheless, 
serum/plasma ‘–omics’ studies does have the advantage of established 
standards and protocols that can be instilled to prevent enzymatic degradation 
and ensure consistency of analysis results, albeit the additional steps involved. 
In view of the complexity and ethical issues associated with CSF sampling 
acquisition, DBS from finger prick is suggested as a favourable surrogate for 
now. 
For the second objective, clinical validation (Chapter 7) and population 
pharmacokinetic modelling (Chapter 8) using DBS derived concentrations 
were conducted to examine their immediate applicability in a clinical setting. 
A previously validated assay with proven recovery and accuracy of CBZ, PHT 
and VPA were utilized. 
Therapeutic drug monitoring with DBS has always been proposed 
(157). The continuous development of validated assays for AEDs quantitation 
using DBS had substantiated its reliability and benefits over conventional 
plasma measurement. In Chapter 7, we had demonstrated the comparability of 
the current proposed DBS and GCMS method with conventional plasma 
immunoassays. For the first time, concurrent DBS quantitation of the 
respective CBZ, PHT and VPA were clinically validated in our population of 
PWE. As subjects were recruited based on their requirement of TDM, they 
should represent the general population who will undergo TDM routinely. 
However, none of the critically ill nor subjects who were just started on AED/s 
were included. Hence, the applicability of this DBS quantitation method 
remains unknown. It is likely that these groups of subjects are 
hemodynamically unstable and theoretical Cplasma may be overestimated, 
especially if DBS is acquired via finger prick. In spite of this, by investigating 





subjects with the typical PWE such as those recruited in this study, the 
conversion could accurately be estimated. 
Cplasma of drugs with narrow therapeutic indexes; low concentrations 
associated with therapeutic failure while high concentrations lead to adverse 
drug reactions, are usually employed in compilation of pharmacokinetic 
parameter estimates such as clearance and volume of distribution. These 
estimates are important to approximate both maintenance and loading doses of 
relevant AEDs which can attain and sustain the desired target concentrations 
within the fastest time and for the longest duration. Using Cdbs of CBZ, AED 
with the highest RBC/plasma ratio among the 3 AEDs studied in Chapter 6, 
the PPK parameter estimation was found to be comparable to those derived 
from Cplasma. The methods and results were explained in Chapter 8. Therefore, 
in terms of PK related monitoring and research work, DBS could perform as 
well as plasma. Further PPK compilation using Cdbs of PHT and VPA, drugs 
with R/P < 1, would be able to reaffirm DBS feasibility and probably a new 
set of target DBD therapeutic ranges could be proposed. 
In relation to research direction, further study which investigates the 
metabolomic profile difference between finger prick and venous DBS from the 
same epilepsy individual can be considered. If permissible, simultaneous 
cerebrospinal dried biofluid spot profiling will be ideal. Quantitation of the 
discriminating metabolites would provide valuable evidence to finger prick 
DBS in the study and monitoring of epileptogenesis. These findings will help 
answer the hypothesis that capillary DBS is significantly different from 
venous’s and delineate the similarity between capillary DBS and CSF.  
To further comprehend the drug resistant epileptogenesis, future work 
should include genomic and proteomic profiling to ascertain the inherent or 
acquired mechanism of the disease. As outlined earlier, genetic and 
transcription abnormalities related to the affected pathways discussed in 
Chapter 6 could be referred. Since this study involved only one time point 





same subject; at seizure free, drug resistant and also in between this period to 
detect potential biomarker that marks the transition phases.  
 Although TDM is usually considered at steady state trough 
concentrations, attempt ought to be made to establish correction factors 
between finger prick DBS with venous plasma during the dose titration phase 
of CBZ, PHT and VPA. Again, multiple sampling is encouraged. Furthermore, 
critically ill patients should be included as this group of patients is projected to 
have elevated whole blood levels that must be adjusted against its venous 
plasma levels to facilitate dosage adjustments. Similar to our research 
approach in Chapter 8, these DBS levels can be subjected to non-linear mixed 
effects modelling to approximate its pharmacokinetic parameters and 
contribution to seizure control. 
In summary, epilepsy is a disease which requires further understanding 
in its pathogenesis and optimization of its treatment drugs. As evidenced by 
results in Chapter 6, 7 and 8, DBS could be a suitable matrix for both aspects. 
Once the relevant biomarkers of epilepsy are established, simultaneous 
monitoring of them together with AEDs could be developed. This, in turn, will 
aid the management of epilepsy patients by rendering monitoring of disease as 
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APPENDIX I. DRIED BLOOD SPOT USE IN METABOLIC 
PROFILING AFTER PHARMACOLOGICAL INHIBITION OF 
THE P-GP EXPRESSION WITH LY335979  
1.1 Objectives 
P-glycoprotein transporters over-expression has been linked to 
pharmacoresistance in epilepsy as well as other diseases such as cancer. As 
Pgp also transports endogenous metabolites, its over-expression will impact 
the metabolites transport as well. These endogenous perturbations are assumed 
to be similar to a ‘diseased’ state. The currently available Pgp functional 
assays detect Pgp efflux activities using chemoluminiscent contrast, which are 
quantitated based on fold changes. Perhaps, there are certain metabolite level 
changes which are associated with its increased or decreased activity. This 
metabolite has the potential to be a quantitative biomarker of Pgp expressions. 
Hence, we had designed an in vivo investigation involving the inhibition of 
this transporter. It is hypothesized to provide insight of some of these 
biomarkers, which could be indicative of the severity of the ‘disease’. Since 
we proposed the use of DBS for metabolite, we will explore the utility of dried 
blood spot for detection of metabolic profiling changes caused by P-
glycoprotein transporters inhibition.   
 
1.2 Methods 
A total of 18 C57BL/6 male mice were equally divided into 3 groups. 
They were aged between 10 - 12 weeks and weighed an average of 25.5 g (24-
28 g). A selective P-glycoprotein inhibitor, LY335979 (zosuquidar 
hydrochloride) was dissolved with miminum DMSO, further diluted with 





relationship, with higher concentration of LY335979 representing greater 




All mice were treated with LY335979 at 9 am daily for 5 consecutive 
days via oral gavage. Dried blood spot were obtained via venipuncture of 
facial vein by sterile lancet. At least 2 drops of blood, ~ 30 µL, were obtained 
from each mouse at 0 hr, 2 hr and 98 hr post treatment (Figure A1.1). The 
mice were fasted for at least 2 hours before and 2 hours after treatment to 
ensure maximum absorption of drugs. On the first and last day of treatment, 
the mice were fasted overnight. Overnight fasting is to allow for measurement 
of baseline endogenous metabolites. 
Day 1 
• - 0.5hr - DBS 
sampling 
• 0hr - 1st dose 
given 
• 2hr - DBS 
sampling 
Day 2 












•96hr - 5th 
dose given 
•98hr - DBS 
sampling 
Table A1.1 Different treatment groups of LY335979 
Groups Group 1 Group 2 Group 3 
LY335979 dose 100mg/kg 50mg/kg 10mg/kg 
Total mice at the 
end of study 
5 
(one died on second 
day of treatment) 
6 5 
(one was excluded due 
to abnormal behavior) 
Figure A1.1. Timeline illustration for the dried blood spot sampling and treatment of 
LY335979 over 5 days. On day 1, 30 mins (-0.5hr) before first dose is given, 2 dried blood 
spots were obtained from all the mice via venipuncture. Similar dried blood spot 







1.2.1 Sample processing and GC-MS GC-MS settings for metabolomics 
DBS samples processing, GC-MS settings and multivariate data 
processing were similar to those described in Chapter 6. Extraction of DBS 
was done twice, on separate occasion, first using 160 µL of methanol and 
subsequently using 160 µL of chloroform, with D27–myristic acid as the 
internal standard at concentration of 6.25 ng/mL and vortexed for 20 mins. 
The total methanol and chloroform extracts were centrifuged at 6 000 g, 22°C 
for 10 mins and 240 µL of the resulting supernatant would be transferred to 15 
mL Kimble centrifuge glass tubes (Gerresheimer Co. Glass, Germany) for 
evaporation. Drying was done at 30°C under a stream of nitrogen.  Thereafter, 
100 µL of toluene was added, vortexed for 15 seconds and subjected to the 
similar condition for drying again. Toluene was used to ensure removal of 
water. Next, derivatization of the dried sample was accomplished using 100 
µL MSTFA with 1% TMCS. The derivatized samples were vortexed for 1 min 
and incubated at 60°C for 1 hour. After being cooled to room temperature, 80 
µL of this final supernatant was transferred into a 200 µL conical base inert 
glass insert placed inside a 2 mL amber autosampler glass vial (Agilent 
Technologies, Germany).  
Analyses were done using GC-MS that comprised of 7890A GC System 
coupled to 5975 inert MSD with Triple-Axis Detector (Agilent Technologies) 
and an in-built Fiehn method of analysis for metabolomic screening.
2
 The in-
built settings include injector temperature at 250°C, split ratio of 10:1 at the 
starting temperature of 60°C held for 1 min, increased at 10°C per min to 
325°C followed by a final hold for 10 mins (total run time of 37.5 mins). Ion 
source temperature was set to 250°C, while the scanning mass range was set 






1.3 Results & Conclusion 
A total of 325 metabolites were detected from all the mice. 113 were 
removed due to presence in less than 25% of the samples. As mice are 
assumed to be homogenous, lower presence were deemed acceptable for an 
exploratory analysis. In the end, 212 metabolites were subjected to 
multivariate analysis using SIMCA P+ v12.0. Significant discriminating 
metabolites which were obtained through the cross-validated PLS-DA model 
using post-98hr of Pgp inhibition were tabulated in Table A1.2. At post-2hr of 
Pgp inhibition, metabolite perturbations were not significantly altered between 
the 2 groups. 
 
Table A1.2. Significant discriminating metabolites from dried blood spot obtained post-
98hr of daily P-glycoprotein inhibition with LY335979 
No Putatively identified 
metabolites 
Level differences 
1 Oleic acid  Higher with increasing inhibition 
2 Myristic acid  Higher with increasing inhibition 
3 L-glutamic acid  Lower with increasing inhibition 
4 L-threonine  Higher with increasing inhibition 
5 L-methionine  Lower with increasing inhibition 
6 L-tyrosine  Higher with increasing inhibition 
7 L-serine  Higher with increasing inhibition 
8 4-pyridoxic acid  Higher with increasing inhibition 








Biological pathway visualization using the ten significant endogenous 
metabolites revealed that glycine-serine-threonine metabolism was the most 
significant pathway affected by Pgp inhibition (Figure A1.2).  Alanine-
aspartate-glutamate metabolism, aminoacyl-tRNA biosynthesis, glutamine-
glutamate metabolism, vitamin B6 metabolism, cysteine-methione metabolism 
and fatty acid metabolism were also affected after selective inhibition of Pgp 
transporter with LY335979. Pgp transporters are present abundantly in liver, 
gut, renal and brain for the transport of xenotbiotics as well as endogenous 
metabolites. Therefore, the metabolite perturbations observed could be the 
effect of inhibition in any of or all these organs in the mice. These 
perturbations were assumed to represent disease-related metabolites 
disturbances. Although it has been shown to act by selectively inhibiting Pgp 
transporters (1), we cannot rule out the possibility of disturbances due to the 
presence of LY335979 itself. However, LY335979 has yet to be proven to 
react enzymatically in vivo, and is thus far, unlikely to cause metabolite 
perturbation via other routes (1). Nevertheless, in a chemical-induced Pgp 








Figure A1.2. Visualization of biological pathway analysis using MetPA. Only the  few 
most significant pathways were highlighted (those in darker shades) 
Legend: 
A – glycine, serine & threonine metabolism 
B – alanine, aspartate & glutamate metabolism 
C – aminoacyl-tRNA biosynthesis 
D – D-glutamine & D-glutamate metabolism 
E – vitamin B6 metabolism 
F – cysteine & methionine metabolism 






post-98 hr of inhibition. DBS is hence, deemed suitable for metabolomic 
profiling of changes in a disease course. 
In addition, a look at the detectable compounds in DBS revealed the 
presence of L-lysine-2, iminodiacetic acid, DL-threo-beta-hydroxyaspartic 
acid, citric acid and adipamide which were not extracted from DBS in our 
previous study (2). The use of double solvents for extraction helped to recover 






APPENDIX II. DRIED BLOOD SPOT USE FOR 
QUANTITATION OF VALPROIC ACID DRUG LEVELS AND 
ITS ASSOCIATED METABOLOMIC CHANGES 
2.1 Objectives 
Valproic acid has been postulated to be able to selectively enhance 
post synaptic brain gamma-aminobutyric acid (GABA) responses, directly 
acting on neuronal membranes, reduce aspartate excitatory transmission and 
inhibit reuptake of GABA into the glia and nerve endings (3-5). 
To minimise inherent metabolic changes due to epilepsy disease itself, 
normal healthy rats were used. The dose of VPA used in this study was the 
lowest in the dosing range employed in previous studies for the investigation 
of its toxicities (6-8). This is in hope to capture snapshots of the immediate 
and delayed metabolite changes that may shed insights into the metabolic 
pathways involved in its pharmacological actions, and generally the 
metabolomic changes induced by drug treatment. 
Similarly, DBS use was coupled with GC-MS analytical platform. 
Since the amount of blood required was very little, we extended the DBS 
applicability to simultaneously quantify a targeted analyte concentration, 
which was VPA. 
 
2.2 Methods 
2.2.1 Animal study 
The in vivo metabolic study was carried out according to the 
‘Guidelines on the Care and Use of Animals for Scientific Purposes’ (National 





animal handling procedures of this study were reviewed and approved by the 
Institutional Animal Care and Use Committee of the National University of 
Singapore (NUS).  
Sprague-Dawley rats (7-8 weeks old, ♂: 10) were purchased from 
Comparative Medicine Center (CMC) of NUS. The rats were kept at a specific 
pathogen free animal facility (24°C, 60% relative humidity) at CMC and 
maintained on a 12-h light/dark cycle with free access to food and water. 
Twenty four hours before the metabolic study, a polyethylene tube (I.D. 0.58 
mm, O.D. 0.965 mm, Becton Dickinson, Sparks, MD 21152, USA) was 
inserted into the right jugular vein under isoflurane anesthesia.  This catheter 
was used for drug injection and blood sampling at 9am on the study day.  
On the study day, 5 rats were injected with VPA at a dose of 200mg/kg 
body weight (treatment group). The other 5 rats were given sodium chloride 
0.9% as placebo (control group). Prior to VPA injection, blood samples 
(approximately 300 µL) from each of the 10 male rats and 10 female rats were 
collected and kept in ice box until they were processed. After the VPA 
injection, blood samples were collected at 0.5 hr, 2.5 hr, 5 hr, 8 hr and 24 hr 
respectively from the 10 rats. The 6 time points were estimated to represent 
the metabolite fluctuations in a day. Within 30 mins of collection, blood 
sample was spotted in duplicates of 25 µL onto 903® cards  and were left 
dried in the fume hood for at least 3 hours, which was the observed minimum 
time required for complete dryness. After drying, the DBS were punched and 
the cores (6 mm) obtained were placed inside their respective Ependorff tubes. 
All the acquired DBS were stored at -80°C until processing for analysis. 
2.2.2 Sample processing and GC-MS settings for metabolomics 







2.2.3 Sample processing and GC-MS settings for valproic acid 
quantitation 
The processing and GC-MS settings were similar to Chapter 7. 
Extraction of VPA from DBS was done using 480 µL of acetonitrile and 20 
µL of Sodium Hydroxide 1N, vortexed for 1 min and followed by sonication 
for 5 mins. The resulting extracts were centrifuged at 3500 g, 22°C for 15 
mins. Four hundred µL of supernatant were transferred into 15 mL Kimble 
centrifuge glass tubes for drying under a stream of nitrogen at 30°C, followed 
by removal of water using toluene and drying under nitrogen again. 
Derivatization was imposed on the dried samples using 50 µL MSTFA with 1% 
TMCS and incubation at 70°C for an optimum time of 50 mins. Dilution with 
50 µL of hexane was carried out and vortexed for a min before 80 µL of the 
final volume is transferred into 200 µL conical base inert glass insert placed 
inside a 2 mL amber autosampler glass vial. 
An assay for the quantitation of VPA concentrations extracted from 
DBS was previously optimized in accordance to International Conference of 
Harmonization (ICH) guideline. The settings included an injection 
temperature of 200°C, ion source temperature of 220°C, split ratio of 1:5, at 
the starting temperature of 90°C for 0.2 min with initial gradient ramp at 
10°C/min to 120°C and held for 0.5 min. The second ramp imposed was 
65°C/min up to 285°C and held for another 0.5 min. The temperature ramp 
was then reduced to 10°C/min to reach a temperature of 291°C and held for 
0.2 min before continuing at 60°C/min to 300°C with a final hold at 300°C for 
5 min. Selective ion monitoring (SIM) mode was applied for identifier ion of 
201 and qualifying ions of 145 and 129. Calibration curve was established 







2.2.4 Pharmacokinetic Analysis 
Concentration-time profiles of VPA after intravenous bolus injection 
were assessed using non compartmental model (WinNonlin Professional, 
Version 5.1, Pharsight Corporation, Mountain View, CA).  
 
2.3 Results and Conclusions 
2.3.1 Metabolomics 
Peak area changes from baseline were utilized for multivariate analysis. 
Each rat served as their own control, where the changes of metabolites at 30 
min, 150 min, 300 min, 480 min and 1440 min were modeled for differences 
between the control and VPA-treated rats. Clear clustering and reliable 
prediction between the 2 groups of rats were only observed at 150 min post 
VPA treatment (Figure A2.1). The comparison of the metabolite profiles at 
other timings did not yield reliable classification groups.  
 
FigureA2.1. Partial least square-discriminant analysis score plots of metabolite profiles of 






The discriminating metabolites after t-test analysis were tabulated in 
Table A2.1 while the biological pathway analysis was shown in Figure A2.2. 
 
Table A2.1. Significant discriminating metabolites from dried blood spot obtained post-
2.5hr of intravenous bolus administration of 200mg/kg of valproic acid 
No Putatively identified metabolites Level differences 
1 DL-3,4-dihydroxyphenyl glycol Higher in VPA-treated Group 
2 phenylacetaldehyde Higher in Control Group 
3 cholesterol Higher in VPA-treated Group 
4 3-hydroxycinnamic acid Higher in Control Group 
5 D-erythrose-4-phosphate  Higher in Control Group 
6 L-glutamic acid Higher in VPA-treated Group 
7 oxalic acid Higher in VPA-treated Group 













Figure A2.2. Visualization of biological pathway analysis using MetPA. Only the  few most 
significant pathways were highlighted (those in darker shades) 
 
Legend: 
A – D-glutamine & D-glutamate metabolism 
B – alanine, aspartate & glutamate metabolism 
C – phenylalanine metabolism 
D – arginine & proline metabolism 
E – steroid biosynthesis  
F – glutathione metabolism 






2.3.2 Quantitation of VPA 
 
Figure A2.3. Calibration curve for valproic acid concentrations extracted from dried blood 
spot samples ranging from 0.5 µg/ml to 5000 µg/ml. The correlation factor, r
2
 = 0.9975 
 
Linearity of VPA concentration was defined using seven calibration 
standard solutions ranging from 0.5 µg/mL to 5 mg/mL (Figure A2.3). Linear 
regression analysis was used to establish the calibration curve which had a 
correlation coefficient (r
2
) of greater than 0.99. Two quality control (QC) 
samples at concentrations of 2 mg/L and 50 µg/mL were used. Their 
experimentally determined values were within 12% of the theoretical values 
and were consistent throughout the triplicates with coefficient of variation 
(CV%) of less than 5%.  
The average concentrations measured from all VPA-treated rats were 
illustrated in Figure A2.4. Generally, with the exception of 0.5hr post-VPA 
treatment, they had displayed very similar pharmacokinetic profiles, most 
notably a seemingly recirculation of VPA at the 5
th
 hr post VPA-treatment (9, 
10).  
 
y = 0.0031x  









































Pearson correlation tests found no significant correlations (p > 0.05, -
0.4 < r < 0.4) between the individual metabolite with VPA concentrations 
(data not shown). Multiple linear regression analysis also did not reveal any 
important metabolite that can account for the measured VPA concentrations as 
well as the inter-individual variations observed.  
Concentration-time profiles of VPA after intravenous (I.V.) injection 
revealed a terminal elimination half life (HL Lambda Z) of 1.71 ± 0.18 hr and 
mean residence time (MRT) of 1.14 ± 0.28 hr using a non-compartmental 
model. The pharmacokinetic parameters obtained were listed in Table A2.2. 
These profiles are comparable to those found from other studies (11, 12). 
Plasma/whole blood concentrations ratio of VPA had been demonstrated to be 
1.46 ± 0.03 (mean ± standard error) (9), therefore it is not surprising to see 
some discrepancies, with generally higher levels obtained from plasma 
calculated values. 
 
Figure A2.4. The concentrations of VPA in rats after intravenous (I.V.) 





Table A2.2. Pharmacokinetic parameters estimated following intravenous bolus 
administration of valproic acid at the dose of 200 mg/kg. Mean ± SD 
Pharmacokinetic parameters Male 
Area under the curve (AUC), µg hr/mL 146.51 ± 48.24 
Clearance (CL), L/hr 0.41 ± 0.12 
Volume of Distribution (Vss), L 0.55 ± 0.22 
HL Lambda Z, hr 1.71 ± 0.18 
Mean Residence Time (MRT), hr 1.14 ± 0.28 
 
In summary, this study has shown that it is possible to use DBS for 
both in vivo non-targeted metabolomic as well as targeted analytes studies.  
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